<SEC-DOCUMENT>0001121404-24-000018.txt : 20240725
<SEC-HEADER>0001121404-24-000018.hdr.sgml : 20240725
<ACCEPTANCE-DATETIME>20240725114322
ACCESSION NUMBER:		0001121404-24-000018
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20240725
DATE AS OF CHANGE:		20240725

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sanofi
		CENTRAL INDEX KEY:			0001121404
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				133529324
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31368
		FILM NUMBER:		241140688

	BUSINESS ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017
		BUSINESS PHONE:		33153774400

	MAIL ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI-AVENTIS
		DATE OF NAME CHANGE:	20040826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI SYNTHELABO SA
		DATE OF NAME CHANGE:	20010104
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a6kcoverpagepressreleaseq2.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i3dc7b966911a4b69a31b3dd2e77308cd_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM&#160;6-K</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF FOREIGN PRIVATE ISSUER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE&#160;13a-16&#160;OR&#160;15d-16</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNDER THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the month of July 2024</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number&#58;&#160;001-31368</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANOFI</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Translation of registrant&#8217;s name into English)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">46, avenue de la Grande Arm&#233;e, 75017 Paris, FRANCE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices)</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F&#160;or Form&#160;40-F.</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form 20-F&#160;&#160;&#9746;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form&#160;40-F&#160;&#160;&#9744;</font></div><div style="margin-top:3pt;text-align:center"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024, Sanofi issued the press release attached hereto as Exhibit 99.1 which is incorporated herein by reference.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:18.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit No.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Description</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Press release dated July 25, 2024&#58; Sanofi Q2&#58; strong performance with 10% sales growth&#59; 2024 guidance upgraded</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURES</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.635%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; July 25, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SANOFI</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#47;s&#47; Alexandra Roger</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alexandra Roger</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Head of Legal Corporate &#38; Finance</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pressreleaseq22024english.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i439f5d1857c344f7b532f54d2ef05291_1"></div><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Press Release                                                              </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><img alt="image.jpg" src="image.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:165px"></div><div style="padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font><br></font></div><div style="padding-left:4.5pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:14pt;font-style:italic;font-weight:400;line-height:112%">Sanofi Q2&#58; strong performance with 10% sales growth&#59; 2024 guidance upgraded</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Paris, July 25, 2024</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-indent:-10.8pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Q2 sales growth of 10.2% at CER and business EPS</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> of &#8364;1.73</font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.35pt">Dupixent sales up 29.2% to &#8364;3,303 million&#59; target of &#126;&#8364;13 billion in 2024 unchanged</font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.35pt">Pharma launches up 80.4% to &#8364;689 million, led by ALTUVIIIO, Nexviazyme, Rezurock, and Sarclisa</font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.35pt">Vaccines sales -4.8% due to COVID-19 sales in 2023</font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.35pt">Opella (former Sanofi Consumer Healthcare) up 9.6%, driven by the Qunol acquisition</font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.35pt">Research and Development expenses grew 5.5%</font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.35pt">Selling, general and administrative expenses grew 4.9%, substantially less than sales growth</font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.9pt">Business EPS</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of &#8364;1.73, down 0.6% reported and up 4.0% at CER</font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.35pt">IFRS EPS of &#8364;0.89, down 22.6% reported</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:15.1pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Q2 pipeline progress</font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.35pt">Three regulatory approvals&#59; Dupixent COPD (EU, July), Kevzara pJIA (US), Altuvoct hemophilia A (EU)</font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.35pt">Four regulatory submissions, including fitusiran in hemophilia A&#47;B and Sarclisa in multiple myeloma</font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.35pt">Increasing pipeline news flow over 2024-2025, including 12 phase 3 data readouts</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:15.1pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Other key updates</font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.35pt">Sanofi ranked world&#8217;s 7th most sustainable company by TIME Magazine</font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.35pt">Opella (Consumer Healthcare) intended separation on track with previously communicated timelines</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">*</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:15.1pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2024 business EPS guidance upgraded</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.35pt">2024 business EPS</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to be stable at CER</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an upgrade from a low single-digit percentage decrease previously, underpinned by accelerated delivery of Sanofi&#8217;s pipeline-driven transformation. Applying the average July 2024 exchange rates, the currency impact on 2024 business EPS is c.-5.5% to -6.5%.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Paul Hudson, Chief Executive Officer, commented&#58;</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8220;We are continuing our strong performance in 2024 and delivered broad-based, double-digit sales growth in the second quarter. We also made important progress in our pipeline of new medicines, including approvals for Dupixent in COPD, Kevzara in pediatric arthritis and ALTUVIIIO (EU) in hemophilia A. With the EU approval in COPD, Dupixent is the first-ever biologic medicine approved in this debilitating disease impacting hundreds of thousands of patients globally. As we accelerate our focused mid- and late-stage pipeline, we started a number of new phase 2 and phase 3 studies that will benefit patients in the future. We are well on track, delivering on our strategic priorities for Sanofi to become a development-driven, tech-powered biopharma company committed to serving patients and accelerating growth. Underpinned by accelerated delivery of Sanofi&#8217;s transformation, we upgrade our earnings per share guidance for 2024.&#8221;</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div id="i439f5d1857c344f7b532f54d2ef05291_4"></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.184%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.856%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q2 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Change</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Change <br>at CER</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">H1 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Change</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Change <br>at CER</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IFRS net sales reported</font></td><td style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;</font></td><td style="background-color:#f4f2f6;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,745&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">m</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+7.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+10.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;</font></td><td style="background-color:#f4f2f6;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,209&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">m</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+5.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+8.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IFRS net income reported</font></td><td style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;</font></td><td style="background-color:#f4f2f6;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,113&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">m</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-22.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;</font></td><td style="background-color:#f4f2f6;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,246&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">m</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-34.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IFRS EPS reported</font></td><td style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;</font></td><td style="background-color:#f4f2f6;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.89&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-22.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;</font></td><td style="background-color:#f4f2f6;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.80&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-34.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-4.05pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Free cash flow</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</font></div></td><td style="background-color:#f4f2f6;border-top:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;</font></td><td style="background-color:#f4f2f6;border-top:0.5pt solid #525ca3;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">854&#160;</font></td><td style="background-color:#f4f2f6;border-top:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">m</font></td><td colspan="2" style="border-top:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-46.4&#160;</font></td><td style="border-top:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#f4f2f6;border-top:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;</font></td><td style="background-color:#f4f2f6;border-top:0.5pt solid #525ca3;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">545&#160;</font></td><td style="background-color:#f4f2f6;border-top:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">m</font></td><td colspan="2" style="border-top:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-82.6&#160;</font></td><td style="border-top:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Business operating income</font></td><td style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;</font></td><td style="background-color:#f4f2f6;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,813&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">m</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+3.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+8.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;</font></td><td style="background-color:#f4f2f6;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,656&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">m</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-6.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+1.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-4.05pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Business net income</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;</font></td><td style="background-color:#f4f2f6;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,161&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">m</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-0.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+4.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;</font></td><td style="background-color:#f4f2f6;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,380&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">m</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-10.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-2.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-4.05pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Business EPS</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.73&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-0.6&#160;</font></td><td style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+4.0&#160;</font></td><td style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.51&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-10.0&#160;</font></td><td style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-2.3&#160;</font></td><td style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:112%">Changes in net sales are expressed at constant exchange rates (CER) unless stated otherwise (definition in Appendix 9). (1) In order to facilitate an understanding of operational performance, Sanofi comments on the business net income statement. Business net income is a non-IFRS financial measure (definition in Appendix 9). The consolidated income statement for Q2 and H1 2024 is provided in Appendix 3 and a reconciliation of reported IFRS net income to business net income is set forth in Appendix 4&#59; (2) 2023 business EPS was &#8364;8.11&#59; (3) Free cash flow is a non-IFRS financial measure (definition in Appendix 9). *Separation subject to market conditions and consultations of social partners and work councils.</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_7"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:16pt;font-style:italic;font-weight:700;line-height:115%">Q2 and H1 2024 summary</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">----------------------------</font></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The performance shown in this press release covers the three-month period to June 30, 2024 (the quarter or Q2 2024) and the six-month period to June 30, 2024 (the half or H1 2024) compared to the three-month period to June 30, 2023 (Q2 2023) and the six-month period to June 30, 2023 (the half or H1 2023) respectively. All percentage changes in sales in this press release are at CER</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">, unless stated otherwise.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">---------------------</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In Q2 2024, sales were &#8364;10,745 million and increased by 10.2%. Exchange rate movements had a negative effect of 2.4 percentage points (pp)&#59; therefore, as reported, sales increased by 7.8%. In H1 2024, sales were &#8364;21,209 million and increased by 8.4%. Exchange rate movements had a negative effect of 3.3pp&#59; reported, sales increased by 5.1%.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Sales breakdown</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:21.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net sales (&#8364; million)</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q2 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Change <br>at CER</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">% of<br>&#160;total sales</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">H1 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Change <br>at CER</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">% of<br>&#160;Total sales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Biopharma</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,439</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+10.3&#160;</font></td><td style="border-top:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">87.8&#160;</font></td><td style="border-top:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18,378</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+8.3&#160;</font></td><td style="border-top:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">86.7&#160;</font></td><td style="border-top:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">&#160;&#160;&#160;Pharma</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,297</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+12.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">77.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,059</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+9.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">75.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">&#160;&#160;&#160;Vaccines</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,142</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-4.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">10.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,319</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+0.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">10.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Opella</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,306</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+9.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">12.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,831</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+9.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">13.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,745</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">+10.2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">100</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21,209</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">+8.4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">100</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">%</font></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Business operating income</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In Q2 2024, business operating income (BOI) was &#8364;2,813 million and increased by 3.2%. At CER, BOI increased by 8.3%. The ratio of BOI to net sales decreased by 1.2pp to 26.2% (down by 0.5pp to 26.9% at CER). This development was mainly caused by lower other revenues as well as higher other operating expenses. In H1 2024, BOI was &#8364;5,656 million and decreased by 6.7%. At CER, BOI increased by 1.4%. The ratio of BOI to net sales decreased by 3.3pp to 26.7% (down by 1.9pp to 28.1% at CER).</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Acquisitions and major collaborations</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May, Sanofi, Formation Bio and OpenAI announced a collaboration to accelerate AI-powered drug development and bring new medicines to patients more efficiently. The three teams will bring together data, software and tuned models to develop custom, purpose-built solutions across the drug development lifecycle. This represents a first collaboration of its kind within the pharma and life sciences industries. Sanofi will leverage this partnership to provide access to proprietary data to develop AI models as it continues on its path to becoming the first biopharma company powered by AI at scale.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Also in May, Sanofi and Novavax announced a co-exclusive licensing agreement to co-commercialize Novavax&#8217;s current stand-alone adjuvanted COVID-19 vaccine worldwide (except in countries with existing advance purchase agreements and in India, Japan, and South Korea where Novavax has existing partnership agreements). The licensing agreement also includes a sole license to Novavax&#8217;s adjuvanted COVID-19 vaccine for use in combination with Sanofi&#8217;s flu vaccines and a non-exclusive license to use the Matrix-M adjuvant in vaccine products. In addition, Sanofi took a minority equity investment in Novavax.</font></div><div id="i439f5d1857c344f7b532f54d2ef05291_13"></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:16pt;font-style:italic;font-weight:700;line-height:115%">Sales by geographic region</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:21.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net sales (&#8364; million)</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q2 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Change <br>at CER</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">H1 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Change <br>at CER</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United States</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,751</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+19.8&#160;</font></td><td style="border-top:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,067</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+13.4&#160;</font></td><td style="border-top:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,402</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-2.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,882</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-3.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of World</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,592</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+8.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,260</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+11.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;of which China</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">765&#160;</font></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-0.5&#160;</font></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">1,522&#160;</font></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+2.8&#160;</font></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The commentary below emphasizes the recent quarterly performance unless stated otherwise.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">US </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">sales were &#8364;4,751 million and increased by 19.8%. Solid performance by Dupixent and Pharma launches was supported by a return to growth of Lantus and Toujeo. Negative sales impacts included Aubagio due to generic competition, Eloctate, and vaccines.</font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:115%">See Appendix 9 for definitions of financial indicators.</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Europe</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales were &#8364;2,402 million and decreased by 2.2%. Strong performance by Dupixent and Pharma launches was more than offset by lower sales of several medicines, including Aubagio due to generic competition, Lantus, Lovenox, and Myozyme and the absence of COVID-19 vaccine sales in 2024.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Rest of World </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">sales were &#8364;3,592 million and increased by 8.3%. Very strong performance by Dupixent and Pharma launches and growth by Toujeo were slightly offset by lower sales of legacy medicines and vaccines. </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">China</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales were &#8364;765 million and decreased by 0.5%, mainly caused by Lantus, Lovenox, and Other medicines. With higher inflation, the contribution of </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Argentina</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> to the total Sanofi sales growth rate was 1.3pp.</font></div><div id="i439f5d1857c344f7b532f54d2ef05291_16"></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:16pt;font-style:italic;font-weight:700;line-height:115%">Biopharma</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Biopharma segment includes </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Pharma</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Vaccines</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. In Q2 2024, sales were &#8364;9,439 million and increased by 10.3%, driven by continued strong performance of Dupixent and Pharma launches. The divestments of medicines&#47;portfolio streamlining had a negative impact of 0.6pp. In H1 2024, sales were &#8364;18,378 million and increased by 8.3% driven by the same aforementioned factors.</font></div><div id="i439f5d1857c344f7b532f54d2ef05291_19"></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:115%">Pharma</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Immunology</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:21.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net sales (&#8364; million)</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q2 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Change <br>at CER</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">H1 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Change <br>at CER</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dupixent</font></div></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,303&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+29.2&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,138&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+27.1&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales were &#8364;3,303 million, the first quarter above the &#8364;3 billion level, and increased by 29.2%. In the US, sales were &#8364;2,407 million and increased by 23.8%. Prescriptions increased in line with sales&#59; total prescriptions by 22% (year-over-year) and new-to-brand prescriptions by 23% from continued use in the approved indications of atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), eosinophilic esophagitis and prurigo nodularis. In Europe, Dupixent sales were &#8364;399 million and increased by 29.0% reflecting continued growth in AD, asthma and CRSwNP. In the Rest of World, sales were &#8364;497 million and increased by 60.8%, driven mainly by sales in China and Japan. In H1 2024, Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">sales were &#8364;6,138 million and increased by 27.1%, and remains on track to achieve &#126;&#8364;13 billion in sales in 2024.</font></div><div id="i439f5d1857c344f7b532f54d2ef05291_22"></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Pharma launches</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:21.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net sales (&#8364; million)</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q2 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Change <br>at CER</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">H1 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Change <br>at CER</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nexviazyme&#47;Nexviadyme</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">168&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+66.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+79.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ALTUVIIIO</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+772.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">280&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+1378.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sarclisa</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+36.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+32.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Rezurock</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+52.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+46.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Cablivi</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-1.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+0.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Xenpozyme</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+85.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+92.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Enjaymo</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+58.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+72.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Tzield</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+83.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+250.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">689</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">+80.4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,295</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">+85.0</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Nexviazyme&#47;Nexviadyme</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (Pompe disease) sales were &#8364;168 million and increased by 66.0%. Growth was high in Europe (112.0%) and in the Rest of World (172.7%) with slower growth in the US (31.3%) where a higher conversion rate from Myozyme&#47;Lumizyme has been achieved in the eligible late-onset Pompe disease population. The Pompe franchise (Nexviazyme&#47;Nexviadyme + Myozyme&#47;Lumizyme) sales were &#8364;348 million and increased by 14.1%. Nexviazyme&#47;Nexviadyme sales were 48% of the Pompe franchise.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ALTUVIIIO</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (hemophilia A) sales were &#8364;158 million, predominantly in the US where ALTUVIIIO growth was driven by patient switches of which an increasing majority came from medicines other than Eloctate. Sales also benefited from supply to the partner in Europe where the medicine obtained regulatory approval. The hemophilia A franchise (ALTUVIIIO + Eloctate) sales were &#8364;263 million and increased by 77.7%. Franchise growth improved Sanofi&#8217;s market share in the factor as well as the overall hemophilia A market.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Sarclisa</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (multiple myeloma) sales were &#8364;121 million and increased by 36.2%, driven by strong growth in the US and the Rest of World, specifically Japan.</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Rezurock</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (chronic graft-versus-host disease) sales were &#8364;114 million and increased by 52.7%, driven by improved patient adherence and new patients, primarily in the US and new launches in China and the UK.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cablivi</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (acquired thrombotic thrombocytopenic purpura) sales were &#8364;54 million, mainly in the US and in Europe, and decreased by 1.8% primarily due to a lower number of patients being diagnosed.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Xenpozyme</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (acid sphingomyelinase deficiency) sales were &#8364;37 million and increased by 85.0%, driven by more patients in the US and Europe.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Enjaymo</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (cold agglutinin disease) sales were &#8364;26 million and increased by 58.8%, mainly from the US and Japan.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Tzield</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (delay onset of type 1 diabetes) sales were &#8364;11 million, a sequential increase from Q1 2024 of c.10%. Growth was driven by a higher number of infusions supported by increased awareness and screening. Efforts to increase knowledge and updates to disease guidelines are expected to support long-term growth.</font></div><div id="i439f5d1857c344f7b532f54d2ef05291_25"></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Other main medicines</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:21.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net sales (&#8364; million)</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q2 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Change <br>at CER</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">H1 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Change <br>at CER</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lantus</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">398&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+21.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">758&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+0.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Toujeo</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">313&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+11.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">634&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+14.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Fabrazyme</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">273&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+12.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">526&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+10.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lovenox</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">256&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-4.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">518&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-9.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plavix</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">235&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+2.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">473&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+4.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Cerezyme</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+19.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">407&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+21.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Myozyme&#47;Lumizyme</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-11.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">371&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-12.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Alprolix</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+3.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+5.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thymoglobulin</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-0.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+5.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Praluent</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+38.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">247&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+31.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Aubagio</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-49.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-66.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Eloctate</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-18.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-21.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cerdelga</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+7.8&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+11.3&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Lantus</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales were &#8364;398 million and increased by 21.0%. In the US, sales increased by 225.0% to &#8364;158 million, reflecting a low base of comparison due to net-price adjustments in the comparable period as well as an increase in volume due to the unavailability of a competitor medicine. In China, sales continued to decrease due to patients shifting to Toujeo.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Toujeo</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales were &#8364;313 million and increased by 11.0%, mainly driven by Europe and China. In Europe, Toujeo has a leading market share of basal insulin while in China, Toujeo recently surpassed the market share of Lantus. In the US, sales benefited from the unavailability of a competitor medicine.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Fabrazyme</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales were &#8364;273 million and increased by 12.4%, driven by growth in the Rest of World where penetration rates are lower.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Lovenox</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">sales were &#8364;256 million and decreased by 4.6%, reflecting the impact from volume-based procurement in China as well as biosimilar competition in the EU.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Plavix</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales were &#8364;235 million and increased by 2.1%, underpinned by use in Rest of World.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cerezyme </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">sales were &#8364;193 million and increased by 19.3%, driven by growth in the Rest of World, including growth in patients. The Gaucher disease franchise (Cerezyme + Cerdelga) sales were &#8364;275 million and increased by 15.9%.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Myozyme&#47;Lumizyme</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales were &#8364;180 million and decreased by 11.5%, reflecting the conversion to Nexviazyme&#47;Nexviadyme.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Alprolix</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales were &#8364;141 million and increased by 3.7%, driven by the US, partly offset by Rest of World.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Thymoglobulin</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales were &#8364;129 million and decreased by 0.7%, reflecting lower sales in China.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Praluent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales were &#8364;126 million and increased by 38.5%, underpinned by Europe the Rest of World.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Aubagio</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">sales were &#8364;107 million and decreased by 49.5%, reflecting the loss of exclusivity starting in the US in March 2023 followed by Europe in September 2023. The negative global impact from generic competitors is anticipated to reduce during 2024 as the losses of exclusivity annualize.</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Eloctate</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales were &#8364;105 million and decreased by 18.5%, reflecting the conversion to ALTUVIIIO in the US partly offset by growth in the Rest of World.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cerdelga</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales were &#8364;82 million and increased by 7.8%, underpinned by continued growth in all regions.</font></div><div id="i439f5d1857c344f7b532f54d2ef05291_28"></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#661de8;font-family:'Georgia',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:115%">Vaccines</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:21.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net sales (&#8364; million)</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q2 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Change <br>at CER</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">H1 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Change <br>at CER</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:174%">Polio&#47;Pertussis&#47;Hib vaccines incl. Boosters</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">712&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-5.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,348&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-2.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:174%">Meningitis, Travel and endemic vaccines </font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">296&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+0.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">582&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+3.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RSV (Beyfortus)</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:174%">Influenza vaccines</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+20.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+27.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,142</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">-4.8</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,319</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+0.3</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Vaccines</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales were &#8364;1,142 million and decreased by 4.8% impacted by the absence of COVID-19 sales in the quarter compared to &#8364;59 million in Q2 2023. In H1 2024, sales were broadly stable (+0.3%), driven by Beyfortus, offset by no COVID-19 sales compared to &#8364;226 million in H1 2023. Excluding the impact from the absence of COVID-19 sales, growth would have been 0.0% and 10.7% respectively.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Polio&#47;Pertussis&#47;Hib</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (PPH) vaccines sales, including Boosters, were &#8364;712 million and decreased by 5.1% driven by unfavorable phasing in the Rest of World and the US, where Vaxelis became market leader in the three-dose primary series market. Vaxelis&#8217; in-market sales are not consolidated by Sanofi but profits are shared equally between Sanofi and Merck &#38; Co.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Meningitis, Travel and endemic</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> vaccines sales were &#8364;296 million and increased by 0.3% reflecting higher travel vaccines sales in Europe offset by lower meningitis sales in the US.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Beyfortus</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales were limited to &#8364;18 million, reflecting the global vaccine seasonality towards the second half-year. In collaboration with AstraZeneca, responsible for Beyfortus manufacturing, the regulatory applications for two additional filling lines have been submitted to health authorities to expand supply for the Northern Hemisphere 2024&#47;2025 season. This is anticipated to augment capacity compared to the one line currently licensed.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Influenza vaccines</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales reached &#8364;115 million, benefiting from higher public sales in Latin America.</font></div><div id="i439f5d1857c344f7b532f54d2ef05291_31"></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Biopharma business operating income</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Biopharma BOI was &#8364;2,566 million and increased by 5.6%. At CER, BOI increased by 10.2% reflecting lower other revenues and higher other operating expenses, but more than offset by a higher gross profit and slower growth in Research and Development (R&#38;D) and Selling, general and administrative expenses (SG&#38;A) expenses. The ratio of BOI to net sales decreased by 0.6pp to 27.2% (stable at 27.8% at CER). In H1 2024, BOI was &#8364;4,931 million and decreased by 5.5% (up by 1.7% at CER). The ratio of BOI to net sales decreased by 3.1pp to 26.8% (down by 1.8pp to 28.1% at CER).</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_34"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#661de8;font-family:'Georgia',serif;font-size:16pt;font-style:italic;font-weight:700;line-height:115%">Pipeline update</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sanofi has 78 projects in a pipeline across four main disease areas (Immunology, Rare diseases, Neurology, and Oncology) and Vaccines, including 38 potential new medicines (NMEs) and vaccines. The following section highlights significant developments in the late- and mid-stage pipeline in the quarter&#58;</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Highlights of the quarter</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:27.950%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.850%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regulatory approvals</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:3pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupixent &#8211; COPD (EU)</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevzara &#8211; polyarticular juvenile idiopathic arthritis (US)</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Altuvoct &#8211; hemophilia A (EU) (by partner)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regulatory submission acceptances</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:3pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupixent &#8211; adolescents with chronic rhinosinusitis with nasal polyposis (US priority review)</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupixent &#8211; chronic spontaneous urticaria (EU)</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fitusiran &#8211; hemophilia A&#47;B (US, CN)</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sarclisa &#8211; MM, 1L TI (IMROZ study) (US priority review, EU, JP, CN)</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Major pipeline advancements</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:3pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">riliprubart &#8211; SOC-refractory CIDP (phase 3)</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">riliprubart &#8211; IVIg-treated CIDP (phase 3)</font></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Immunology</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (dupilumab)</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.55pt">The European Commission approved Dupixent in the European Union (EU) as an add-on maintenance treatment for adults with uncontrolled </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">chronic obstructive pulmonary disease</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (COPD) characterized by raised blood eosinophils. Specifically, the approval covers patients already on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate. Dupixent is the first biologic medicine approved for COPD and the EU is the first jurisdiction in the world to approve it. Other reviews are underway, including in Japan and China.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.55pt">The US Food and Drug Administration (FDA) has extended by three months the prescription drug user fee act (PDUFA) date of its priority review of the supplemental biologics license application (sBLA) for Dupixent as an add-on maintenance treatment in certain adult patients with uncontrolled </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">COPD</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The revised PDUFA date is September 27, 2024. The FDA did not raise any concerns regarding the approvability of Dupixent for this indication.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.55pt">The FDA accepted for priority review the sBLA for Dupixent as an add-on maintenance treatment for adolescents aged 12 to 17 years with inadequately controlled </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">chronic rhinosinusitis with nasal polyposis</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (CRSwNP). The PDUFA date is September 15, 2024.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.55pt">The European Committee for Medicinal Products for Human Use accepted for review the regulatory submission for Dupixent in </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">chronic spontaneous urticaria</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy, based on the results from the LIBERTY-CSU CUPID Study A and Study B (pivotal).</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:12.55pt">The New England Journal of Medicine</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> published results from a positive phase 3 study of Dupixent in children aged one to 11 years with </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">eosinophilic esophagitis</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (EoE). Data from the study were the basis for the FDA priority review and approval in the US earlier this year, as well as for the regulatory submission currently under review in EU for this age group.</font></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Kevzara</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (sarilumab)</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA approved Kevzara for the treatment of patients weighing 63 kg or greater with active </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">polyarticular juvenile idiopathic arthritis</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (pJIA), a form of arthritis that impacts multiple joints at a time. The approval in this patient population is supported by evidence from adequate and well-controlled studies and pharmacokinetic data from adults with rheumatoid arthritis as well as a pharmacokinetic, pharmacodynamic, dose finding and safety study in pediatric patients with pJIA.<br></font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">amlitelimab</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (OX40L mAb)</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.55pt">The phase 2 study assessing efficacy and safety of subcutaneous injections of amlitelimab in patients aged 18 years and older with severe </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">alopecia areata</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> enrolled the first patients (clinical study identifier&#58; NCT06444451).</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.55pt">The CONQUEST phase 2 study assessing efficacy and safety of subcutaneous injections of amlitelimab in patients aged 18 years and older with </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">systemic sclerosis</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> enrolled the first patients (clinical study identifier&#58; NCT06195072).</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">rilzabrutinib</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (BTK inhibitor)</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Encouraging results from a phase 2 study showed that treatment with oral rilzabrutinib at both high dose and low doses led to a numerical reduction in loss of asthma control events (the primary endpoint) and improvements in symptoms in adult patients with uncontrolled moderate-to-severe </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">asthma</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. These results were presented at the American Thoracic Society 2024 International Conference, San Diego, US.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">duvakitug</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (TL1A mAb)</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The enrollment of the RELIEVE UCCD phase 2 study in </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ulcerative</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">colitis</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Crohn&#8217;s disease</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was accelerated with a top-line analysis now anticipated in H2 2024 (clinical study identifier&#58; NCT05499130).</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Rare diseases</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ALTUVIIIO</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (efanesoctocog alfa)</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.55pt">The European Commission granted marketing authorization for Altuvoct (ALTUVIIIO in the EU) for the treatment and prevention of bleeds and perioperative prophylaxis in </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">hemophilia A</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> to Sanofi&#8217;s partner in the EU, Sobi. The EU also endorsed the retention of orphan designation, granting a ten-year market exclusivity period.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.55pt">The FDA updated the label for ALTUVIIIO to include full results from the XTEND-Kids phase 3 study showing that once-weekly dosing with ALTUVIIIO delivers highly effective bleed protection in children with </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">hemophilia A</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. ALTUVIIIO was first approved in February 2023 for adults and children with hemophilia A for routine prophylaxis and on-demand treatment to control bleeding episodes as well as for perioperative management (surgery), and this label update builds on the interim XTEND-Kids data from 2023 to include full results.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">fitusiran</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (RNAi targeting anti-thrombin)</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Regulatory submissions for fitusiran for the treatment of </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">hemophilia A or B</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in adults and adolescents with or without inhibitors have been completed in China, Brazil, and the US with a PDUFA date of March 28, 2025. The FDA granted fitusiran breakthrough therapy designation for hemophilia B with inhibitors in December 2023.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">New data were presented at the International Society on Thrombosis and Haemostasis congress in Bangkok, Thailand, and included information on surgical experience as well as long-term safety from the ATLAS phase 3 development program in adults and adolescents with hemophilia A or B, regardless of inhibitor status.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">losmapimod</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (p38&#945;&#47;&#946; MAPK inhibitor)</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May, Sanofi and Fulcrum Therapeutics entered into a license agreement for exclusive commercialization rights for losmapimod outside the US. Losmapimod is a selective p38&#945;&#47;&#946; mitogen-activated protein kinase (MAPK) small-molecule inhibitor in phase 3 for the treatment of </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">facioscapulohumeral muscular dystrophy</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (FSHD). FSHD is a chronic and progressive genetic muscular disorder that is characterized by significant muscle cell death and fat infiltration into muscle tissue. Fulcrum expects top-line data from the REACH phase 3 study during H2 2024 followed by regulatory submissions (clinical study identifier&#58; NCT05397470). Losmapimod has orphan drug designation in US, orphan designation in the EU, FDA fast track designation and FSHD is included on the list of rare diseases in China.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SAR447537</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (AAT fusion protein)</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May, the acquisition of Inhibrx, Inc. closed and added SAR447537 (formerly INBRX-101) to Sanofi&#8217;s rare disease phase 2 pipeline (ELEVAATE, clinical study identifier&#58; NCT05856331). SAR447537 is a human recombinant protein that holds the promise of allowing </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">alpha-1 antitrypsin deficiency</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (AATD) patients to achieve normalization of serum AAT levels with less frequent (monthly vs. weekly) dosing. AATD is an inherited rare disease characterized by low levels of AAT protein, predominantly affecting the lung with progressive deterioration of the tissue. SAR447537 may help to reduce inflammation and prevent further deterioration of lung function in affected individuals.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">riliprubart</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (C1s inhibitor)</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The development of riliprubart in </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">cold agglutinin disease</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, a rare autoimmune disorder characterized by the premature destruction of red blood cells (hemolysis), will not advance to phase 3 due to prioritization of other projects. As of now, the data confirmed pharmacological activity and a well-tolerated safety profile as in other indications.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SAR442501</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (FGFR3 Ab)</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The upreACH phase 2 study of SAR442501 in pediatric patients with </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">achondroplasia</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> will remain ongoing but is not expected to advance further.</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Neurology</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">frexalimab</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (CD40L mAb)</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">New phase 2 data showed significant reduction in plasma levels of neurofilament light chain (Nfl) after one year of treatment. Nfl is a biomarker of nerve cell damage that is typically elevated in people living with </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">multiple sclerosis</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (MS). These data were presented at the 10th Congress of the European Academy of Neurology in Helsinki, Finland.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">riliprubart</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (C1s inhibitor)</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">New phase 2 data from an ongoing study showed encouraging efficacy and safety for patients with </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">chronic inflammatory demyelinating polyneuropathy</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (CIDP). In part A results at 24 weeks, riliprubart showed promising disease-controlling benefits, with the majority of study patients improving or remaining stable, including those who experienced failure or inadequate response to standard-of-care treatment (SOC-refractory), and those having residual disability despite treatment with SOC (IVIg-treated). In part B, after approximately one year of treatment, riliprubart continued to show promising disease-controlling benefits across all enrolled cohorts. Additional results indicated that riliprubart may improve patient-reported fatigue and quality-of-life measurements as well as biomarkers associated with CIDP disease progression. These data were presented at the 2024 Peripheral Nerve Society Annual Meeting in Montreal, Canada.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Supported by the phase 2 data, two phase 3 studies, evaluating riliprubart in </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SOC-refractory CIDP</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (MOBILIZE, clinical study identifier&#58; NCT06290128) and </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">IVIg-treated CIDP</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (VITALIZE, clinical study identifier&#58; NCT06290141) are currently recruiting patients.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Oncology</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Sarclisa</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (isatuximab)</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA accepted for priority review the sBLA for Sarclisa in combination with bortezomib, lenalidomide and dexamethasone (VRd) for the treatment of patients with newly diagnosed (front-line, 1L) </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">multiple myeloma</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (MM) who are transplant-ineligible (TI). If approved, Sarclisa would be the first anti-CD38 medicine in combination with standard-of-care VRd in newly diagnosed patients ineligible for transplant, which would be the third indication in MM. The PDUFA date is September 27, 2024. Other regulatory submissions are currently under review in the EU, Japan, and China.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The potential new indication is supported by data presented at the American Society of Clinical Oncology 2024 Annual Meeting in Chicago, US. The IMROZ phase 3 study demonstrated that Sarclisa in combination with VRd followed by Sarclisa-Rd significantly reduced the risk of disease progression or death by 40%, compared to VRd followed by Rd.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SAR443579</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (trifunctional CD123 NK cell engager)</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The first patient enrolled in the dose-expansion part of a phase 2 study of SAR443579 as a monotherapy for the treatment of blood cancers with high unmet needs, including relapsed or refractory </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">acute myeloid leukemia</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (AML), B-cell acute lymphoblastic leukemia and high-risk myelodysplasia (clinical study identifier&#58; NCT05086315). SAR443579 is a CD123-NKp46-CD16 NK cell engager from a research collaboration with Innate Pharma and has FDA fast track designation for the treatment of AML.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Vaccines</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">MenQuadfi</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (meningococcal ACWY conjugate vaccine)</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The phase 3 study of MenQuadfi to protect infants from six weeks of age against invasive </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">meningococcal disease</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> caused by serogroups ACWY read out positively on safety and immunogenicity, supporting regulatory submission in the US in H2 2024 to extend the indication down to six weeks of age.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SP0230</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (meningococcal ABCWY vaccine)</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The phase 1&#47;2 study of SP0230, a pentavalent vaccine against invasive </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">meningococcal disease</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> caused by serogroups ABCWY in adults and adolescents enrolled the first patients (clinical study identifier&#58; NCT06128733). Data readout is expected in H2 2025.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SP0237</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (flu mRNA vaccine)</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A new phase 1&#47;2 study of SP0237 with an enhanced mRNA formulation against </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">flu</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> enrolled the first patients (clinical study identifier&#58; NCT06361875). This study is part of efforts to develop a next-generation, enhanced flu vaccine containing hemagglutinin and neuraminidase designed to offer improved efficacy and provide protection beyond flu.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SP0268</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (acne mRNA vaccine)</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The phase 1&#47;2 study of SP0268, a novel mRNA-based vaccine against </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">acne </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">enrolled the first patients (clinical study identifier&#58; NCT06316297). The vaccine, designed for adolescents and adults with moderate to severe acne, is the only therapeutic vaccine for acne in development.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Anticipated major upcoming pipeline milestones</font></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:13.006%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.933%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#330e74;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#330e74;border-left:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Medicine&#47;vaccine</font></td><td colspan="3" style="background-color:#330e74;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Indication</font></td><td colspan="3" style="background-color:#330e74;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Description</font></td></tr><tr style="height:15pt"><td colspan="3" rowspan="19" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:115%">H2 2024</font></td><td colspan="3" rowspan="5" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Dupixent</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">COPD</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Regulatory decision (US)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">CRSwNP adolescents</font></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Regulatory decision (US)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">EoE children</font></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Regulatory decision (EU)</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">CSU (Study C)</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 3 data<br>Regulatory submission (US)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Bullous pemphigoid (BP)</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 3 data</font></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">rilzabrutinib</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">ITP</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Regulatory submission (US, EU)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">IgG4-related disease</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 2 data</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Warm autoimmune hemolytic anemia</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 2 data</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">amlitelimab</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Asthma</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 2 data</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">duvakitug</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Inflammatory bowel disease</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 2 data</font></td></tr><tr style="height:15pt"><td colspan="3" rowspan="4" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">tolebrutinib</font></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Relapsing MS</font></td><td colspan="3" rowspan="2" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 3 data<br>Regulatory submission (US)</font></td></tr><tr style="height:15pt"><td colspan="12" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Non-relapsing secondary progressive MS</font></td><td colspan="3" rowspan="2" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 3 data<br>Regulatory submission (US)</font></td></tr><tr style="height:15pt"><td colspan="12" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">losmapimod</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">FSHD</font></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 3 data (by partner)</font></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Sarclisa</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">MM, 1L TI (IMROZ)</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Regulatory decision (US)</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">MM, 1L transplant eligible (TE) (HD7 study)</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 3 data<br>Regulatory submission (EU)</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">MM, relapsed&#47;refractory (R&#47;R) (IRAKLIA study), subcutaneous</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 3 data</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">MenQuadfi</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Meningitis six weeks+</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Regulatory submission (US)</font></td></tr></table></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:13.006%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.933%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.164%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:115%">H1 2025</font></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Dupixent</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">COPD</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Regulatory decision (JP, CN)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">BP</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Regulatory submission (US)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">CSU</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Regulatory decision (EU)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">amlitelimab</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Hidradenitis suppurativa (HS)</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 2 data</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">TNFa&#47;OX40L</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">HS</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 2 data</font></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">IRAK4 degrader</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">HS</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 2 data</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">AD</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 2 data</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">fitusiran</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Hemophilia A&#47;B</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Regulatory decision (US)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">losmapimod</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">FSHD</font></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Regulatory submission (EU)</font></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Sarclisa</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">MM, 1L TI (IMROZ)</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Regulatory decision (EU, JP, CN)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">MM, 1L TE (HD7)</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Regulatory submission (US)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">MM, R&#47;R (IRAKLIA), subcutaneous</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Regulatory submission (US, EU)</font></td></tr><tr style="height:24pt"><td colspan="3" rowspan="12" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:115%">H2 2025</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">itepekimab</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">COPD</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 3 data<br>Regulatory submission (US, EU)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">lunsekimig</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Asthma</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 2 data</font></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Oral TNFR1si</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Psoriasis</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 2 data</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Rheumatoid arthritis</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 2 data</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">AAT recombinant Fc </font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Alpha-1 antitrypsin deficiency</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 2 data</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">fitusiran</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Hemophilia A&#47;B</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Regulatory decision (CN)</font></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">venglustat</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Fabry disease</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 3 data</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Gaucher disease type 3</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 3 data</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">tolebrutinib</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Primary progressive MS</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 3 data<br>Regulatory submission (US)</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">SP0087</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Rabies</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 3 data<br>Regulatory submission (US)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">SP0230</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Meningitis</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 2 data</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">SP0256</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">RSV older adults</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:150%">Phase 2 data</font></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">An update of the Sanofi pipeline as of June 30, 2024, is available at&#58; https&#58;&#47;&#47;www.sanofi.com&#47;en&#47;our-science&#47;our-pipeline.</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_37"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:16pt;font-style:italic;font-weight:700;line-height:115%">Opella (Consumer Healthcare)</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:21.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net sales (&#8364; million)</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q2 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Change </font></div><div style="text-align:right"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">at CER</font></div></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">H1 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Change </font></div><div style="text-align:right"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">at CER</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Seasonal symptoms &#38; pain relief </font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">523&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+0.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,216&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-0.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Wellness brands </font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">598&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+16.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,258&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+21.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Others</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+16.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">357&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+4.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,306</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+9.6</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,831</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+9.2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Opella sales were &#8364;1,306 million and increased by 9.6% with organic sales growth of 2.4%. Growth was enhanced by the acquisition of Qunol (c.7%) and industrial sales transferred from Biopharma in January 2024 (c.2%) but tempered by divestments (c.2%) and Q1 phasing. In North America, growth benefited from Qunol and some Focus brands, such as Dulcolax while sales in Europe were lower due to a weak flu season and a high comparison for the key brand Doliprane. In H1 2024, sales increased by 9.2%, driven by Qunol (c.6%) and industrial sales (c.2%) and offset by divestments (c.2%). As a result, organic growth was 3.8%.</font></div><div id="i439f5d1857c344f7b532f54d2ef05291_40"></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Opella business operating income</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Opella BOI was &#8364;267 million and decreased by 15.5% mainly driven by increased SG&#38;A in anticipation of the communicated Opella separation and a lower gross margin reflecting a greater Vitamins, Minerals and Supplements sales contribution following the Qunol integration and adverse mix. Furthermore, there were lower divestment gains relative to last year, which benefited from the significant portfolio transformation. At CER, BOI decreased by 9.8%. The ratio of BOI to net sales decreased by 5.4pp to 20.4% (down by 4.6pp to 21.2% at CER). In H1 2024, BOI was &#8364;739 million and decreased by 13.1%. At CER, BOI decreased by 1.8%. The ratio of BOI to net sales decreased by 5.2pp to 26.1% (down by 3.2pp to 28.1% at CER).</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the intent to separate Opella at the earliest in Q4 2024 announced on October 27, 2023, Opella has prepared audited combined financial statements in accordance with IFRS. Please see Appendix 11 for more.</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_43"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:115%">Corporate Social Responsibility update at the end of Q2 2024</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Environment</font></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Sanofi&#8217;s Planet care strategy&#58; concrete actions towards net zero emissions</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For several years, Sanofi has been implementing its Planet care strategy, aiming for net zero greenhouse gas emissions across all scopes by 2045, with an intermediate carbon neutrality milestone in 2030. The company has already achieved a 43% decrease in scopes 1 and 2 emissions, targeting 55% by 2030, and a 10% reduction in scope 3 emissions, aiming for 30% by 2030.</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For scopes 1 and 2, Sanofi is focusing on the following key decarbonization levers to reach its 2030 targets&#58;</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Energy decarbonization&#58; increasing renewable electricity share from 11% in 2019 to 85% in Q2 2024 through solar panels, power purchase agreements (PPA), and guarantees of origin. In France, three PPAs have been signed with the Compagnie Nationale du Rh&#244;ne, for a volume of 83 GWh&#47;year over a twenty-year period, covering 19% of Sanofi&#8217;s annual electricity needs in France. Sanofi also has a renewable electricity PPA in Mexico to supply energy to its three Mexican sites and is exploring PPA opportunities in other European countries and the US. Sanofi is also incorporating biomethane and biomass to reduce reliance on fossil fuels.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Energy reduction and efficiency&#58;</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">aiming to reduce energy consumption by 15% in existing facilities by 2025 compared to 2021.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Eco-fleet&#58; converting Sanofi&#8217;s car fleet to an 80% eco-fleet (biofuel, hybrid and electric vehicles) by 2030.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Refrigerant gas&#58; replacing existing refrigerant gases with lower global warming potential alternatives and improving leak prevention.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For scope 3, the majority of greenhouse gas (GHG) emissions come from raw materials and subcontracting, thus representing the primary target for the decarbonization efforts. Sanofi's eco-design program aims to integrate environmental criteria from product design. The company is seeking less carbon-intensive suppliers and considering the country of manufacture in supplier selection. For example, sourcing of a highly carbon-intensive raw material from China has been reduced from over 50% of the volume in 2019 to just 5% in 2024, with a shift to European suppliers. Additionally, Sanofi is implementing comprehensive measures to reduce emissions across multiple areas&#58; addressing business travel and employee commuting through remote work and low-carbon travel options, shifting from air to sea freight for product transport, setting ambitious waste management goals, and focusing on energy use. </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Community-centric carbon offsetting</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By 2045, the residual emissions will remain under 10% of the 2019 total emissions, in line with the Science Based Targets Initiative net zero commitment. Understanding that not all emissions can be immediately abated, Sanofi also created a community-focused carbon offsetting program. These initiatives not only compensate for residual emissions but also generate substantial environmental, social, and economic benefits in local communities.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sanofi's carbon offsetting program has invested around &#8364;60 million in four strategic projects since 2019. These include the Sundari Mangrove Restoration project in India, which has restored 380 hectares of mangroves since 2022 with plans to rehabilitate an additional 3,750 hectares. In Kenya, 18,250 energy-saving biomass cookstoves have been distributed. A new project in Mozambique aims to rehabilitate 1,040 water handpumps, reducing the need to burn biomass for boiling water and providing clean water access to 312,000 people.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Business resilience to environmental changes</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sanofi is also actively working to strengthen its business resilience to environmental challenges which could impact its ability to support patients across the world. For instance, Sanofi has undertaken an end-to-end internal study, in order to better identify the associations between environmental change impacts with its portfolio and pipeline of products. </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Among its conclusions, the study reported that 70% of Sanofi&#8217;s portfolio indications and 78% of the R&#38;D pipeline indications are already targeting diseases impacted by at least one environmental hazard (air pollution, shift in seasonal patterns, chemical pollution, extreme temperatures, water pollution).</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ESG ratings</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sanofi has been ranked among the world&#8217;s most sustainable companies of 2024 by TIME Magazine, ranking 7th overall and 1st in the pharma industry. This ranking is based on the recognition of the </font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">comprehensive ESG disclosures, the ambitious commitments, alignment with key international standards and initiatives and the performance across a large selection of ESG ratings.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Latest Sanofi ESG rankings&#58;</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><img alt="image1.jpg" src="image1.jpg" style="height:297px;margin-bottom:5pt;vertical-align:text-bottom;width:716px"></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_46"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:115%">Q2 and H1 2024 financial results</font></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Business net income</font><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:7.8pt;font-weight:700;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">2</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net sales</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> were &#8364;10,745 million and increased by 7.8% (up by 10.2% at CER). In H1 2024, net sales were &#8364;21,209 million and increased by 5.1% (up by 8.4% at CER).</font></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Other revenues</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> were &#8364;635 million and decreased by 11.4% (down by 10.3% at CER), including VaxServe sales of non-Sanofi products of &#8364;447 million (down by 0.7% at CER). In H1 2024, other revenues were &#8364;1,289 million and decreased by 5.1% (down by 0.8% at CER), including VaxServe sales of non-Sanofi products of &#8364;854 million (up by 2.3% at CER).</font></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Gross profit</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> was &#8364;7,974 million and increased by 7.5% (up by 10.4% at CER). The gross margin decreased by 0.3pp to 74.2% (up by 0.1pp to 74.6% at CER). The higher gross margin at CER benefited from overall improved product and country mix in Biopharma and the reducing impact from the loss of exclusivity for Aubagio. In H1 2024, the gross profit was &#8364;15,668 million and increased by 3.1% (up by 7.3% at CER). The gross margin decreased by 1.4pp to 73.9% (down by 0.8pp to 74.5% at CER). </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Research and Development </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">expenses were &#8364;1,704 million and increased by 4.5%. At CER, R&#38;D expenses increased by 5.5%, reflecting increased activity in mid- and late-stage development offset by a one-time reimbursement of half of past ALTUVIIIO development expenses. The ratio of R&#38;D to sales decreased by 0.5pp to 15.9%. In H1 2024, R&#38;D expenses were &#8364;3,423 million and increased by 7.2% (up by 8.6% at CER).The ratio of R&#38;D to sales increased by 0.3pp to 16.1%.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Selling, general and administrative</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> expenses were &#8364;2,655 million and increased by 3.1% (up by 4.9% at CER), substantially less than sales growth. The ratio of SG&#38;A to sales decreased by 1.1pp to 24.7%. In H1 2024, SG&#38;A expenses were </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:line-through">&#8364;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,260 million and increased by 1.5% (up by 3.9% at CER). The ratio of SG&#38;A to sales decreased by 0.9pp to 24.8%.</font></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total operating expenses</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> were &#8364;4,359 million and increased by 3.7% (up by 5.2% at CER). In H1 2024, operating expenses were &#8364;8,683 million and increased by 3.7% (up by 5.7% at CER).</font></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Other current operating income net of expenses</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> were -&#8364;831 million compared to -&#8364;501 million in Q2 2023. Other current operating income net of expenses included an expense of &#8364;1,012 million from the share of profit to Regeneron from the monoclonal antibodies alliance, the share of profit paid by Regeneron towards development costs and the reimbursement of commercialization-related expenses incurred by Regeneron compared to an expense of &#8364;744 million in Q2 2023. This line also included &#8364;68 million of capital gains from divestments of medicines&#47;portfolio streamlining, compared to &#8364;92million in Q2 2023. Sanofi expects the amount of capital gains from divestments of medicines&#47;portfolio streamlining to exceed &#8364;500 million in 2024. In H1 2024, expenses from the monoclonal antibodies alliance with Regeneron were &#8364;1,837 million compared to &#8364;1,418 million in H1 2023 (see appendix 7 for further details).</font></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Share of profit from associates </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">was &#8364;31 million compared to &#8364;22 million in Q2 2023 and included the share of US profit related to Vaxelis. In H1 2024, share of profit from associates was &#8364;75 million compared to &#8364;55 million in H1 2023.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Business operating income</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> was &#8364;2,813 million and increased by 3.2%. At CER, BOI increased by 8.3%. The ratio of BOI to net sales decreased by 1.2pp to 26.2% (down by 0.5pp at CER). In H1 2024, business operating income was &#8364;5,656 million and decreased by 6.7% (up by 1.4% at CER). The ratio of BOI to net sales decreased by 3.3pp to 26.7% (down by 1.9pp at CER).</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net financial expenses</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> were &#8364;86 million compared to &#8364;42 million in Q2 2023, reflecting increased net debt and higher interest rates. In H1 2024, net financial expenses were &#8364;129 million compared to &#8364;49 million in H1 2023.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">The</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">effective tax rate</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> increased to 21.0% from 19.0% in Q2 2023 and H1 2023. Sanofi expects its effective tax rate to be around 21% in 2024.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Business net income</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> was &#8364;2,161 million and decreased by 0.7% (up by 4.0% at CER). The ratio of business net income to net sales decreased by 1.7pp to 20.1% (down by 1.2pp at CER). In H1 2024, business net income was &#8364;4,380 million and decreased by 10.2% (down by 2.3% at CER). The ratio of business net income to net sales decreased by 3.5pp to 20.7% (down by 2.4pp at CER).</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Business earnings per share</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(EPS) was &#8364;1.73, down by 0.6% on a reported basis (up by 4.0% at CER). The average number of shares outstanding was 1,250.1 million compared to 1,250.6 million in Q2 2023. In H1 2024, business earnings per share was 3.51, down by 10.0% on a reported basis (down by 2.3% at CER). The average number of shares outstanding was 1,249.4 million compared to 1,249.9 million in H1 2023.</font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">S</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">ee Appendix 3 for Q2 and H1 2024 consolidated income statement&#59; see Appendix 9 for definitions of financial indicators, and Appendix 4 for reconciliation of IFRS net income reported to business net income</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_49"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Reconciliation of IFRS net income reported to business net income (see Appendix 4)</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In H1 2024, the IFRS net income was &#8364;2,246 million. The main items excluded from the business net income were&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.19pt">An amortization charge of &#8364;1,061 million related to intangible assets measured at their acquisition-date fair values for &#8364;1,023 million (mainly Bioverativ &#8364;320 million, Genzyme &#8364;114 million, Provention Bio &#8364;108 million, Boehringer Ingelheim consumer healthcare business &#8364;90 million, Ablynx &#8364;84 million, Kadmon &#8364;82 million, Beyfortus &#8364;58 million and Qunol &#8364;40 million) and to intangible assets from separate acquisitions &#8211; measured initially at acquisition cost (licenses&#47;products) &#8364;38 million. These items had no cash impact.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.55pt">A net reversal of impairment losses of &#8364;371 million of which &#8364;354 million recorded in Q2 2024 mainly due to an increase in the expected recoverable amounts of certain marketed products and other rights in the Biopharma segment.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.55pt">Restructuring costs and similar items of &#8364;1,331 million mainly related to redundancy plans announced during H1 2024 and separation costs of the Opella business.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.55pt">Other gains and losses, and litigation charge of &#8364;442 million mainly comprising a provision recognized in respect of the litigation related to Plavix (clopidogrel) in the US State of Hawaii.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.55pt">A financial charge of &#8364;176 million related to the remeasurement of expected future royalty of Beyfortus US sales.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.55pt">A &#8364;691 million tax effect arising from the items listed above, mainly comprising &#8364;193 million of deferred taxes generated by amortization of intangible assets and &#8364;408 million associated with restructuring costs and similar items (see Appendix 4).</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.55pt">A loss of &#8364;88 million corresponding to the equity stake in EUROAPI.</font></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Capital allocation</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In H1 2024, free cash flow before restructuring, acquisitions and disposals amounted to &#8364;1,380 million, after negative change of net working capital (-&#8364;2,419 million), notably including the decrease of US rebates provisions (&#8364;1,279 million) following the decision to reduce the Lantus list price effective January 1, 2024, and capital expenditures (-&#8364;980 million). After acquisitions</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (-&#8364;545 million), proceeds from disposals</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (&#8364;568 million) and payments related to restructuring and similar items (-&#8364;858 million), </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">free cash flow</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> was &#8364;545 million. After the acquisition of Inhibrx Inc. (-&#8364;1,884 million) and the dividend paid by Sanofi (-&#8364;4,704 million), net debt increased from &#8364;7,793 million on December 31, 2023 to &#8364;15,112 million on June 30, 2024 (amount net of &#8364;6,795 million cash and cash equivalents).</font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Not exceeding &#8364;500 million per transaction (inclusive of all payments related to the transaction).</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:120%">N</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">on-IFRS financial measure (definition in Appendix 9).</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_52"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Forward-looking statements</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:115%">This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, business transformations, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words &#8220;expects&#8221;, &#8220;anticipates&#8221;, &#8220;believes&#8221;, &#8220;intends&#8221;, &#8220;estimates&#8221;, &#8220;plans&#8221;, &#8220;potential&#8221;, &#8220;outlook&#8221;, &#8220;guidance&#8221; and similar expressions. Although Sanofi&#8217;s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi&#8217;s ability to benefit from external growth opportunities, to complete capital markets or other transactions and&#47;or obtain regulatory clearances, risks associated with developing standalone businesses, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and capital market conditions, cost containment initiatives and subsequent changes thereto, and the impact that pandemics, political disruption or armed conflicts or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under &#8220;Risk Factors&#8221; and &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; in Sanofi&#8217;s annual report on Form 20-F for the year ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.</font></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:115%">All Sanofi trademarks mentioned in this document are protected.</font></div><div id="i439f5d1857c344f7b532f54d2ef05291_55"></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:115%">Appendices</font></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:12.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a href="#i439f5d1857c344f7b532f54d2ef05291_58" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">Appendix&#160;1&#58;</a>&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2 and H1 2024<a href="#i439f5d1857c344f7b532f54d2ef05291_58" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none"> sales by medicine&#47;vaccine&#47;business and geographic region </a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a href="#i439f5d1857c344f7b532f54d2ef05291_64" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">Appendix 2&#58;</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2<a href="#i439f5d1857c344f7b532f54d2ef05291_64" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none"> </a><a href="#i439f5d1857c344f7b532f54d2ef05291_64" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">and H1 </a><a href="#i439f5d1857c344f7b532f54d2ef05291_64" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">2024 business net income statement</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a href="#i439f5d1857c344f7b532f54d2ef05291_70" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">Appendix 3&#58;</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q2 and H1 <a href="#i439f5d1857c344f7b532f54d2ef05291_70" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">2024 consolidated income statement</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a href="#i439f5d1857c344f7b532f54d2ef05291_73" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">Appendix 4&#58;</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a href="#i439f5d1857c344f7b532f54d2ef05291_73" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">Reconciliation of IFRS net income reported to business net income</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:174%"><a href="#i439f5d1857c344f7b532f54d2ef05291_76" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:174%;text-decoration:none">Appendix 5&#58;</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:174%"><a href="#i439f5d1857c344f7b532f54d2ef05291_76" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:174%;text-decoration:none">Change in net debt</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Appendix 6&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Simplified consolidated balance sheet</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Appendix 7&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current operating income net of expenses &#8211; Regeneron Alliances</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Appendix 8&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency sensitivity</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a href="#i439f5d1857c344f7b532f54d2ef05291_88" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">Appendix </a>9&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a href="#i439f5d1857c344f7b532f54d2ef05291_88" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">Definitions of non-IFRS financial indicators</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Appendix 10&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CSR dashboards</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Appendix 11&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Opella</font></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><font><br></font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Media Relations</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Sandrine Guendoul </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#124; + 33 6 25 09 14 25 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">sandrine.guendoul&#64;sanofi.com</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Evan Berland</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> &#124; +1 215 432 0234 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">evan.berland&#64;sanofi.com</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Nicolas Obrist </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#124; + 33 6 77 21 27 55 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">nicolas.obrist&#64;sanofi.com</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:115%">L&#233;o Le Bourhis </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#124; + 33 6 75 06 43 81 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">leo.lebourhis&#64;sanofi.com </font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Victor Rouault </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#124; + 33 6 70 93 71 40 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">victor.rouault&#64;sanofi.com</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Timothy Gilbert </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#124; + 1 516 521 2929 &#124; </font><font style="color:#8213e8;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">timothy.gilbert&#64;sanofi.com</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Investor Relations</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Thomas Kudsk Larsen</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> &#124; +44 7545 513 693 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">thomas.larsen&#64;sanofi.com</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Aliz&#233; Kaisserian</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> &#124; +33 6 47 04 12 11 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">alize.kaisserian&#64;sanofi.com</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Arnaud Del&#233;pine </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#124; + 33 6 73 69 36 93 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">arnaud.delepine&#64;sanofi.com</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Felix Lauscher </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#124; + 1 908 612 7239 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">felix.lauscher&#64;sanofi.com</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Keita Browne </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#124; + 1 781 249 1766 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">keita.browne&#64;sanofi.com</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Nathalie Pham </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#124; + 33 7 85 93 30 17 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">nathalie.pham&#64;sanofi.com</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Tarik Elgoutni </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#124; + 1 617 710 3587 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">tarik.elgoutni&#64;sanofi.com</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Thibaud Ch&#226;telet </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#124; + 33 6 80 80 89 90 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">thibaud.chatalet&#64;sanofi.com</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_58"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Appendix 1&#58; Q2 2024 net sales by medicine&#47;vaccine&#47;business and geographic region</font></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:21.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.289%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q2 2024 (&#8364; million)</font></td><td colspan="3" style="background-color:#23004c;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Sales</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">% CER</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">% reported</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">United States</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">% CER</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">% CER</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Rest of World</font></td><td colspan="3" style="background-color:#23004c;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">% CER</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Dupixent</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,303</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+29.2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+28.9</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,407</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+23.8</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">399</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+29.0</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">497</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+60.8</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Nexviazyme&#47;Nexviadyme</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">168</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+66.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+63.1&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">89</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+31.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">52</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+112.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">27</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+172.7&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sarclisa</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">121</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+36.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+28.7&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">51</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+30.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">33</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+17.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">37</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+63.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">ALTUVIIIO</font></div></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">158</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+772.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+777.8&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">144</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+787.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">14</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+650.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Rezurock</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">114</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+52.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+54.1&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">104</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+39.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">7</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+600.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-400.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Cablivi</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">54</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-1.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-1.8&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">28</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-6.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">20</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-9.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">6</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+100.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Xenpozyme</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">37</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+85.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+85.0&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">19</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+72.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">12</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+71.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">6</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+200.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Enjaymo</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">26</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+58.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+52.9&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">15</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+50.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">4</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+33.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">7</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+100.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Tzield</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">11</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+83.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+83.3&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">10</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+66.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Total Pharma launches </font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">689</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+80.4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+78.0</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">460</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+80.2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">129</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+51.2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">100</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+133.3</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Toujeo</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">313</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+11.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+7.6&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">61</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+15.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">122</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+8.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">130</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+11.1&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Lantus</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">398</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+21.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+12.7&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">158</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+225.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">83</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-11.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">157</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-11.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Lovenox</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">256</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-4.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-9.9&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+200.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">150</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-3.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">103</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-7.8&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Plavix</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">235</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+2.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-2.1&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-50.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">23</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-4.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">211</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+3.3&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Fabrazyme</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">273</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+12.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+9.2&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">135</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+4.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">66</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+10.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">72</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+30.6&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Myozyme</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">180</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-11.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-13.5&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">62</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-6.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">69</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-19.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">49</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-5.4&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Alprolix</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">141</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+3.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+4.4&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">116</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+6.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">25</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-7.4&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Cerezyme</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">193</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+19.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+6.6&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">48</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">61</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+1.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">84</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+45.9&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Aubagio</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">107</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-49.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-50.5&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">55</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-26.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">43</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-66.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">9</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-8.3&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Praluent</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">126</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+38.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+38.5&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">87</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+22.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">39</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+95.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Thymoglobulin</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">129</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-0.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-3.7&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">84</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+3.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">9</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">36</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-8.9&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Aprovel</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">108</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+4.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+3.8&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">19</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-5.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">87</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+7.3&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Kevzara</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">102</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+12.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+10.9&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">60</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+13.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">30</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+11.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">12</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+7.1&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Eloctate</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">105</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-18.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-19.2&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">65</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-34.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">40</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+31.3&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Multaq</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">84</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+3.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+5.0&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">75</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+4.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-25.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">6</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+20.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Jevtana</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">73</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-24.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-24.7&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">53</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-28.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-50.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">18</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-5.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Cerdelga</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">82</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+7.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+6.5&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">44</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+2.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">33</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+10.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+50.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Aldurazyme</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">78</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+15.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+8.3&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">18</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+12.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">22</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+4.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">38</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+22.9&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Soliqua&#47;iGlarLixi</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">56</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+34.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+30.2&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">18</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+38.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">12</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+33.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">26</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+33.3&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Fasturtec</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">44</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-2.2&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">29</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-9.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">12</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+20.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+25.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Mozobil</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">21</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-69.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-69.6&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-95.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">12</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-36.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">7</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-12.5&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Others </font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1,080</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-8.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-12.3&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">99</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-11.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">323</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-4.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">658</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-9.3&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Industrial Sales</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">121</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-16.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-16.6&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-50.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">118</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-14.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-50.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Total other medicines</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,305</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">-2.1</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">-5.8</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,190</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+1.3</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,299</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">-8.5</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,816</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+0.4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharma</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,297</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+12.8</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+10.4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,057</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+20.2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,827</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+0.7</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,413</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+11.5</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Influenza vaccines</font></div></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">115</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+20.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+16.2&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">11</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-15.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">29</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-9.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">75</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+46.3&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Polio&#47;Pertussis&#47;Hib vaccines &#38; Boosters</font></div></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">712</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-5.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-7.2&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">147</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-4.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">139</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+13.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">426</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-9.9&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">RSV (Beyfortus)</font></div></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">18</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">16</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Meningitis, Travel and endemic vaccines</font></div></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">296</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+0.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-0.3&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">164</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-4.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">49</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+31.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">83</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-3.4&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Vaccines</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,142</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">-4.8</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">-6.6</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">324</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">-4.2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">217</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">-13.5</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">601</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">-1.7</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Biopharma</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,439</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+10.3</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+8.0</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,381</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+18.0</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,044</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">-1.0</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,014</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+8.7</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Opella</font></div></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,306</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+9.6</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+6.6</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">370</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+45.8</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">358</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">-8.7</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">578</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+6.2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company</font></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-left:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,745</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+10.2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+7.8</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,751</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+19.8</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,402</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">-2.2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,592</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+8.3</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-right:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td></tr></table></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_61"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Appendix 1&#58; H1 2024 net sales by medicine&#47;vaccine and geographic region </font></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:21.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.289%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">H1 2024 (&#8364; million)</font></td><td colspan="3" style="background-color:#23004c;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Sales</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">% CER</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">% reported</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">United States</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">% CER</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">% CER</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Rest of World</font></td><td colspan="3" style="background-color:#23004c;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">% CER</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Dupixent</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,138</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">+27.1</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">+25.8</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,437</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">+20.4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">770</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">+31.2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">931</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">+63.9</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Nexviazyme&#47;Nexviadyme</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">320</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+79.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+73.9&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">174</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+41.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">95</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+126.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">51</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+221.1&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sarclisa</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">227</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+32.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+25.4&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">100</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+31.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">64</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+14.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">63</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+55.1&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">ALTUVIIIO</font></div></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">280</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+1378.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+1373.7&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">259</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+1423.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">21</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+1000.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Rezurock</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">207</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+46.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+46.8&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">188</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+34.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">12</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+500.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">7</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-800.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Cablivi</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">113</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+0.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">60</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+3.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">43</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-12.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">10</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+83.3&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Xenpozyme</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">72</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+92.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+89.5&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">37</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+76.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">24</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+60.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">11</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+500.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Enjaymo</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">55</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+72.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+66.7&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">30</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+57.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">10</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+150.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">15</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+70.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Tzield</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">21</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+250.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+250.0&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">20</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+233.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="border-right:2pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Total Pharma launches </font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,295</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">+85.0</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">+81.1</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">868</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">+88.7</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">249</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">+48.2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">178</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">+136.8</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Toujeo</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">634</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+14.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+9.3&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">117</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-0.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">241</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+9.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">276</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+27.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Lantus</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">758</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+0.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-5.3&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">270</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+50.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">175</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-8.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">313</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-16.1&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Lovenox</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">518</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-9.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-14.7&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">6</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+20.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">305</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-7.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">207</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-12.5&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Plavix</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">473</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+4.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-0.6&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-25.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">46</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-4.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">424</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+5.7&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Fabrazyme</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">526</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+10.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+6.0&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">261</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+4.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">129</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+5.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">136</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+26.8&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Myozyme</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">371</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-12.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-14.9&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">122</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-9.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">145</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-20.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">104</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-4.2&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Alprolix</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">271</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+5.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+4.2&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">225</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+4.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">46</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+6.7&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Cerezyme</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">407</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+21.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+8.0&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">96</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+2.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">126</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+5.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">185</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+44.2&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Aubagio</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">209</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-66.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-67.1&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">96</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-72.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">95</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-61.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">18</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-36.8&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Praluent</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">247</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+31.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+30.7&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-100.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">170</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+19.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">77</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+64.6&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Thymoglobulin</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">246</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+5.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+1.2&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">157</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+5.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">19</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">70</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+6.7&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Aprovel</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">213</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+1.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-0.5&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-33.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">37</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-7.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">174</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+4.7&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Kevzara</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">189</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+17.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+14.5&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">105</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+19.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">59</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+9.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">25</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+25.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Eloctate</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">191</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-21.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-23.0&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">127</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-30.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">64</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+4.6&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Multaq</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">162</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-1.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-1.2&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">145</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-1.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">6</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-14.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">11</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+10.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Jevtana</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">141</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-18.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-19.9&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">100</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-21.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">4</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-50.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">37</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Cerdelga</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">165</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+11.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+10.0&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">90</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+8.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">65</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+10.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">10</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+50.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Aldurazyme</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">161</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+14.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+7.3&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">36</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+5.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">45</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+7.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">80</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+21.6&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Soliqua&#47;iGlarLixi</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">114</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+11.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+7.5&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">38</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-15.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">23</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+35.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">53</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+29.5&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Fasturtec</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">86</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-3.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-4.4&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">56</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-3.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">23</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">7</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-11.1&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Mozobil</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">46</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-65.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-66.2&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-94.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">28</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-22.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">13</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-12.5&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Others </font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2,220</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-7.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-11.4&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">185</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-13.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">658</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-6.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1,377</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-6.8&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Industrial Sales</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">278</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-0.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-0.7&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-33.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">274</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+3.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-84.6&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Total other medicines</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,626</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">-5.1</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">-9.0</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,245</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">-12.6</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,673</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">-7.0</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,708</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">+1.0</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharma</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,059</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+9.6</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+6.5</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,550</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+12.5</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,692</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+1.7</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,817</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+11.6</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Influenza vaccines</font></div></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">188</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+27.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+16.0&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">16</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-15.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">30</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-18.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">142</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+50.9&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Polio&#47;Pertussis&#47;Hib vaccines &#38; Boosters</font></div></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1,348</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-2.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-5.6&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">311</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-10.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">248</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+7.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">789</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-2.6&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">RSV (Beyfortus)</font></div></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">200</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">116</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">7</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">77</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Meningitis, Travel and endemic vaccines</font></div></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">582</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+3.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+2.3&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">301</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+3.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">97</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">+34.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">184</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-5.8&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Vaccines</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,319</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+0.3</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">-3.0</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">744</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+13.1</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">382</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">-33.0</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,193</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+9.3</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Biopharma</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,378</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+8.3</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+5.2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,294</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+12.5</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,074</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">-3.0</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,010</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+11.1</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Opella</font></div></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,831</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+9.2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+4.1</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">773</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+24.4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">808</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">-4.0</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,250</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+10.6</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company</font></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-left:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,209</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+8.4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+5.1</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,067</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+13.4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,882</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">-3.2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,260</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+11.0</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-right:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td></tr></table></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_64"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Appendix 2&#58; Business net income statement</font></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.860%"><tr><td style="width:1.0%"></td><td style="width:17.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.687%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Second quarter 2024</font></td><td colspan="9" style="background-color:#23004c;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Biopharma</font></td><td colspan="9" style="background-color:#23004c;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Opella</font></div><div style="text-align:center"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consumer Healthcare</font></div></td><td colspan="9" style="background-color:#23004c;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</font></div></td><td colspan="9" style="background-color:#23004c;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total group</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8364; million</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Q2 2024</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Q2 2023</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">Change</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Q2 2024</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Q2 2023</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">Change</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Q2 2024</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Q2 2023</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">Change</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Q2 2024</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Q2 2023</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net sales</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">9,439</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">8,740</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">8.0%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">1,306</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">1,225</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">6.6%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#8212;%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">10,745</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">9,965</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">7.8%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">618</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">705</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-12.3%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">17</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">12</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">41.7%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">&#8212;%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">635</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">717</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-11.4%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of Sales</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2,894)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2,819)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">2.7%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(512)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(441)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">16.1%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-100.0%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3,406)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3,263)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">4.4%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">As % of net sales</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(30.7%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(32.3%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(39.2%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(36.0%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(31.7%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(32.7%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross profit</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">7,163</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">6,626</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">8.1%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">811</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">796</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">1.9%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(3)</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">-100.0%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">7,974</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">7,419</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">7.5%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">As % of net sales</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">75.9%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">75.8%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">62.1%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">65.0%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">74.2%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">74.5%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1,656)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1,572)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">5.3%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(48)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(58)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-17.2%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">&#8212;%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1,704)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1,630)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">4.5%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">As % of net sales</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(17.5%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(18.0%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(3.7%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(4.7%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(15.9%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(16.4%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2,167)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2,124)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">2.0%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(488)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(452)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">8.0%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-100.0%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2,655)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2,575)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">3.1%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">As % of net sales</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(23.0%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(24.3%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(37.4%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(36.9%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(24.7%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(25.8%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current operating income&#47;expenses</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(800)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(511)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(11)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">29</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(20)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(19)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(831)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(501)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit&#47;loss of associates* and joint ventures</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">28</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">18</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">31</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">22</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</font></div></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(6)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(9)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Business operating income</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2,566</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2,431</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">5.6%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">267</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">316</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">-15.5%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(20)</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(21)</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">-4.8%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2,813</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2,726</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">3.2%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">As % of net sales</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">27.2%</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">27.8%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">20.4%</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">25.8%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">26.2%</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">27.4%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial income and expenses</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(86)</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(42)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax expenses</font></td><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(566)</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(507)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Tax rate**</font></td><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">21.0%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">19.0%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Business net income</font></td><td colspan="9" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2,161</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2,177</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">-0.7%</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">As % of net sales</font></td><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">20.1%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">21.8%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Business earnings &#47; share(in euros)***</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">1.73</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">1.74</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">-0.6%</font></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">* Net of tax.</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">** Determined on the basis of Business income before tax, associates, and non-controlling interests.</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">*** Based on an average number of shares outstanding of 1,250.1 million in the second quarter of 2024 and 1,250.6 million in the second quarter of 2023.</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">19</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_67"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:4.49pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.834%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First half 2024</font></td><td colspan="9" style="background-color:#23004c;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Biopharma</font></td><td colspan="9" style="background-color:#23004c;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Opella</font></div><div style="text-align:center"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consumer Healthcare</font></div></td><td colspan="9" style="background-color:#23004c;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</font></div></td><td colspan="9" style="background-color:#23004c;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total group</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8364; million</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">6M 2024</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:120%">6M 2023</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">Change</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">6M 2024</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:120%">6M 2023</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">Change</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">6M 2024</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:120%">6M 2023</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">Change</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">6M 2024</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:120%">6M 2023</font></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">Change</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net sales</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">18,378</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">17,467</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">5.2%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2,831</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2,720</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">4.1%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#8212;%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">21,209</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">20,187</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">5.1%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1,257</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1,331</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-5.6%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">32</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">27</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">18.5%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">&#8212;%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1,289</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1,358</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-5.1%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of Sales</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(5,756)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(5,388)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">6.8%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1,077)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(949)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">13.5%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(5)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-160.0%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(6,830)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(6,342)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">7.7%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">As % of net sales</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(31.3%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(30.8%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(38.0%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(34.9%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(32.2%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(31.4%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross profit</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">13,879</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">13,410</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">3.5%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">1,786</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">1,798</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">-0.7%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">3</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(5)</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">-160.0%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">15,668</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">15,203</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">3.1%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">As % of net sales</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">75.5%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">76.8%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">63.1%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">66.1%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">73.9%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">75.3%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3,331)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3,082)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">8.1%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(92)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(111)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-17.1%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">&#8212;%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3,423)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3,193)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">7.2%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">As % of net sales</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(18.1%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(17.6%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(3.2%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(4.1%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(16.1%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(15.8%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(4,260)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(4,248)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">0.3%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1,002)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(936)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">7.1%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">&#8212;%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(5,260)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(5,182)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">1.5%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">As % of net sales</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(23.2%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(24.3%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(35.4%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(34.4%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(24.8%)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(25.7%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current operating income&#47;expenses</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1,417)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(897)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">43</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">100</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(19)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(8)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1,393)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(805)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit&#47;loss of associates* and joint ventures </font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">66</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">48</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">9</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">7</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">75</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">55</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</font></div></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(6)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(11)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(5)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(8)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(11)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(19)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Business operating income</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </font></div></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">4,931</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">5,220</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">-5.5%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">739</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">850</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">-13.1%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(14)</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(11)</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">27.3%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">5,656</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">6,059</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">-6.7%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">As % of net sales</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">26.8%</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">29.9%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">26.1%</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">31.3%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">26.7%</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">30.0%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial income and expenses</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(129)</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(49)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax expenses</font></td><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1,147)</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1,134)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Tax rate**</font></td><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">21.0%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">19.0%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Business net income</font></td><td colspan="9" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">4,380</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">4,876</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">-10.2%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">As % of net sales</font></td><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">20.7%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">24.2%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Business earnings &#47; share(in euros)***</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">3.51</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">3.90</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">-10.0%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:1pt;text-indent:4.49pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">    </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">    * Net of tax.&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">** Determined on the basis of Business income before tax, associates, and non-controlling interests.</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">*** Based on an average number of shares outstanding of 1,249.4 million in the first semester of 2024 and 1,249.9 million in the first semester of 2023.</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_70"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Appendix 3&#58; Consolidated income statements</font></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:54.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8364; million</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Q2 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Q2 2023</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">H1 2024</font></div></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">H1 2023</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net sales</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,745</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9,965</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21,209</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20,187</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenues</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">635&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">717&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,289&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,358&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,410)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,268)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,849)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,347)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross profit</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,970</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,414</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15,649</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15,198</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,704)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,630)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,423)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,193)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling and general expenses</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,655)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,575)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,260)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,182)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other operating income</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">617&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">617&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other operating expenses</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,004)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(682)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,010)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,422)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(499)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(546)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,061)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,035)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:10pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impairment of intangible assets</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">354&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(86)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs and similar items</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(591)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(307)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,331)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(547)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:10pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other gains and losses, and litigation</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(363)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(442)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating income</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,595</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,859</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,044</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,322</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial expenses</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(333)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(202)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(586)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(370)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial income</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Income before tax and associates and joint ventures</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,392</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,782</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,739</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,238</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(299)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(271)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(463)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(730)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share of profit&#47;(loss) of associates and joint ventures</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(64)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net income</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,117</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,447</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,263</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,456</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net income attributable to equity holders of Sanofi</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,113</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,435</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,246</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,430</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average number of shares outstanding (million)</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250.1&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,249.4&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,249.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;border-top:2pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">IFRS Earnings per share (in euros)</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;border-top:2pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.89</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;border-top:2pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;border-top:2pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.15</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;border-top:2pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;border-top:2pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.80</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;border-top:2pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;border-top:2pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.74</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;border-top:2pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_73"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Appendix 4&#58; Reconciliation of net income attributable to equity holders of Sanofi to business net income</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:52.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.933%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8364; million</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Q2 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Q2 2023</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">H1 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:120%">H1 2023</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net income attributable to equity holders of Sanofi</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,113</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,435</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,246</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,430</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of intangible assets </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">499&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">546&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,061&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,035&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Impairment of intangible assets</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(354)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(371)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expenses arising from the impact of acquisitions on inventories</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring costs and similar items</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">591&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,331&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">547&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other gains and losses, and litigation </font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">363&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">442&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Financial (income) &#47; expense related to liabilities carried at amortized cost other than net indebtedness</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax effect of the items listed above&#58;</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(267)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(242)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(691)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(415)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Amortization and impairment of intangible assets</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">5&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(132)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(96)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(226)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(20)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(1)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(17)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(6)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Expenses arising from the impact of acquisitions on inventories</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(3)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Restructuring costs and similar items</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(136)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(103)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(408)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(157)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other items</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(116)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(6)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(167)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(26)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other tax effects</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other items</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Business net income</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,161</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,177</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,380</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,876</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:120%">IFRS earnings per share </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in euros)</font></div></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.89</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.15</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.80</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.74</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:112%">(1)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:112%;padding-left:7.21pt">Of which related to amortization expense generated by the intangible assets measured at their acquisition-date fair values&#58; &#8364;476 million in the second quarter of 2024 and &#8364;525 million in the second quarter of 2023.</font></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">(2)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:112%;padding-left:5.66pt">Q2&#58; based on an average number of shares outstanding of 1,250.1 million in the second quarter of 2024 and 1,250.6 million in the second quarter of 2023.</font></div><div style="margin-bottom:3pt;padding-left:18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:112%">HY&#58; based on an average number of shares outstanding of 1,249.4 million in the first semester of 2024 and 1,249.9 million in the first semester of 2023.</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">22</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_76"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Appendix 5&#58; Change in net debt</font></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.766%"><tr><td style="width:1.0%"></td><td style="width:70.039%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.330%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8364; million</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">H1 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:120%">H1 2023</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Business net income</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,380</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,876</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation, amortization and impairment of property, plant and equipment and software</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">746&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">731&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other items</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(347)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(391)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating cash flow</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,779</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,216</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in Working Capital</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,419)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(856)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment and software</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(980)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(796)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Free cash flow before restructuring, acquisitions and disposals</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,380</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,564</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acquisitions of intangibles assets, investments and other long-term financial assets </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(545)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(396)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs and similar items paid</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(858)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(595)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets net of taxes</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;(1)</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">568&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">556&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Free cash flow</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">545</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,129</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acquisitions </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,493)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,580)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Proceeds net of taxes </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Sanofi shares</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of treasury shares</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(302)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(363)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends paid to shareholders of Sanofi</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,704)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,454)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other items</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(386)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(509)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in net debt</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(7,319)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(4,746)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;border-top:2pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Beginning of period</font></td><td colspan="2" style="background-color:#f4f2f6;border-top:2pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,793</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-top:2pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;border-top:2pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,437</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-top:2pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Closing of net debt</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15,112</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11,183</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:7.21pt">Free cash flow includes investments and divestments not exceeding a cap of &#8364;500 million per transaction (inclusive of all payments related to the transaction).</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:7.21pt">Includes transactions that are above a cap of &#8364;500 million per transaction (inclusive of all payments related to the transaction).</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">23</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_79"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Appendix 6&#58; Simplified consolidated balance shee</font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">t</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.022%"><tr><td style="width:1.0%"></td><td style="width:22.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:83%">Assets (&#8364; million)</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:83%">June 30, 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:83%">December 31, 2023</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:83%">Liabilities and equity (&#8364; million)</font></div></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:83%">June 30, 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:83%">December 31, 2023</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">Equity attributable to equity holders of Sanofi</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">72,690</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">74,040</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">Equity attributable to non-controlling interests</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">307</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">313</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:83%">Total equity</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:83%">72,997</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:83%">74,353</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">Long-term debt</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">12,503</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">14,347</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">Property, plant and equipment &#8211; owned assets</font></div></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">10,264</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">10,160</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">Non-current lease liabilities</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">1,733</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">1,755</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">Right-of-use assets</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">1,616</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">1,654</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">Non-current liabilities related to business combinations and to non-controlling interests</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">527</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">501</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">Intangible assets (including goodwill)</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">76,733</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">73,723</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">Non-current provisions and other non-current liabilities</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">8,219</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">7,602</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">Non-current income tax assets</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">129</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">188</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">Non-current income tax liabilities</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">1,949</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">1,842</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">Other non-current assets, investments in associates and joint-ventures and deferred tax assets</font></div></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">10,932</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">10,069</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">Deferred tax liabilities</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">1,800</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">1,857</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:83%">Non-current assets</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:83%">99,674</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:83%">95,794</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:83%">Non-current liabilities</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:83%">26,731</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:83%">27,904</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">Accounts payable and other current liabilities</font></div></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">20,179</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">21,069</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">Current liabilities related to business combinations and to non-controlling interests</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">201</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">208</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">Inventories, accounts receivable and other current assets</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">22,989</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">21,554</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">Current income tax liabilities</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">132</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">597</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">Current income tax assets</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">295</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">391</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">Current lease liabilities</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">279</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">275</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">Cash and cash equivalents</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">6,795</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">8,710</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">Short-term debt and current portion of long-term debt</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">9,236</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">2,045</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:83%">Current assets</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:83%">30,079</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:83%">30,655</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:83%">Current liabilities</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:83%">30,027</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:83%">24,194</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">Assets held for sale or exchange</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">2</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">15</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">Liabilities related to assets held for sale or exchange</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">0</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:83%">13</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:83%">Total assets</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;text-indent:13.5pt;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:83%">129,755</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;text-indent:13.5pt;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:83%">126,464</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:83%">Total equity and liabilities</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;text-indent:13.5pt;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:83%">129,755</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;text-indent:13.5pt;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:83%">126,464</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">24</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_82"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Appendix 7&#58; Other current operating income net of expenses related to Regeneron </font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.318%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:83%">&#8364; million</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:83%">H1 2024</font></div></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:83%">H1  2023</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Monoclonal a</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ntibodies alliance</font></div></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:10pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Income and expense related to profit&#47;loss sharing</font></div></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:83%">(1,934)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1,449)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:10pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Additional share of profit paid by Regeneron related to development costs</font></div></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:83%">389</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;text-indent:10pt;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">291</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:10pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Regeneron commercial operating expenses reimbursement</font></div></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:83%">(292)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;text-indent:10pt;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(260)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:10pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total&#58; monoclonal antibody alliance</font></div></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:83%">(1,837)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;text-indent:10pt;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(1,418)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Other Regeneron</font></div></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:10pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total others related to Regeneron (mainly Libtayo</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:115%">and Zaltrap)</font></div></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:83%">92</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">97</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total related to Regeneron</font></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,745)</font></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:1pt solid #525ca3;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,321)</font></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_85"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Appendix 8&#58; Currency sensitivity</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024 business EPS currency sensitivity</font></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.698%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Currency</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Variation</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Business EPS Sensitivity</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">US Dollar</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+0.05 USD&#47;EUR</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;-EUR 0.17</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japanese Yen</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+5 JPY&#47;EUR</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;-EUR 0.02</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chinese Yuan</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+0.2 CNY&#47;EUR</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;-EUR 0.02</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazilian Real</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+0.4 BRL&#47;EUR</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;-EUR 0.01</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Russian Ruble</font></td><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+10 RUB&#47;EUR</font></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;-EUR 0.01</font></td></tr></table></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:87%">Currency exposure on Q2 2024 sales</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:87%"> </font></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Currency</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Q2 2024</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">US Dollar</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.5&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Euro</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.5&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chinese Yuan</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.7&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japanese Yen</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexican pesos</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazilian Real</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canadian Dollar</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">British Pound</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Russian ruble</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australian Dollar</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Others</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.7&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:80%">Currency average rates </font></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Q2 2023</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Q2 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Change</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8364;&#47;$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.089&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.077&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">-1.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8364;&#47;Yen</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149.527&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167.783&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">+12.2%</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8364;&#47;Yuan</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.648&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.813&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">+2.2%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8364;&#47;Real</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.394&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.619&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">+4.2%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8364;&#47;Ruble</font></td><td colspan="2" style="border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.436&#160;</font></td><td style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.409&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">+10.1%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">26</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_88"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Appendix 9&#58; Definitions of non-IFRS financial indicators</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Company sales at constant exchange rates (CER)</font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to changes in net sales &#8220;at constant exchange rates&#8221; (CER) means that it excludes the effect of changes in exchange rates.</font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effect of exchange rates are eliminated by recalculating net sales for the relevant period at the exchange rates used for the previous period.</font></div><div style="margin-bottom:3pt;margin-top:3pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Reconciliation of net sales to company sales at constant exchange rates for Q2 and H1 2024.</font></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8364; million</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Q2 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">H1 2024</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net sales</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,745</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21,209</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rates</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(238)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(682)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Company sales at constant exchange rates</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,983</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21,891</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:7pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Business net income</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sanofi publishes a key non-IFRS indicator. Business net income is defined as net income attributable to equity holders of Sanofi excluding&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">amortization of intangible assets,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">impairment of intangible assets, </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">fair value remeasurement of contingent consideration related to business combinations or to disposals,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">expenses arising from the impact of acquisitions on inventories</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">restructuring costs and similar items</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">other gains and losses (including gains and losses on disposals of non-current assets</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">),</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">costs or provisions associated with litigation</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">financial (income)&#47;expense related to liabilities carried at amortized cost other than net indebtedness, </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.55pt">tax effects related to the items listed above as well as effects of major tax disputes,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.55pt">the share of profits&#47;losses from investments accounted for using the equity method, except for joint ventures and associates with which Sanofi has a strategic alliance,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">net income attributable to non-controlling interests</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to the items listed above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(1) Reported in the line items </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">and similar items</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Gains and losses on disposals, and litigation</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">, which are defined in Notes B.16. and B.17. to our consolidated financial statements.</font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Free cash flow </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Free cash flow is a non-IFRS financial indicator which is reviewed by management, and which management believes provides useful information to measure the net cash generated from Sanofi&#8217;s operations that is available for strategic investments</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (net of divestments</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), for debt repayment, and for capital return to shareholders. Free cash flow is determined from the Business net income adjusted for depreciation, amortization and impairment, share of profit&#47;loss in associates and joint ventures net of dividends received, gains and losses on disposals, net change in provisions including pensions and other post-employment benefits, deferred taxes, share-based expense and other non-cash items. It comprises net changes in working capital, capital expenditures and other asset acquisitions</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net of disposal proceeds</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and payments related to restructuring and similar items. Free cash flow is not defined by IFRS and it is not a substitute measure for the IFRS aggregate net cash flows in operating activities.</font></div><div style="margin-bottom:3pt;margin-top:3pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1 </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Amount of the transaction above a cap of &#8364;500 million per transaction (inclusive of all payments related to the transaction).</font></div><div style="margin-bottom:3pt;margin-top:3pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2 </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Not exceeding a cap of &#8364;500 million per transaction (inclusive of all payments related to the transaction).</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">27</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_91"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Reconciliation from net cash provided by&#47;(used in) operating activities to free cash flow</font></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.419%"><tr><td style="width:1.0%"></td><td style="width:74.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8364; million</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;H1 2024</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">H1  2023</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash provided by&#47;(used in) operating activities in the Consolidated statements of cash flows</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,423</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,563</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of property, plant and equipment and software</font></td><td colspan="2" style="background-color:#f4f2f6;border-top:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(980)</font></td><td style="background-color:#f4f2f6;border-top:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(796)</font></td><td style="border-top:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acquisitions of intangibles assets, investments and other long-term financial assets</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(545)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(396)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets net of taxes</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">568&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">556&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayment of lease liabilities</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(144)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(127)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Others</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">223&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #525ca3;border-top:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Free cash flow</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</font></div></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;border-top:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">545</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;border-top:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #525ca3;border-top:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,129</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:0.5pt solid #525ca3;border-top:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">1 </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Most directly comparable IFRS measure to free cash flow.</font></div><div style="margin-bottom:3pt;margin-top:3pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">2 </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Transactions up to &#8364;500 million per transaction.</font></div><div style="margin-bottom:6pt;margin-top:3pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Non IFRS indicator (see definition in Appendix 9).</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_94"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Appendix 10&#58; CSR dashboards</font></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Data are presented in YTD unless stated otherwise.</font></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:18.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.737%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.740%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Topic</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ambition</font></td><td colspan="6" style="border-bottom:0.5pt solid #21004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Progress</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Affordable access </font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Q2 2024</font></td><td colspan="3" style="background-color:#f4f2f6;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Q1 2024</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sanofi global health</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reach 1.5 million NCD patients by 2026 (cumulative since 2022) and 2 million by 2030<br></font><font style="font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><br></font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,746 patients treated in 24 countries<br></font><font style="font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46 active healthcare partnerships in 21 countries<br></font><font style="font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 investments signed through the Impact Fund</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,889 patients treated in 18 countries<br></font><font style="font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44 active healthcare partnerships in 21 countries<br></font><font style="font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 investment signed through the Impact Fund</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vials donations</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Donate 100,000 vials a year to treat people with rare diseases</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,164 patients treated<br>46,124 vials donated</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,112 patients treated<br>17,287 vials donated</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Global access plans</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Develop a global access plan for all new medicines&#47;vaccines to make them available within two years after first launch</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 global access plans initiated or developed covering more than 14 indications</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 global access plans initiated or developed covering more than 14 indications</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">R&#38;D for unmet needs</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FY 2023</font></td><td colspan="3" style="background-color:#f4f2f6;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FY2022</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sleeping sickness</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Develop and supply innovative treatments to support the elimination of sleeping sickness by 2030 (annual update)</font></div><div><font><br></font></div></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4 million patients tested<br>699 patients treated</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5 million patients tested<br>837 patients treated</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Q2 2024</font></td><td colspan="3" style="background-color:#f4f2f6;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Q1 2024</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Polio</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provide inactivated polio vaccines (IPV) to UNICEF for GAVI countries to support polio eradication efforts</font></div></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.2 million IPV doses supplied to UNICEF for GAVI countries</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.4 million IPV doses supplied to UNICEF for GAVI countries</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pediatric cancer treatment development<br></font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Develop innovative treatments to eliminate cancer death in children</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 projects undergoing pre-clinical assessment<br></font><font style="font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 project in clinical study<br></font><font style="font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 partnerships on scientific projects and engagement </font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 projects undergoing pre-clinical assessment<br></font><font style="font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 project in clinical study</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Planet care</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Q2 2024</font></div></td><td colspan="3" style="background-color:#f4f2f6;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Q1 2024</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Climate change &#8211; carbon footprint </font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(CO</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:1.26pt;vertical-align:baseline">2 </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">emissions)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55% reduction in scope 1&#38;2 greenhouse gas emissions (CO</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:1.26pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> equivalent) by 2030 (cumulative vs 2019 baseline) to contribute to carbon neutrality by 2030 and net zero emissions by 2045 (all scopes)</font></div></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43% GHG reduction vs 2019</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42% GHG reduction vs 2019</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Renewable electricity</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100% of renewable electricity in all sites by 2030<br></font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eco-car fleet</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100% eco-car fleet in 2030<br></font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48% eco-car fleet </font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44% eco-car fleet</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Blister-free syringe vaccines</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100% blister-free syringe vaccines by 2027</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Data updated annually, next update in Q4 2024</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39% blister-free syringe vaccines in 2023</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eco-design</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All new medicines&#47;vaccines to be eco-designed by 2025<br></font><font style="font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><br></font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 LCAs completed and 2 in progress (new and marketed medicines&#47;vaccines)</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 LCAs completed and 5 in progress (new and <br>marketed medicines&#47;vaccines)</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="12" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">In and beyond the workplace<br></font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Q2 2024</font></div></td><td colspan="3" style="background-color:#f4f2f6;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Q1 2024</font></td><td colspan="3" style="display:none"></td></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Global gender balance</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ambition of 50% of women in senior leadership roles by 2025</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45%</font></td><td colspan="3" style="display:none"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ambition of 40% of women in executive roles by 2025</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Engagement with communities</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Engage socially and economically with all communities with operations</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,732 volunteers<br>25,945 hours</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not reported in Q1</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">From leaders to citizens</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100% of leaders have CSR in their development path</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77% of leaders have completed the eLearning phase<br><br>33% of leaders have completed the full program</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70% of leaders have completed the eLearning phase<br><br>30% of leaders have completed the full program</font></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">29</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_342"></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Appendix 11&#58;</font><font style="color:#000000;font-family:'Sanofi Serif',serif;font-size:26pt;font-style:italic;font-weight:400;line-height:115%"><br>Three-year historical and restated financial information of Opella</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:112%">In connection with the intent to separate Opella (formerly Sanofi Consumer Healthcare) at the earliest in Q4 2024 announced on October 27, 2023, Opella (i) has prepared audited* combined financial statements in accordance with IFRS and (ii) presents restated alternative performance measures for 2021, 2022 and 2023, as set forth in Appendix 11, to reflect Opella's financial performance as if it had operated independently.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Because the combined historical financial statements do not reflect the target operating structure of the Group once separated from Sanofi, restated alternative performance measures have been prepared for 2021, 2022 and 2023, to account for the contractual agreements signed with Sanofi and for Opella&#8217;s targeted operating model (e.g., standalone cost base).</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">CONTENTS</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #6d6d6d;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.02pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">A. Combined primary financial statements extracted from the audited* 2023 combined financial statements of Opella </font></div></td><td colspan="3" style="border-top:1pt solid #6d6d6d;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12.02pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Statements of combined financial position &#8211; Assets</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a href="#i439f5d1857c344f7b532f54d2ef05291_348" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">3</a><a href="#i439f5d1857c344f7b532f54d2ef05291_348" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">2</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12.02pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Statements of combined financial position &#8211; Equity and liabilities</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a href="#i439f5d1857c344f7b532f54d2ef05291_351" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">3</a><a href="#i439f5d1857c344f7b532f54d2ef05291_351" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Combined income statements</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a href="#i439f5d1857c344f7b532f54d2ef05291_354" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">3</a><a href="#i439f5d1857c344f7b532f54d2ef05291_354" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Combined statements of comprehensive income</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a href="#i439f5d1857c344f7b532f54d2ef05291_357" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">3</a><a href="#i439f5d1857c344f7b532f54d2ef05291_357" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Combined statements of changes in equity</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a href="#i439f5d1857c344f7b532f54d2ef05291_360" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">3</a><a href="#i439f5d1857c344f7b532f54d2ef05291_360" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Combined statements of cash flows</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a href="#i439f5d1857c344f7b532f54d2ef05291_363" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">3</a><a href="#i439f5d1857c344f7b532f54d2ef05291_363" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">8</a></font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.02pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">B. Notes to the Combined Financial Statements</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12.02pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Introduction</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a href="#i439f5d1857c344f7b532f54d2ef05291_369" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">40</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12.02pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Basis of preparation of the combined financial statements</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a href="#i439f5d1857c344f7b532f54d2ef05291_1232" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">4</a><a href="#i439f5d1857c344f7b532f54d2ef05291_1232" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">0</a></font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.02pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">C. Non-IFRS Alternative Performance Measures (APMs)</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12.02pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">C.1. Definitions of non-IFRS APMs</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a href="#i439f5d1857c344f7b532f54d2ef05291_393" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">4</a><a href="#i439f5d1857c344f7b532f54d2ef05291_393" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12.02pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">C.2. Reconciliation of IFRS historical financial information to non-IFRS APMs</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a href="#i439f5d1857c344f7b532f54d2ef05291_408" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">4</a><a href="#i439f5d1857c344f7b532f54d2ef05291_408" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12.02pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">C.3. Reconciliation of historical non-IFRS APMs to restated APMs</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><a href="#i439f5d1857c344f7b532f54d2ef05291_420" style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:none">48</a></font></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:139%"> fin</font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:112%">* The combined financial statements have been audited in accordance with the professional standards applicable in France and the national auditor's professional doctrine.</font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> The sections below are an extract from the notes to the 2023-22-21 combined financial statements of the Opella group.</font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_345"></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="padding-right:-0.1pt;text-align:center;text-indent:-8.5pt"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:139%">A. Combined primary financial statements extracted from the audited* 2023 combined financial statements of Opella</font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10.4pt;font-style:italic;font-weight:400;line-height:139%;position:relative;top:-5.6pt;vertical-align:baseline">2</font></div><div id="i439f5d1857c344f7b532f54d2ef05291_348"></div><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:18pt;font-weight:400;line-height:112%">Combined Statements of Financial Position &#8211; Assets</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.145%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">January 1, 2021</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">457</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,056</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">385&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">387&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">378&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Property, plant and equipment</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">688&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">649&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">629&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">597&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Right-of-use assets</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">91</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">93&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other non-current assets</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">76</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred tax assets</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,386&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,469&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,214&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,285&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current assets</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,779</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,634</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,327</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,351</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Inventories</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">877&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">792&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">654&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">688&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts receivable</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,221</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,103&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">982&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">921&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current assets </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,393</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,257&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">822&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">360&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current income tax assets</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">23</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">106&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current assets</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,619</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,267</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,497</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,022</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Assets held for sale or exchange</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total assets</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,400</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,901</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,824</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,373</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:5pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">(a) This line item mainly comprises current account balances in respect of the combined group&#8217;s net cash positions in credit with Sanofi, which acts as the cash pooling entity under the terms of the centralized cash pooling agreement contracted with subsidiaries of the combined group (notes D.11. and D.27.).</font></div><div style="margin-top:1pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">(b) This amount comprises cash held by the dedicated entities of the combined group. Payments made by non-dedicated entities within the scope of the combined group before the Pre-Separation Carve-Out Transactions (note E) in settlement of transactions entered into by Opella activities are reflected in the net assets of the combined group as net contributions of Sanofi equity holders to the combined group (note A.2.4.).</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-top:1pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> References in the text relate to the notes to the Opella group&#8217;s 2023-22-21 combined financial statements.</font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">31</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_351"></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"><div style="padding-left:0.02pt"><font><br></font></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:18pt;font-weight:400;line-height:139%">Combined Statements of Financial Position &#8211; Equity&#160;and&#160;Liabilities</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">January 1, 2021</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity attributable to equity holders of the combined group</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(808)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,091)</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,368)</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,250)</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity attributable to non-controlling interests</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.25pt"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total equity </font><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(794)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,077)</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,358)</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,241)</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.25pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,523&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,828&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,166&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,513&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current lease liabilities</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current provisions and other non-current liabilities</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">471&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">516&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">346&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">346&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-current income tax liabilities</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred tax liabilities</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current liabilities</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,120</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,459</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,583</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,922</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts payable</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,002&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">846&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">783&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">591&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current provisions and other current liabilities</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,003</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">781</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">695</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">588</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current income tax liabilities</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current lease liabilities</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,966&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,799&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,064&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,483&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current liabilities</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,072</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,519</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,599</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,692</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liabilities related to assets held for sale or exchange</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total equity and liabilities</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,400</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,901</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,824</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,373</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:5pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">(a)&#160;&#160;&#160;&#160;The combined entity was not constituted on the basis of a separate legal scope as of the ends of the reporting periods for which the combined financial statements are presented. Consequently, the total presented for combined equity represents the aggregate amount of equity as derived from Opella activities carried on within the scope of combination by Sanofi group dedicated and non-dedicated legal entities under common control, including the net contribution of Sanofi equity holders to the combined group (note A.2.4.).</font></div><div style="margin-top:1pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">(b)&#160;&#160;&#160;&#160;This line item mainly comprises current account balances in respect of the combined group&#8217;s net cash positions in debit with Sanofi, which acts as the cash pooling entity under the terms of the centralized cash pooling agreement contracted with subsidiaries of the combined group (note D.16.1.).</font></div><div style="margin-top:1pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">32</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_354"></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1.02pt 0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:18pt;font-weight:400;line-height:139%">Combined Income Statements</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.174%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.144%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</font></td><td colspan="2" style="background-color:#dbdbdb;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,174</font><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dbdbdb;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,201</font><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,565</font><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.25pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</font></div></td><td colspan="2" style="background-color:#dbdbdb;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">606&#160;</font></td><td style="background-color:#dbdbdb;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">629&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">632&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</font></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,206)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,191)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,081)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross profit</font></td><td colspan="2" style="background-color:#dbdbdb;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,574</font><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dbdbdb;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,639</font><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,116</font><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(224)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(220)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(177)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</font></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,333)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,381)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,970)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other operating income and expenses</font></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">216&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">183&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">211&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating income</font></td><td colspan="2" style="background-color:#dbdbdb;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,233</font><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dbdbdb;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,221</font><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,180</font><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial income and expenses</font></td><td colspan="2" style="background-color:#dbdbdb;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(128)</font></td><td style="background-color:#dbdbdb;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(91)</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(51)</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3.25pt"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using </font></div><div style="margin-bottom:1.5pt"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">the equity method</font></div></td><td colspan="2" style="background-color:#dbdbdb;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,105</font><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dbdbdb;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,130</font><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,130</font><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="background-color:#dbdbdb;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(314)</font></td><td style="background-color:#dbdbdb;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(319)</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(301)</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3.75pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit&#47;(loss) from investments accounted for using </font></div><div style="margin-bottom:1.5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">the equity method</font></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income of the combined group</font></div></td><td colspan="2" style="background-color:#dbdbdb;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">811</font><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dbdbdb;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">831</font><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">844</font><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</font></td><td colspan="2" style="background-color:#dbdbdb;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="background-color:#dbdbdb;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #21004c;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.25pt"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Net income attributable to equity holders of the combined group </font><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:0.5pt solid #21004c;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">796</font><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dbdbdb;border-bottom:0.5pt solid #21004c;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #21004c;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">820</font><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:0.5pt solid #21004c;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #21004c;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">813</font><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:0.5pt solid #21004c;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">(a)&#160;&#160;&#160;&#160;This line item comprises revenue generated (i) from manufacturing services agreements under which Opella manufactures pharmaceutical products on behalf of Sanofi as customer and (ii) further to divestments of products historically owned by Opella, the rights for which have been transferred to third parties (notes A.2.3., B.15.2. and D.27.)</font><font style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">.</font></div><div style="margin-top:1pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">(b)&#160;&#160;&#160;&#160;Because the Opella group was not legally constituted during the three twelve-month periods ended December 31, 2023, 2022 and 2021, the number of shares outstanding cannot be determined. Consequently, no earnings per share figure is presented in the combined financial statements for any of the three periods presented.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-top:1pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font><br></font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">33</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_357"></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt 0 1.02pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:18pt;font-weight:400;line-height:139%">Combined Statements of Comprehensive Income</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.174%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.144%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income of the combined group</font></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">811</font></td><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">831</font></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">844</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Attributable to equity holders of the combined group</font></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">796</font></td><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">820</font></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">813&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Attributable to non-controlling interests</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">15</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">11</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">31&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other comprehensive income&#58;</font></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt;padding-left:11.35pt;text-indent:-11.35pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.96pt">Actuarial gains&#47;(losses)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt;padding-left:11.35pt;text-indent:-11.35pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.96pt">Change in fair value of equity instruments included in&#160;financial assets and financial liabilities</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt;padding-left:11.35pt;text-indent:-11.35pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.96pt">Tax effects</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Sub-total&#58; items not subsequently reclassifiable to profit or loss (A)</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.25pt;padding-left:11.35pt;text-indent:-11.35pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.96pt">Change in currency translation differences </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(26)</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt;padding-left:11.35pt;text-indent:-11.35pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.96pt">Tax effects</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Sub-total&#58; items subsequently reclassifiable to profit or loss (B)</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">60</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(26)</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other comprehensive income for the period, net of taxes (A+B)</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">60</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">29</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8)</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Comprehensive income of the combined group</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">870</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">861</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">836</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Attributable to equity holders of the combined group</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">857&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">849&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">804&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Attributable to non-controlling interests</font></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">13&#160;</font></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">11&#160;</font></td><td style="border-bottom:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">32&#160;</font></td><td style="border-bottom:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">(a)&#160;&#160;&#160;&#160; Currency translation differences arise primarily on the US dollar ($) and Mexican peso (MXN).</font></div><div style="margin-top:1pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%"> </font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">34</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_360"></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:18pt;font-weight:400;line-height:139%">Combined Statements of Changes in&#160;Equity</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%"> </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.918%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Other equity items</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Stock options&#160;and other&#160;share-based payments</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:0.02pt;text-align:right"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Other combined comprehensive income</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:0.02pt;text-align:right"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Attributable to&#160;equity holders of the combined group</font></div></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Attributable to non-controlling interests</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:0.02pt;text-align:right"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Total&#160;equity of the combined group</font></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January 1, 2023</font></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,104)</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">33</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(20)</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,091)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,077)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other combined comprehensive income for&#160;the period</font></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net combined income for the period</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">796&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">796&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">811&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Comprehensive income of the combined group for&#160;the&#160;period</font></div></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">796</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">61</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">857</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">871</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividend paid out of 2022 earnings</font></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(330)</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(330)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(330)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payment of dividends to non-controlling interests</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based payment plans&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt;padding-left:11.35pt;text-indent:-11.35pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.96pt">Value of services obtained from&#160;employees </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net contribution of Sanofi equity holders to the combined group </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(268)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(268)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(276)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2023</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(905)</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">57</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">41</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(808)</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(794)</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">(a)&#160;&#160;&#160;&#160;This line item corresponds to compensation plans based on shares of the Sanofi group awarded to employees of the combined group who were employed by the Sanofi group as of the date of preparation of the combined financial statements.</font></div><div style="margin-top:1pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">(b)&#160;&#160;&#160;&#160;The contribution of Sanofi equity holders to the combined group as recorded in combined equity (notes A.2.4. and D.14.) represents the corresponding entries arising from (i) related party transactions (note D.27.) pre-dating the Pre-Separation Carve-Out Transactions (note E.) and (ii) the recognition of tax loss carry-forwards generated by dedicated entities within the combined group that belong to a group tax election, including tax losses transferred to the lead company in the tax group (&#8364;49 million for the period) and by non-dedicated entities. In addition, the net assets of non-dedicated entities were deemed to have been distributed in cases where the Pre-Separation Carve-Out Transactions involved a change in operating model such that the distribution of Opella products in 16 countries is handled through a third-party intermediary (&#8364;9 million for the period).</font></div><div style="margin-top:1pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.704%"><tr><td style="width:1.0%"></td><td style="width:24.825%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.250%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Other equity items</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Stock options&#160;and other&#160;share-based payments</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:0.02pt;text-align:right"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Other combined comprehensive income</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:0.02pt;text-align:right"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Attributable to&#160;equity holders of the combined group</font></div></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Attributable to non-controlling interests</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:0.02pt;text-align:right"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Total&#160;equity of the combined group</font></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January 1, 2022 </font></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,355)</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(27)</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,368)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,358)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other combined comprehensive income for&#160;the period</font></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net combined income for the period</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">820&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">820&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">831&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Comprehensive income of the combined group for&#160;the&#160;period</font></div></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">842</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">849</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">860</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.25pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividend paid out of 2021 earnings</font></div></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(41)</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(41)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(41)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payment of dividends to non-controlling interests</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based payment plans&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt;padding-left:11.35pt;text-indent:-11.35pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.96pt">Value of services obtained from&#160;employees </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net contribution of Sanofi equity holders to the combined group </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">450&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">450&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">444&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2022</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,104)</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">33</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(20)</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,091)</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,077)</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">(a)&#160;&#160;&#160;&#160;See note (a) in the preceding table.</font></div><div style="margin-top:1pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">(b)&#160;&#160;&#160;&#160;See note (b) in the preceding table. The net contribution to equity holders of Sanofi arising from unrecognized tax loss carry-forwards deemed to have been transferred (note A.2.4.) amounted to &#8364;11 million in the period. In addition, the amount of net assets deemed to have been distributed in the period for the six countries that changed their operating model in connection with the Pre-Separation Carve-Out Transactions was &#8364;15 million (note D.14.).</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.704%"><tr><td style="width:1.0%"></td><td style="width:24.825%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.250%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Other equity items</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Stock options&#160;and other&#160;share-based payments</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:0.02pt;text-align:right"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Other combined comprehensive income</font></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:0.02pt;text-align:right"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Attributable to&#160;equity holders of the combined group</font></div></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Attributable to non-controlling interests</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:0.02pt;text-align:right"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Total&#160;equity of the combined group</font></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January 1, 2021</font></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,250)</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,250)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,241)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other combined comprehensive income for&#160;the period</font></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(27)</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net combined income for the period</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">813&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">813&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">844&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Comprehensive income of the combined group for&#160;the&#160;period</font></div></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">831</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(27)</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">804</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">32</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">836</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividend paid out of 2020 earnings</font></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(55)</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(55)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(55)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payment of dividends to non-controlling interests</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based payment plans&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt;padding-left:11.35pt;text-indent:-11.35pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.96pt">Value of services obtained from&#160;employees </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net contribution of Sanofi equity holders to the combined group </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(880)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(880)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(908)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2021</font></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,355)</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(27)</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,368)</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,358)</font></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">(a)&#160;&#160;&#160;&#160;See note (a) in the preceding table.</font></div><div style="margin-top:1pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">(b)&#160;&#160;&#160;&#160;See note (b) in the preceding table. The net contribution to equity holders of Sanofi arising from unrecognized tax loss carry-forwards deemed to have been transferred (note A.2.4.) amounted to &#8364;51 million in the period. In addition, the amount of net assets deemed to have been distributed in the period for the 15 countries that changed their operating model in connection with the Pre-Separation Carve-Out Transactions was &#8364;22 million (note D.14).</font></div><div style="margin-top:1pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font><br></font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">36</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_363"></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:18pt;font-weight:400;line-height:139%">Combined Statements of Cash Flows</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.377%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(&#8364; million)</font></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.02pt"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net income attributable to equity holders of the combined group</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">796</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">820</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">813</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-controlling interests</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of undistributed earnings from investments accounted for using the equity method</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">151&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">141&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains and losses on disposals of non-current assets, net of tax </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(173)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(164)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(151)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in deferred taxes </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(321)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(84)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in non-current provisions and other non-current liabilities </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(137)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based payment expense</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of the workdown of acquired inventories remeasured at fair value</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other profit or loss items with no cash effect on cash flow from operating activities </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">147&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">114&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating cash flow before changes in working capital</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">870</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">843</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">803</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Increase)&#47;decrease in inventories</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(39)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(119)</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Increase)&#47;decrease in accounts receivable</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(115)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(100)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(40)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increase&#47;(decrease) in accounts payable</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">179&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in other current assets and other current liabilities</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">215&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">87&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.25pt"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by&#47;(used in) operating activities </font><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</font></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,067</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">776</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,082</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment and intangible assets</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(138)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(132)</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(117)</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of undertakings included in the scope of combination and of investments accounted for using the equity method </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,335)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other equity investments</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">218&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">177&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">158&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in other non-current assets</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by&#47;(used in) investing activities</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,259)</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">39</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">41</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividends paid&#58;</font></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt;text-indent:-6.75pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:4.83pt">to equity holders of Sanofi</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(330)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(41)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(55)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt;text-indent:-6.75pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:4.83pt">to non-controlling interests</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments received&#47;(made) on changes of ownership interest in a subsidiary without loss of control</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Repayments of long-term debt</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(300)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(342)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(348)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in short-term debt </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,252&#160;</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">666&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">504&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in short-term financial investments </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(110)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,355)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(317)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Repayments of lease liabilities</font></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(16)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(16)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(14)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest (paid)&#47;received </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(h)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(117)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(88)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(54)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increase&#47;(decrease) in net contribution of Sanofi equity holders to the combined group </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(i)</font></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(150)</font></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">434&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(831)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #4a70b7;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by&#47;(used in) financing activities</font></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">216</font><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(751)</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#23004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,147)</font></td><td style="border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Impact of exchange rates on cash and cash equivalents</font></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8)</font></td><td style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1)</font></td><td style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net change in cash and cash equivalents</font></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;border-top:0.5pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">63</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;border-top:0.5pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(23)</font></td><td style="background-color:#7802e6;border-top:0.5pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:0.5pt solid #ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash and cash equivalents, beginning of period</font></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">91</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;border-top:0.5pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">28</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;border-top:0.5pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">51</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#7802e6;border-top:0.5pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of period</font></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">106</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">91</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">28</font><font style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">(a) This line item mainly comprises proceeds from divestments of certain non-core Opella brands. Under the ongoing portfolio streamlining strategy known as &#34;SIMPLY&#34;, announced in 2021, Opella received total pre-tax proceeds of &#8364;272 million in 2023 from divestments of certain brands in Asia, the Middle East, Africa, the United States and Canada, and completed a disposal program begun in 2022 for certain other brands (mainly in France and Hungary). Total pre-tax proceeds of &#8364;216 million and &#8364;198 million were received in the years ended 2022 and 2021, respectively, mainly in Europe and India (divestment of &#8220;Wellness&#8221; category products).</font></div><div style="margin-top:1pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">(b)&#160;&#160;&#160;&#160;For 2022, the net change in deferred taxes relates mainly to the Pre-Separation Carve-Out Transactions carried out in the United States (note E.).</font></div><div style="margin-top:1pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">(c)&#160;&#160;&#160;&#160;This line item mainly comprises provisions for certain obligations to which the combined group is exposed and which required a liability to be recognized in accordance with IAS 37 (notes B.14. and D.17.).</font></div><div style="margin-top:1pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">(d)&#160;&#160;&#160;&#160;This line item mainly comprises (i) unrealized foreign exchange gains and losses arising on remeasurement of monetary items from the functional currency and (ii) the cost of debt (note D.16.).</font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">(e) Including&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #21004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.25pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Taxes paid by dedicated entities </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e1)</font></div></td><td colspan="2" style="background-color:#dbdbdb;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(231)</font></td><td style="background-color:#dbdbdb;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(179)</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(97)</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which paid to Sanofi</font></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(97)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(119)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(52)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Taxes deemed paid by non-dedicated entities </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e2)</font></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(38)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(386)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(131)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividends received from entities not included in the scope of combination</font></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">(e1) This line includes (but is not limited to) net tax payments made (by entities entirely dedicated to Opella activities which belong to a group tax election) to the lead entity of a tax group, primarily in France, the United States, the United Kingdom and Germany, in cases where the lead entity is liable for income taxes payable by the tax group to the authorities in those jurisdictions. </font></div><div style="margin-top:1pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">(e2) For the year ended December 31, 2022, the year-on-year change is related primarily to the Pre-Separation Carve-Out Transactions (note E.) carried out in the United States, in an amount of &#8364;286 million (note A.2.4.).</font></div><div style="margin-top:1pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">(f)&#160;&#160;&#160;&#160;For the year ended December 31, 2023, this line includes the net cash outflow on the acquisition of QRIB Intermediate Holdings, LLC (note D.1.).</font></div><div style="margin-top:1pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">(g)&#160;&#160;&#160;&#160;This line includes movements in current accounts held by subsidiaries with the Sanofi group, corresponding to cash positions generated by legal entities dedicated exclusively to Opella activities that are parties to the Sanofi group cash pooling agreement (note D.16.1.).</font></div><div style="margin-bottom:1pt;margin-top:1pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">(h) This line breaks down as follows &#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest paid</font></td><td colspan="2" style="background-color:#dbdbdb;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(186)</font></td><td style="background-color:#dbdbdb;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(104)</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(65)</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest received on short-term financial investments (see note (g) above)</font></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">69&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">(i)&#160;&#160;&#160;&#160;Transactions carried out by non-dedicated entities are presented as cash flows related to operating activities within the statement of cash flows, with the corresponding entry presented as cash flows related to financing activities within the line item &#34;Increase&#47;(decrease) in net contribution of Sanofi equity holders to the combined group&#34;&#59; they are treated as contributions from or distributions to the Sanofi group and deemed to have been settled on customary payment terms.</font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_366"></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:139%">B. Notes to the combined financial statements</font><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:10.4pt;font-style:italic;font-weight:400;line-height:139%;position:relative;top:-5.6pt;vertical-align:baseline">2</font></div><div id="i439f5d1857c344f7b532f54d2ef05291_369"></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:139%">Introduction</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As announced on 27 October 2023, Sanofi intends to proceed with the introduction of its Consumer Healthcare business (a separate operating segment of the Sanofi group) on the Euronext Paris regulated market (the &#8220;Transaction&#8221;). </font></div><div><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:112%">The creation of a standalone Consumer Healthcare business unit, bringing together all Opella activities carried on by the Sanofi group, was effected through successive waves of pre-separation legal reorganizations which began in the second half of 2021 and had been completed in most countries as of the date of preparation of the combined financial statements for the year ended December 31, 2023. The only exceptions are (i) India, where the legal transfer will take place in the second half of 2024&#59; (ii) hospital sales of Opella products in China, for which the transfer of the market authorizations from Sanofi to Opella will be finalized no later than 2028 after a transitional period required to complete the transfer plan agreed with Sanofi in the context of public tendering arrangements (note E.)&#59; and (iii) Brazil, where the transfer of manufacturing activities took place on July 1, 2024, thereby finalizing the Pre-Separation Carve-Out Transactions.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Historically housed within over 150 dedicated and non-dedicated Sanofi group entities, the combined group now comprises around 70 legal entities dedicated to the research, development, manufacture, promotion, distribution and commercialization of consumer healthcare products. With a presence in 45 countries, the combined group offers consumers (directly, or via local commercial partners) global coverage in the supply of such products&#59; those products are manufactured mainly in France, the United States, Japan, Brazil and Hungary, and fall within three categories&#58; &#34;Seasonal Symptoms &#38; Pain&#34;, &#34;Wellness&#34;, and &#34;Other&#34;.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following sections </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">describe the basis of preparation and accounting conventions </font><font style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(note A.2.) used to establish the </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">combined financial statements of Opella, prepared in anticipation of the Transaction and presenting historical information of the combined group for the three 12-month accounting periods ended December 31, 2023, 2022 and 2021</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div id="i439f5d1857c344f7b532f54d2ef05291_1232"></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:400;line-height:139%">A&#47; Basis of preparation of the combined financial statements</font></div><div id="i439f5d1857c344f7b532f54d2ef05291_372"></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:139%">A.1. General information</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">The combined financial statements may not be indicative of the future performances of the combined group, and do not necessarily reflect what the comprehensive income, financial position or cash flows of the group would have been if the combined group had operated as a standalone group presenting separate financial statements from those of Sanofi during all of the periods presented.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The combined financial statements, which were prepared on a going concern basis and in accordance with the historical cost convention, were signed off by the Chairwoman of Opella Healthcare France SAS on July 4, 2024.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The combined financial statements are presented in millions of euros unless otherwise indicated.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Scope of combination</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The scope of combination reflects the activities of Opella, which constitutes a separate operating segment of the Sanofi group. It represents the ring-fenced grouping of those activities, as carried on within a common management structure that is objectively distinct from the other economic activities carried on within the Sanofi group.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Opella activities, which have been gradually restructured into around 70 dedicated legal entities (the &#8220;Pre-Separation Carve-Out Transactions&#8221;), are controlled by the Sanofi group as of the date of the present combined financial statements. The final phase of the Pre-Separation Carve-Out Transactions calls for the equity interests held by Sanofi group subsidiaries in the newly-constituted Sanofi-owned dedicated entities to be legally transferred to Opella Healthcare France SAS (the &#8220;Company&#8221;, &#8220;the Opella group&#8221; or &#8220;the Group&#8221;), a </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">soci&#233;t&#233; par actions simplifi&#233;e</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> &#91;simplified limited company&#93; with its registered office at 157 Avenue Charles de Gaulle, 92200 Neuilly-sur-Seine, France, thereby completing the creation of a standalone group consisting of the Company and its subsidiaries in preparation for the admission of the Company&#8217;s shares to listing on the Euronext Paris regulated market (the &#8220;Transaction&#8221;).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On completion of the Pre-Separation Carve-Out Transactions, assets and liabilities associated with Opella activities included in the scope of combination but not yet transferred will be deemed to have been contributed to Sanofi equity holders (note B.2.4.) as of the date of the Transaction. This applies specifically to (i) hospital sales of Opella products in China, due to be transferred no earlier than 2028 after a transitional period required to complete the transfer plan agreed with Sanofi in the context of public tendering arrangements and (ii) the newly-formed dedicated entity in Russia (note E.), the transfer of the equity interests in which will take effect on the date the requisite local clearances are obtained.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Pre-Separation Carve-Out Transactions are presented in note E.</font></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The scope of the combined group is presented in note F. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The combined financial statements include all assets, liabilities, income, expenses and cash flows specifically attributable to the combined group, plus allocations of indirect costs and expenses related to the activities of the combined group and incurred by Sanofi (as described in notes A.2.3. and A.2.4.).</font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Transactions between entities belonging to the combined group (other than share-based transactions) have been eliminated, while transactions between the combined group and the Sanofi group have been presented as related party transactions.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div id="i439f5d1857c344f7b532f54d2ef05291_375"></div><div style="margin-bottom:5pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:139%">A.2. Basis of preparation of the financial statements</font></div><div id="i439f5d1857c344f7b532f54d2ef05291_1056"></div><div style="margin-bottom:5pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.2.1. First-time preparation of financial information under IFRS</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The financial statements of Opella have been prepared in accordance with IFRS standards and interpretations as issued by the IASB, and as endorsed by the EU as of December 31, 2023. They present the combined financial position, combined results of operations and comprehensive income, changes in combined equity and combined cash flows, as extracted from the historical consolidated financial statements of the Sanofi group, and using the historical carrying amounts of assets and liabilities attributable to Opella activities as presented in the consolidated financial statements of the Sanofi group.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In preparing the combined financial information, management exercised significant judgment to determine certain accounting conventions used in the preparation of combined financial information.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Those significant judgments and conventions are described below.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The combined financial statements of the Opella cover the twelve-month periods ended December 31, 2021, December 31, 2022 and December 31, 2023.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accounting policies described below have been applied consistently for all periods presented, including in the opening financial position as of January 1, 2021.</font></div><div id="i439f5d1857c344f7b532f54d2ef05291_378"></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">A.2.2. Accounting policies applied in accordance with IFRS 1</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">The combined financial statements of the combined group as of December 31, 2023 are its first financial statements to have been prepared under IFRS. They were prepared in accordance with IFRS 1 (First-time Adoption of International Financial Reporting Standards). The Group has not previously prepared financial statements for this scope under IFRS or under any other generally accepted accounting principles.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal positions adopted by the Group for those financial statements were&#58;</font></div><div style="margin-bottom:5pt;padding-left:42.51pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.65pt">Assets and liabilities attributable to Opella activities were measured at their historical carrying amount as derived from the Sanofi financial statements, under the option permitted in paragraph D16(a) of IFRS 1.</font></div><div style="margin-bottom:5pt;padding-left:42.51pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.65pt">Consequently, the assets and liabilities were measured on the basis of Sanofi&#8217;s date of transition to IFRS (January 1, 2005) before adjustments made for the consolidation procedures of the Sanofi group, in particular adjustments arising from the application of IFRS 3 (Business Combinations) &#8211; such as fair value adjustments to identifiable assets and liabilities, and the recognition of goodwill &#8211; recorded by Sanofi as parent company.</font></div><div style="margin-bottom:5pt;padding-left:42.51pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.65pt">Cumulative currency translation differences accounted for within combined reserves in the opening statement of financial position were deemed to be zero, under the option permitted in paragraph D12(a) of IFRS 1.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The combined financial statements were prepared without taking into account events after the reporting date of the Sanofi group financial statements for the years ended December 31, 2022 and 2021. Events after the end of the reporting date of the Sanofi group financial statements for the year ended December 31, 2023 were taken into account in preparing the combined financial statements for the year ended December 31, 2023, in accordance with IAS 10 (Events After the Reporting Period).</font></div><div id="i439f5d1857c344f7b532f54d2ef05291_381"></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">A.2.3. Basis of preparation of the combined income statement</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The combined income statement presents the historical income and expenses attributable to Opella activities as derived from the accounting records of the Sanofi group, plus income and expenses on transactions incurred by Sanofi on behalf of Opella and reported as related party transactions (note D.27.).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Past transaction flows that relate to the activities of the combined group, and constitute transactions for legal purposes recorded in the Sanofi financial statements, have been attributed directly to Opella activities in the combined financial statements.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In some specific circumstances, the combined income statement reflects certain principles of combination applied in the absence of past transaction flows, or where it was not possible to attribute transactions directly.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principles of combination applied in the combined income statement in such circumstances are described below.</font></div><div style="margin-bottom:5pt;margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue generated by Opella with the Sanofi group</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Revenues of the combined group include sales of Opella products, classified within the line item </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net sales</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the combined income statement.</font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Revenues generated by transactions with Sanofi, classified in the line item </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the combined income statement, derive mainly from the following activities&#58;</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Intra-legal entity sales between Opella and the Sanofi group</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Transactions carried out within a single legal entity between Opella industrial sites and Sanofi pharmaceutical sites do not constitute a transaction for legal purposes. However, such transactions have been separately identified and recorded as deemed transactions between the combined group and the Sanofi group in the combined income statement.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Such transactions are measured at the transfer price used by the Sanofi group for similar transactions as of the date of the transaction, in accordance with the currently applicable transfer pricing policy.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Manufacture of Sanofi products carried out by Opella on behalf of Sanofi as customer</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Revenue from services involving the manufacture of Sanofi products by manufacturing sites within the combined group on behalf of Sanofi as customer are reflected within </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in the combined income statement, as related party transactions. Transactions between entities in the combined group and Sanofi group entities are measured at the historical internal transfer price, in accordance with the internal transfer pricing policy applicable on the date of the transaction.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Distribution of Sanofi products by Opella to third-party customers of Sanofi</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Where dedicated combined group entities provide distribution services relating to Sanofi pharmaceutical products, the revenue is reflected within </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in the combined statement of comprehensive income as a related party transaction, and is measured at the historical price at which the relevant transactions were recorded in the books of the Sanofi group in accordance with the contractual arrangements applicable as of the date of the transaction.</font></div><div style="margin-bottom:5pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases from the Sanofi group of manufacturing services for Opella products</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The cost of sales of Opella products reflects the historical cost of sales as recorded in the books of the Sanofi group. The purchase cost of Opella products manufactured by Sanofi and commercialized by Opella is the historical Sanofi group internal transfer price. In cases where the historical Sanofi transfer price is determined so as to give consideration for the roles of both manufacturer and intellectual property rights holder, the historical transfer price has been allocated such that the cost of goods sold reflects the distribution margin granted as consideration for the distribution activities carried out by Opella.</font></div><div style="margin-bottom:5pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other bought-in services necessary for the standalone operation of Opella</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In order to reflect the total historical cost of Opella activities, Sanofi resources and infrastructure shared with Opella have been allocated based on the use made of them by Opella.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principles used for such allocations were designed to reflect the nature of the underlying expenses, so as to ensure they were relevant and consistently applied for all periods presented. Consequently, allocation principles were determined for each function involved. For example, full time equivalent (FTE) allocated hours per Sanofi employee whose service benefits Opella activities was determined to be an appropriate basis for allocating the costs of the Sanofi group&#8217;s global support functions. Allocation formulae based on business activity or size, such as net sales, purchases, value added (for industrial sites) or total assets, were used for that purpose. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Such allocations relate primarily to the following global support functions&#58;</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.65pt">support functions such as legal affairs, finance, information systems, communications, human resources, and property rental&#47;management (note A.2.4.)&#59; expenses related to customer relationship management, order processing, and procurement&#59; and costs relating to Sanofi&#8217;s executive management (for example, the Executive Committee)&#59;</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.65pt">medical and regulatory activities, and promotional and commercial support such as business intelligence, market access, and analytical&#47;predictive intelligence&#59;</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.65pt">industrial support activities such as Health, Safety &#38; Environment (HSE), global quality, and industrial excellence, along with costs incurred relating to REACH regulations and recognized in profit or loss for the period&#59;</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.65pt">insurance and risk coverage programs including property and loss of profits, public liability, product liability, inventory and goods-in-transit cover, and environmental risks&#59; and</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.65pt">centralized cash pooling, including netting arrangements and hedging of foreign exchange risk.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">To the extent that they provide no benefit to Opella's activities, costs relating to the creation of the Opella standalone unit do not impact the statements of comprehensive income in the combined financial statements of Opella over all the periods presented.</font></div><div style="margin-bottom:5pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee compensation and payroll-related charges</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Personnel costs mainly represent the costs of transferred employees dedicated to Opella activities.</font></div><div style="margin-bottom:5pt;text-align:justify;text-indent:5.85pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Those costs include&#58;</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.65pt">salaries and bonuses (including social security charges) and other long-term post-employment benefits, as reflected in Sanofi&#8217;s payroll systems&#59;</font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">41</font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.65pt">expenses related to equity-based compensation plans, determined (i) by reference to the existing equity-based plans awarded by the Sanofi group to employees belonging to Opella activities and deemed to be Opella group employees and (ii) on the basis of the historical fair values of those plans in the financial statements of the Sanofi group in accordance with IFRS 2 (Share-Based Payment), given that Opella is not constituted as a separate legal group&#59; and</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.65pt">statutory and voluntary profit-sharing schemes for employees of the Opella group.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The payroll contribution for non-transferred Sanofi employees whose service benefits Opella activities is included within the total costs of central support functions incurred by the Sanofi group and allocated to Opella using the principles described in the previous section.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The combined financial statements include the current and non-current portions of employee-related liabilities for employees of the combined group. A net asset or liability position has been recognized in the combined statements of financial position for contributions in respect of Sanofi employees not transferred to the combined group (notes A.2.5. and D.27.).</font></div><div style="margin-bottom:5pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income taxes</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Income tax expense comprises current and deferred taxes, determined as if the activities within the scope of combination constitute separate taxable entities.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The accounting principles applied to current and deferred taxes receivable and payable, and to deferred tax assets and liabilities, are described in the section on the basis of preparation of the statement of financial position (note A.2.4.).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Although the approach used to determine income tax expense (or gain) is appropriate for the purposes of preparing combined financial statements, it is a purely indicative measure of what the income tax expense (or gain) of the combined group would have been if it had been constituted of separate taxable entities.</font></div><div id="i439f5d1857c344f7b532f54d2ef05291_384"></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">A.2.4. Basis of preparation of the combined statement of financial position</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">The combined financial statements present assets and liabilities directly attributable to the combined group, plus assets and liabilities derived from related party transactions.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal conventions used for allocations in the combined statement of financial position are described below.</font></div><div style="margin-bottom:5pt;margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The goodwill reported in the combined financial statements results from the application of purchase accounting to assets and liabilities acquired in business combinations carried out by legal entities included within the scope of combination in accordance with IFRS 3 (Business Combinations) (note A.2.2.).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The goodwill carried in the statement of financial position relates to the acquisition on September 29, 2023 by Chattem Inc., a company included in the scope of combination, of QRIB Intermediate Holdings, LLC (notes D.1. and F.).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Right-of-use assets and lease liabilities</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Leases attributed to Opella activities for which a right-of-use asset and lease liability are recognized comprise&#58;</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.65pt">office space leases contracted by the Sanofi group with floor areas identified as dedicated exclusively to Opella activities and covered by a signed sub-lease on completion of the Pre-Separation Carve-Out Transactions (otes C.2. and E.), for which a right-of-use asset and lease liability are reported in the Opella combined financial statements for the portion attributable to Opella activities&#59; and</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.65pt">leases relating to industrial buildings or storage centers contracted (i) by dedicated legal entities included in the scope of combination, for which the right-of-use asset and lease liability are recognized at their historical carrying amounts as recorded in the financial statements of the entity in question&#59; and (ii) by Sanofi subsidiaries, for which the right-of-use asset and corresponding lease liability have been allocated proportionately to the portion attributable under the overall agreement entered into by Sanofi with the lessor and for which a separate lease agreement has been established on completion of the Pre-Separation Carve-Out Transactions (note E).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Minimum future lease payments under non-cancellable leases may change following the Pre-Separation Carve-Out Transactions (see note E.).</font></div><div style="margin-bottom:5pt;margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts payable</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Accounts payable (other than those involving related parties) are directly attributed to the combined group where the amounts payable relate to purchases of goods and services related to products falling within the scope of Opella activities.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Where it is not possible to attribute accounts payable directly on the basis described above, a historical liability has been allocated based on accounts payable as recognized in the Sanofi consolidated statement of financial position, using allocation formulae consistent with those used for the underlying expenditure or purchases of materials, taking account of the historical payment terms observed for total purchases over the period.</font></div><div style="margin-bottom:5pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Combined equity, and financing of the combined group</font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As a combination of Sanofi activities under common control, Opella has no share capital for all of the periods presented. Combined equity represents the sum total of (i) net income attributable to Opella and (ii) net additional contributions from equity holders of the Sanofi group to Opella. The impacts of those contributions are recorded in equity, which reflects contributions and distributions (repayments) deemed to have been made between equity holders of Opella and equity holders of Sanofi.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in combined equity arise from (i) comprehensive income for the period&#59; (ii) dividends paid by legal entities within the scope of combination (note F.)&#59; (iii) the value of services obtained from employees under equity-based compensation plans (note D.22.)&#59; and (iv) net contributions from equity holders of the Sanofi group, reflecting cash flows from Opella activities carried on by Sanofi subsidiaries (note B.13.). </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Financing provided by Sanofi for Opella activities during all the periods presented is reflected in the combined financial position of Opella (i) as net contributions from equity holders of Sanofi, where such activities are carried on by Sanofi subsidiaries and (ii) by current financial assets and liabilities vis-&#224;-vis Sanofi, where such activities are housed within dedicated subsidiaries included in the scope of combination that are parties to Sanofi&#8217;s cash pooling agreement.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The ultimate creation of the parent entity of the Opella group on completion of the Pre-Separation Carve-Out Transactions may alter the financing structure of Opella activities as reflected in the combined financial statements. The combined financial statements presented below were prepared without anticipating the effects of the legal reorganization, which will take place in 2024.</font></div><div style="margin-bottom:5pt;margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Long-term debt</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Long-term bank borrowings and debt instruments are presented in the combined statement of financial position where they were either (i) contracted directly by entities carrying on dedicated Opella activities or (ii) represented a component of contributions to the newly-formed entities created as a result of the Pre-Separation Carve-Out Transactions.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Because the bulk of financing is provided by the Sanofi group, long-term debt mainly comprises loans and borrowings contracted with the Sanofi group (notes D.16 and D.27.).</font></div><div style="margin-bottom:5pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-term debt, cash and cash equivalents</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Bank borrowings and debt instruments are initially measured at fair value of the consideration received, net of directly attributable transaction costs.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Cash and cash equivalents as shown in the statement of financial position and statement of cash flows comprise cash, plus liquid short-term investments that are readily convertible into cash and are subject to an insignificant risk of changes in value in the event of movements in interest rates and are held by legal entities included in the Opella group.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">With the exception of legal entities dedicated to Opella activities (note F.), cash flows derived from Opella activities housed within non-dedicated legal entities included in the scope of combination are treated as equity transactions with equity holders of the Sanofi group, the effects of which are recorded within combined equity.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Legal entities that exclusively carry on Opella activities (note F.) are included in the Sanofi group cash pooling agreement. Consequently, the related year-end balances are included in Other financial assets (in the case of debit balances) or Other financial liabilities (in the case of credit balances) in the Opella combined statement of financial position.</font></div><div style="margin-bottom:5pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current and deferred income tax assets and liabilities</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Current and deferred income tax expenses, and tax receivables and liabilities, have been determined in accordance with the principles described above for the preparation of the combined income statement (note A.2.3.).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are recognized where temporary differences arise between the carrying amount and taxable base of assets and liabilities reflected in the Opella combined financial statements, in accordance with the principles specified in IAS 12 (note B.21.).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Deferred tax assets arising from temporary differences between carrying amounts and tax bases, or from tax losses available for carry-forward, are recognized if their recovery is regarded as probable.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the absence of an offset clause, no deferred tax assets have been recognized in the statement of financial position in respect of tax losses which have generated tax savings that were transferred to Sanofi as parent entity under group tax agreements. Transfers of tax savings are reflected in equity as contributions or distributions vis-&#224;-vis the equity holders of Sanofi for each period presented.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Tax receivables and liabilities generated by Opella activities of non-dedicated entities that are not required to submit separate tax returns have been recognized in the combined financial statements in the periods during which they were generated, and are deemed to have been distributed or transferred to the taxable entities of the Sanofi group in line with the tax payment schedule applying to each entity.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Tax payments made by dedicated legal entities or deemed to have been made by non-dedicated legal entities in the scope of combination are presented in the statement of cash flows in the same way as the underlying transaction.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Tax receivables and tax liabilities determined for non-dedicated legal entities and for dedicated legal entities belonging to a group tax election are presented within the line items </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other non-current assets</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other current assets</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other non-current liabilities</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other current liabilities </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in the Opella combined statement of financial position.</font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">43</font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#008080;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The impacts of deferred taxes on the Opella combined statement of financial position are presented in note D.13.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The basis of preparation described above enables the financial information to reflect the assets and liabilities of Opella, the results of its operations, and the costs of the support functions that would be necessary for it to operate independently. However, because Opella did not operate as a standalone entity during the periods presented, the financial information may not be representative of the future performance of the business, and may not necessarily reflect what the results of operations, financial position or cash flows would have been if Opella had been a standalone entity operating separately from the Sanofi group during the periods presented.</font></div><div id="i439f5d1857c344f7b532f54d2ef05291_387"></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">A.2.5. Related party transactions</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">Transactions with (i) entities over which Sanofi exercises control or significant influence and (ii) joint ventures, which are customarily accounted for as intragroup transactions and eliminated as part of the consolidation procedures applied for the purposes of preparing the Sanofi consolidated financial statements, have been treated as related party transactions where they are not intragroup transactions within the Opella group. Such transactions are reported as related party transactions in the Opella combined financial statements, in accordance with IAS 24 (Related Party Disclosures) (note D.27.).</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Transactions between related parties (the combined group and Sanofi) comprise the following types of transaction&#58;</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.65pt">sales of services in the form of the distribution of pharmaceutical products on behalf of Sanofi as customer&#59;</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.65pt">sales of services in the form of the manufacture of pharmaceutical products for Sanofi as customer&#59;</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.65pt">purchases of services in the form of the manufacture by Sanofi of products from the Opella portfolio&#59;</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.65pt">purchases of other general and administrative services necessary for carrying on Opella activities, mainly comprising (i)&#160;the costs of Sanofi personnel engaged on Opella activities but who are not intended to be transferred and (ii) the costs of using shared resources. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition to short-term current accounts with Sanofi (note A.2.4.), the combined statement of financial position includes the following positions with related parties&#58;</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Accounts receivable and other current receivables with related parties (notes D.11 and D.27.)</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.65pt">Accounts receivable resulting from commercial transactions entered into with Sanofi group companies, representing the last two months of sales in line with historical payment terms applied within the Sanofi group&#59; and</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.65pt">Other current receivables resulting from services provided by the combined group to the Sanofi group, estimated on the basis of internal payment terms applied within the Sanofi group.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Accounts payable and other current liabilities with related parties (notes D.16.1 and D.27.)</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.65pt">Accounts payable, representing liabilities arising on Opella products supplied by Sanofi manufacturing facilities, and reflecting internal payment terms applied within the Sanofi group&#59;</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.65pt">Liabilities related to shared central services and other liabilities, after taking account of internal payment terms applied within the Sanofi group&#59; and</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:12.65pt">Other liabilities relating to (i) personnel costs and social security charges incurred by Sanofi on behalf of the combined group in respect of employees not intended to be transferred (note D.21.), and (ii) income taxes of entities that were not separate legal entities as of the end of the reporting period.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As specified in the section on combined equity (note A.2.4.), payments in respect of related party transactions are ultimately reflected in cash flows from financing activities within the statement of cash flows, and recognized within the equity of the combined group as net contributions from equity holders of Sanofi to the combined group.</font></div><div style="margin-bottom:5pt"><font><br></font></div><div id="i439f5d1857c344f7b532f54d2ef05291_1081"></div><div style="margin-bottom:5pt;margin-top:9pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.2.6. Impact of climate change</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In preparing the combined financial statements, the impact of climate change on the current valuation of assets and liabilities has been taken into account. The combined group does not consider there to be any material impact on judgments relating to financial information or estimates as a result of climate change, and consequently the valuation of assets and liabilities has not been materially affected by climate risks during all three periods presented. The impact of climate change on growth rates and cash flow projections used in connection with impairment testing of goodwill and license agreements (note D.5.) was specifically considered.</font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">44</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_390"></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:12pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:139%">C&#47;Non-IFRS Alternative Performance Measures (APMs)</font></div><div id="i439f5d1857c344f7b532f54d2ef05291_393"></div><div><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">C.1. Definitions of non-IFRS APMs</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">In addition to IFRS performance measures like Operating income (EBIT), Opella also uses several alternative, non-IFRS performance measures to monitor and evaluate its operating and financial performance. Adjusted Gross Profit, Adjusted EBIT (and Adjusted EBIT Margin), Adjusted EBITDA, and Free Cash Flow are alternative performance measures within the meaning of AMF position statement 2015-12.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">Opella believes that these non-IFRS alternative performance measures provide useful and relevant information regarding its performance and improve its ability to assess its financial position. While similar measures are widely used in the industry in which it operates, the financial measures Opella uses may not be comparable to other similarly titled measures used by the Sanofi Group (such as Net Debt or Free Cash Flow) or by other companies, nor are they intended to be regarded as substitutes for measures of financial performance or financial position as prepared in accordance with IFRS. </font></div><div id="i439f5d1857c344f7b532f54d2ef05291_396"></div><div style="margin-bottom:3pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:139%">C.1.1. Adjusted Gross Profit</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">Adjusted Gross Profit, which is reviewed by management and which Opella regards as providing useful information to measure its operational performance, is determined by making the following adjustments to </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:139%">Gross profit</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%"> &#58; </font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%;padding-left:15.1pt">eliminating amortization and impairment losses charged against intangible assets (other than software and other rights of an industrial or operational nature) and recognized in </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:139%">Cost of sales</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">&#59; </font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%;padding-left:15.1pt">eliminating amounts recognized in </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:139%">Cost of sales</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%"> arising from the effects of restructuring programs, including (i) costs associated with collective employee separation plans, (ii) compensation paid to third parties for early termination of contracts or commitments entered into as a result of transformation and reorganization decisions, (iii) accelerated depreciation associated with the closure of sites (including leased sites), and (iv) losses on asset divestments resulting from such decisions&#59; and</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%;padding-left:15.1pt">eliminating expenses recognized in </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:139%">Cost of sales</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%"> arising from the remeasurement of assets acquired in a business combination (IFRS 3) or from acquisitions of groups of assets that do not constitute a business within the meaning of paragraph 2(b) of IFRS 3. </font></div><div id="i439f5d1857c344f7b532f54d2ef05291_399"></div><div style="margin-bottom:3pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:139%">C.1.2. Adjusted EBIT (and adjusted EBIT margin)</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">Opella reports segment operating results on the basis of Adjusted EBIT.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">Adjusted EBIT, used internally by management to measure the operational performance of each operating segment and to allocate resources, is determined by making the following adjustments to </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:139%">Operating income</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%"> (EBIT) as reported under IFRS&#58;</font></div><div style="margin-bottom:5pt;padding-left:21.25pt;text-align:justify;text-indent:-14.2pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%;padding-left:11.87pt">eliminating amortization and impairment losses charged against intangible assets (other than software and other rights of an industrial or operational nature)&#59;</font></div><div style="margin-bottom:5pt;padding-left:21.25pt;text-align:justify;text-indent:-14.2pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%;padding-left:11.87pt">eliminating fair value adjustments to contingent consideration related to (i) business combinations (IFRS 3) or (ii) business divestitures&#59;</font></div><div style="margin-bottom:5pt;padding-left:21.25pt;text-align:justify;text-indent:-14.2pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%;padding-left:11.87pt">eliminating expenses arising from the remeasurement of assets acquired in a business combination (IFRS&#160;3), or from acquisitions of groups of assets that do not constitute a business within the meaning of paragraph&#160;2(b) of IFRS&#160;3&#59;</font></div><div style="margin-bottom:5pt;padding-left:21.25pt;text-align:justify;text-indent:-14.2pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%;padding-left:11.87pt">eliminating the effects of restructuring programs, including (i) costs associated with collective employee separation plans, (ii) compensation paid to third parties for early termination of contracts or commitments entered into as a result of transformation or reorganization decisions, (iii) accelerated depreciation associated with the closure of sites (including leased sites), and (iv) losses on asset divestments resulting from such decisions&#59;</font></div><div style="margin-bottom:5pt;padding-left:21.25pt;text-align:justify;text-indent:-14.2pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%;padding-left:11.87pt">eliminating the costs of the separation of the Sanofi group's activities, including marginal and non-recurring costs associated with the separation of the combined group's activities from those of the Sanofi group to enable full standalone operation of the combined group and the eventual exit from the transitional service agreements entered into with Sanofi&#59;</font></div><div style="margin-bottom:5pt;padding-left:21.25pt;text-align:justify;text-indent:-14.2pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%;padding-left:11.87pt">eliminating other gains and losses, litigation, and other items regarded as being of an unusual nature or amount&#59;</font></div><div style="margin-bottom:5pt;padding-left:21.25pt;text-align:justify;text-indent:-14.2pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%;padding-left:11.87pt">adding back the share of profits&#47;losses from investments accounted for using the equity method, to the extent that this relates to joint ventures and associates with which the combined group has a strategic alliance&#59; and</font></div><div style="margin-bottom:5pt;padding-left:21.25pt;text-align:justify;text-indent:-14.2pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%;padding-left:11.87pt">deducting the share attributable to non-controlling interests.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">&#34;Adjusted EBIT margin&#34; is the ratio of Adjusted EBIT to net sales.</font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">45</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_402"></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:139%">C.1.3. Adjusted EBITDA</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">Adjusted EBITDA is an alternative, non-IFRS financial measure monitored by management, which is considered by Opella to provide useful information for measuring its operational performance.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">Adjusted EBITDA is calculated by adding the following items back to Adjusted EBIT&#58; depreciation, amortization and impairment of (i) property, plant and equipment (including rights of use relating to leased assets) and (ii) software and other rights of an industrial or operational nature.</font></div><div id="i439f5d1857c344f7b532f54d2ef05291_405"></div><div style="margin-bottom:3pt;margin-top:9pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:139%">C.1.4. Free Cash Flow</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">Free Cash Flow is an alternative, non-IFRS financial measure monitored by management, which is considered by Opella to provide useful information for measuring the net cash generated by its operations and available for (i) strategic M&#38;A activity, (ii) repayment of debt and (iii) returning capital to equity holders.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">Free cash flow is determined by reference to the closest IFRS measure, </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:139%">Net cash provided by&#47;(used in) operating activities</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">, as presented in the combined financial statements. That figure is adjusted for the amounts reported for &#34;Acquisitions of property, plant and equipment and intangible assets&#34;, &#34;Acquisitions of equity interests and other non-current assets&#34;, and &#34;Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax&#34;&#59; for cash flows related to significant litigation and other items regarded as unusual due to their nature or amount (including the impact of exchange rates on intragroup financing transactions), while excluding strategic investments (net of divestments).</font></div><div id="i439f5d1857c344f7b532f54d2ef05291_408"></div><div style="margin-bottom:12pt;margin-top:9pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:139%">C.2. Reconciliation of IFRS historical financial information to non-IFRS APMs</font></div><div id="i439f5d1857c344f7b532f54d2ef05291_411"></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:139%">C.2.1. Reconciliation of Gross Profit to Adjusted Gross Profit</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">A reconciliation of Adjusted Gross Profit to Gross Profit for the years ended December 2023, 2022, and 2021 is provided below.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(in &#8364; million unless otherwise indicated)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross profit</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,574</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,639</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,116</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring, and separation costs and similar expenses*</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization and impairment losses charged against intangible assets (other than software and other rights of an industrial or operational nature)*</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expenses arising from fair value remeasurements of inventories under IFRS 3</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjusted gross profit</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,642</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,691</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,152</font></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">(*) Only the amounts recognized in cost of sales are included in this calculation.</font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">46</font></div></div></div><div id="i439f5d1857c344f7b532f54d2ef05291_414"></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:139%">C.2.2. Reconciliation of IFRS operating income (EBIT) to adjusted EBITDA</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">A reconciliation of Adjusted EBITDA to EBIT for the years ended December 31, 2023, 2022, and 2021 is provided below.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(in &#8364; million unless otherwise indicated)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:2.25pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:133%">EBIT </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:700;line-height:133%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;1,233&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;1,221&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;1,180&#160;&#160;&#160;&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring, and separation costs and similar expenses*</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">171</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization and impairment losses charged against intangible assets (other than software and other rights of an industrial or operational nature)</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other gains and losses, and litigation</font></div></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">205</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#8212;&#160;&#160;&#160;&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expenses arising from fair value remeasurements of inventories under IFRS 3</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#8212;&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#8212;&#160;&#160;&#160;&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit&#47;(loss) from investments accounted for using the equity method</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(15)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(11)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(31)</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjusted EBIT</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;1,480&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;1,555&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;1,247&#160;&#160;&#160;&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets**</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">95</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjusted EBITDA</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;1,575&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;1,645&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;1,328&#160;&#160;&#160;&#160;</font></td></tr></table></div><div style="margin-top:5pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">(a) This line item corresponds to &#34;Operating income&#34; as per the IFRS combined income statement.</font></div><div style="margin-top:1pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">(*) Related cash outflows amounted to &#8364;95 million, &#8364;37 million and &#8364;52 million for the years ended December 31, 2023, 2022 and 2021, respectively.</font></div><div style="margin-top:1pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">(**) Excluding &#8364;57 million, &#8364;51 million and &#8364;30 million already restated in Adjusted EBIT for the years ended December 31, 2023, 2022 and 2021, respectively.</font></div><div id="i439f5d1857c344f7b532f54d2ef05291_417"></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:139%">C.2.3. Reconciliation of Net cash provided by&#47;(used in) operating activities to Free Cash Flow</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">The table below sets forth a reconciliation between </font><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:139%">Net cash provided by&#47;(used in) operating activities</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%"> and Free Cash Flow for the years ended December 31, 2023, 2022, and 2021&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(in &#8364; million unless otherwise indicated)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net cash provided by&#47;(used in) operating activities</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,067</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">776</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,082</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment and intangible assets</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(138)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(132)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(117)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.02pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from disposals of property, plant and equipment and intangible assets and other non-current assets, net of tax**</font></div></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">218</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">177</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">158</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.02pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other items***</font></div></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">264</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(2)</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Free Cash Flow</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;1,197&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;1,086&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;1,122&#160;&#160;&#160;&#160;</font></td></tr></table></div><div style="margin-top:5pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">(**) The pre-tax gains on divestments carried out in 2023, 2022 and 2021 presented in &#8220;Other operating income and expenses&#8221; of the combined income statements amount at &#8364;236 million, &#8364;213 million and &#8364;195 million respectively.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(***) Includes a one-off tax charge of &#8364;273 million in 2022 related to Reorganization operations in the United States.</font></div><div id="i439f5d1857c344f7b532f54d2ef05291_420"></div><div style="margin-bottom:12pt;margin-top:9pt"><font style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:139%">C.3. Reconciliation of historical non-IFRS APMs to restated APMs</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">Certain performance measures have been presented on a restated basis in order to reflect how Opella would have operated if it had been separated from the Sanofi group since January 1, 2021. The restatements made to the historical financial information are set forth in the table below&#58;</font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">47</font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.655%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.962%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.655%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.660%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(in &#8364; million unless otherwise indicated)</font></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Historical financial information</font></td><td colspan="12" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restatements</font></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restated financial information</font></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Scope adjustments</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">FAO</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi agreements</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:100%">Year ended December 31, 2023</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net Sales</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,174&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(160)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,015&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:0.02pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</font></div></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">606&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(65)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">516&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjusted gross profit</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,642&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(174)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,463&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjusted EBIT</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,480&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(82)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(60)</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,339&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjusted EBITDA</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,575&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(82)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(60)</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,433&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Free Cash Flow</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,197&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(37)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(50)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,094&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:100%">Year ended December 31, 2022</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net Sales</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,201&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(177)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,024&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:0.02pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</font></div></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">629&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(109)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(19)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">501&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjusted gross profit</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,691&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(199)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,481&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjusted EBIT</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,555&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(91)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(90)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,371&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjusted EBITDA</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,645&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(91)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(90)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,460&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Free Cash Flow</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,086&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(90)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(68)</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">931&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:100%">Year ended December 31, 2021</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net Sales</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,565&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(133)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,432&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:0.02pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</font></div></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">632&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(140)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">463&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjusted gross profit</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,152&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(135)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,030&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjusted EBIT</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,247&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(50)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(100)</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,119&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjusted EBITDA</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,328&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(50)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(100)</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,201&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Free Cash Flow*</font></td><td colspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,122&#160;</font></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N&#47;A</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr></table></div><div style="margin-top:5pt;padding-left:11.35pt;text-align:justify;text-indent:-11.35pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:139%">*Due to practical considerations, Free Cash Flow has not been restated for the year ended December 31, 2021.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">The historical organization of Opella's activities differs from the target organizational structure on implementation of the Reorganization. To give investors a better understanding of the contractual and organizational implications of the implementation of Opella&#8217;s new business model resulting from the Reorganization, Opella is voluntarily providing financial information restated as though the Reorganization had been implemented as of January 1, 2021, for the following indicators&#58; restated Net Sales, restated Other Revenues, restated Adjusted Gross Profit, restated Adjusted EBIT, restated Adjusted EBIT margin, restated Adjusted EBITDA and Free Cash Flow.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">This restated financial information is unaudited, and relies on certain assumptions and estimates regarded as reasonable by management.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">The restatements primarily consist of the following&#58;</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:139%;padding-left:15.1pt">&#8220;Scope restatements&#8221;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">&#58; for the following items, revenues and costs as recognized in the combined financial statements have been replaced by revenues and costs reflecting Opella's new business model&#58;</font></div><div style="padding-left:56.69pt;text-indent:-14.18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.85pt">Opella products in China, for which the transfer of the market authorizations from Sanofi to Opella will be finalized no later than 2028, at the end of a transitional period required to complete the transfer plan agreed with Sanofi in the context of public tendering arrangements. The restatement reflects (i) the loss of the associated net sales, and (ii) the share of </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> generated as a result of Opella supplying Sanofi with the active ingredients required for the manufacture of those products&#59; </font></div><div style="padding-left:20.69pt;text-align:justify;text-indent:3.82pt"><font><br></font></div><div style="padding-left:56.69pt;text-align:justify;text-indent:-14.18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.85pt">prescription products in Japan distributed by the Sanofi group. The restatement reflects the loss of </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">associated with those products as consideration for (i) the royalties that Opella will receive from the Sanofi group as holder of the intellectual property rights, and (ii) other revenues generated as a result of some of the production being provided by the manufacturing capability of Opella&#59; and</font></div><div style="padding-left:20.69pt;text-align:justify;text-indent:3.82pt"><font><br></font></div><div style="padding-left:56.69pt;text-align:justify;text-indent:-14.18pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.85pt">the Russian legal entity, historically part of the consumer healthcare business within Sanofi, which will not be transferred (due to legal constraints) by the date of Opella&#8217;s initial public offering. The relevant activity in that </font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">48</font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="padding-left:56.69pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">country will be conducted via a distribution agreement with effect from the Separation date (see Section 17.1, &#34;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Agreements entered into between Sanofi and Opella for completion of the Separation</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#34;), until such time as the transfer can be completed. The restatement reflects the impact of the loss of distribution profits, which will be retained by Sanofi under the new business model.</font></div><div style="padding-left:20.69pt;text-indent:3.82pt"><font><br></font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:139%;padding-left:15.1pt">&#8220;Functional Autonomy Organization (FAO)&#8221;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">&#58;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">the restatement involves cancelling some of Sanofi's central costs invoiced to Opella, and applying retrospectively the effects of implementing the target organizational structure expected to be in effect from the Separation date. The additional costs relative to the historical financial statements mainly relate to the setting up of (i) the IT function and (ii) other functions (in particular Insurance, Science, Finance and Real Estate Facility Management). These additional costs include but are not limited to&#58;</font></div><div style="margin-bottom:5pt;padding-left:56.7pt;text-align:justify;text-indent:-14.2pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%;padding-left:11.87pt">personnel costs calculated on the basis of the number of full-time equivalents (FTEs) required per function and of applicable market salaries&#59; and</font></div><div style="margin-bottom:5pt;padding-left:56.7pt;text-align:justify;text-indent:-14.2pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%;padding-left:11.87pt">costs related to the Forward Transitional Services Agreements, which govern the provision of services between Opella and Sanofi and will take effect from the Separation date in order to ensure continuity of functions not yet carried out by Opella (such as &#91;certain back office and distribution services&#93;).</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%;padding-left:15.1pt">&#8220;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:139%">Sanofi agreements</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">&#8221;&#58; the restatement involves applying retrospectively the supply prices set out in the following agreements entered into between Opella and Sanofi, which will come into force from the Separation date&#58;</font></div><div style="margin-bottom:5pt;padding-left:56.7pt;text-align:justify;text-indent:-14.2pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%;padding-left:11.87pt">Forward MSA&#58; covers non-consumer healthcare products manufactured by Opella for supply to Sanofi. This restatement involves retroactively applying the sales prices as agreed at the effective date in those agreements to historical business volumes.</font></div><div style="margin-bottom:5pt;padding-left:56.7pt;text-align:justify;text-indent:-14.2pt"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%;padding-left:11.87pt">Reverse MSA&#58; covers consumer healthcare products manufactured by Sanofi for supply to Opella. This restatement involves retroactively applying the purchase prices as agreed at the effective date of these agreements to historical business volumes.</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%;padding-left:15.1pt">&#34;</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:139%">Other</font><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">&#34;&#58; the restatement involves cancelling the other revenues and costs associated with certain products not intended for the consumer healthcare sector, which Opella has decided to discontinue in the first half of 2025.</font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">Notwithstanding this restatement, Opella expects to continue benefiting from services and from some synergies for as long as Sanofi remains the controlling shareholder of Opella.</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#661de8;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">End.</font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">49</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image.jpg
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J=PU<#\/^4J5*E2I5JE2I4J7FMIS['Q-1/-?G =S"     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image1.jpg
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M@RP@;.^M[X57BIY@P 42D $$P%')#(Y(DO>(X#$.%((_(1* O*%Q ?)> 2B
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MKVFY:>#?F&+/^4/>/Y^!3-45_'S^%[8:?#57"&(1    BF58269-30 J
M"  $ 1H !0    $    ^ 1L !0    $   !& 2@  P    $  @  AVD !
M  $   !.         )     !    D     $  Y*&  <    2    >* "  0
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M,I/,3&;N_4XR<\\]=Y]]SOZ=<V>?M;Z]UO9EN4"+"(B "(B "(B "(B "(B
M"(B "(B "(B "(B "(B "(B "(B "(B "(C @"?@DP \X*^A&B "(B "(B "
M(B "(B "(B "(B "(B "(B "(B "(B "(B "(B "(B "CH $8-T((B "(B "
M(B "(B "(B "(B "(B "(B "(B "(B "(B "(B "(B "(I G!"0 Y\F%5#-$
M0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 *P[@$1
M$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1R!,"$H#S
MY$*J&2(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@
M 5CW@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ CD
M"0$)P'ER(=4,$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !
M$1 !$9  K'M !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1
M!$1 !/*$@ 3@/+F0:H8(B( (B( (B( (B( (B( (B( (B( (B( (B( (B( (
MB( (B( (B( (2 #6/2 "(B "(B "(B "(B "(B "(B "(B "(B "(B "(B "
M(B "(B "(B ">4)  G">7$@U0P1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$
M0 1$0 1$0 1$0 1$0 0D .L>$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1
M$ $1$ $1$ $1$ $1$($\(2 !.$\NI)HA B(@ B(@ B(@ B(@ B(@ B(@ B(@
M B(@ B(@ B(@ B(@ B(@ B(@ A* =0^(@ B(@ B(@ B(@ B(@ B(@ B(@ B(
M@ B(@ B(@ B(@ B(@ B(@ B(0)X0D "<)Q=2S1 !$1 !$1 !$1 !$1 !$1 !
M$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !"<"Z!T1 !$1 !$1 !$1 !$1 !$1
M!$1 !$1 !$1 !$1 !$1 !$1 !$1 !$0@3PA( ,Z3"ZEFB( (B( (B( (B( (
MB( (B( (B( (B( (B( (B( (B( (B( (B( (B( $8-T#(B "(B "(B "(B "
M(B "(B "(B "(B "(B "(B "(B "(B "(B "(I G!"0 Y\F%5#-$0 1$0 1$
M0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 *P[@$1$ $1$ $1
M$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1R!,"$H#SY$*J&2(@
M B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ 5CW@ B(
M@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ CD"0$)P'ER
M(=4,$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$9
MK'M !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !/*$
M@ 3@/+F0:H8(B( (B( (B( (B( (B( (B( (B( (B( (B( (B( (B( (B( (
MB( (2 #6/2 "(B "(B "(B "(B "(B "(B "(B "(B "(B "(B "(B "(B "
M(B ">4)  G">7$@U0P1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$
M0 1$0 1$0 0D .L>$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1
M$ $1$ $1$($\(2 !.$\NI)HA B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@
M B(@ B(@ B(@ B(@ A* =0^(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(
M@ B(@ B(@ B(@ B(0)X0D "<)Q=2S1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !
M$1 !$1 !$1 !$1 !$1 !$1 !"<"Z!T1 !$1 !$1 !$1 !$1 !$1 !$1 !$1
M!$1 !$1 !$1 !$1 !$1 !$0@3PA( ,Z3"ZEFB( (B( (B( (B( (B( (B( (
MB( (B( (B( (B( (B( (B( (B( (B( $8-T#(B "(B "(B "(B "(B "(B "
M(B "(B "(B "(B "(B "(B "(B "(I G!"0 Y\F%5#-$0 1$0 1$0 1$0 1$
M0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 *P[@$1$ $1$ $1$ $1$ $1
M$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1R!,"$H#SY$*J&2(@ B(@ B(@
M B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ 5CW@ B(@ B(@ B(
M@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ CD"0$)P'ER(=4,$1 !
M$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$9  K'M !$1
M!$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !/*$@ 3@/+F0
M:H8(B( (B( (B( (B( (B( (B( (B( (B( (B( (B( (B( (B( (B( (2 #6
M/2 "(B "(B "(B "(B "(B "(B "(B "(B "(B "(B "(B "(B "(B ">4)
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M)!HH>PK ;>&9P=:J,/'5%Z @'"BC4%7M10F;.)Q3=]KNIO6\)Y!O#Y<F_IJ
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MZ:;"V3#>G/<&_(SZ?<\QIV/5FV]CR>MOX8P/G8JJJ57<,X+2R""\^<R;6/#
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M^BB".P'82Z%V0,^W%PXN1T<O0%65!45@X/1%!759U-@!1D!]T0"[8#K=?D=
M?=&>E\12*]L@SSA]!*LWKL-U-_T4_M($MFY?AD$4@"LH^-94C<:\EU>BI'08
MBDO+$.:\N26<M]?/_?S</\A!M35\;U/FE$:*4#%D,(*A*-:\MAS/_>-)'#OG
M&#PW[T4<?]:I&#EC#+:V;*;0R_VB3,',?Y8"NIF";L+$7@J\]N.E@K9(7Q.
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MH-MB]V+']V-]71/^Z_-?Q;P7F7(,C/QEY*Z?Z;O<%R47S=L5 =B.81:,WR*
MN4JG@1EX,P^>C%_]]MNHJ*(RR\_\V0@=$@'<_L+S^-W#]W%^*CH[_&8P<7^+
M-&Z=1]@?KG/KF82E$XLC0 ,NU5*,$>7K<<;A2S!Q, W'%B8F2W-.X1 -*HK
M[GMH![>F6U6VWG'3[=.^7UK/Q_Y$&*ZL#9,GFJ+@8,P8\Q4,J9G#J&8Z85S$
M]JY&:]^?;.\<L= <';U#4;46,H&!U1<5\I52V_LS ?5%_?GJZ-P& @'U1=Y5
M,M$W)_PF&7D;"#'2EW;)KV[[#5;7K\:*]4M0W[@&Q>$T!I>58_8A1^.MMS9S
MBIPJ%!53]&'9<"C"%,L13GL31!FW%06"G(>W&9%@ %%&X19'*K'QC148Y"]#
M,I;&/QY] !_^W+\C5!7%R@TK,'1H#5,W)]QY6$KG-(V,)#,]V;8$WSL!V$4
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M:!%MO0YAZ@/U16WO 8NF!WY]_6/XQ=4/8<Z[QN-;/ST?H\?6X/Z[7\:/O_D
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MJUD"%@'\>Q<!/.OP"?CEGR_>I43;-]=\ZU[\Y7?/8\SX0;B9$<"EG+/W>0K
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MC+F_?!9C)U7CWS]W DYA9&N @[KM?K3%;.(W%ZS!C[[] -8MWX*#F.;Y0 K
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MF5;N5]L]^\&ZNQZMY]':5#-\K4TI&H%IL@C[2S![RE6<!]A& 5,0I&$99$3
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M0):ZBGYF,O[OS]M^H]:> 8,&WD;>K'#R%LTKO\/#S^*F.X;A MT^:Z@I*X)
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MYUY9A=-G+YK)&=?%Z =[8/R(OK3L=55UB!7T[(4_8/6&O]2S%1E3UI72?G:
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ME;Y8^LJY44-P6IJ634,16?-Z*EMXN#E3;$)P.9GYS^OA8'""@6WOW*<K)KU
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MX).M>&/1C_GTV [W#>B H0,Z*=?4>_Z.4 !M)F,T2KIW0$>ZM+Z?GL>T* L
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MYU")@C4:M01^M4A))C"KIX*0SH5S)1VI.><0$!  T?N1T&>&7-[GE-50V5X
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MP?+(J 0<.GP.J6Q/44!=^MVT<6ULWC -OC7,"KC& L#JG>4O&)F<N5E9F$5
M=M*X43QPV6H)2.S?;KT'(38Q01W Y85)DD4@2<J7!P"O6;L18R?-Q$4% #M
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MML)K[ZW#ARMVL'\&!<XNG_<8.M%:V3H)&-[OH?E(H,*@N()^X9G;,&;X+<4
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M809A007\#"PY>AP&\A=5!<I*RUWXCN\+:X"&7MZ*&RD8VH(65<V7RJ9%%06
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M@J9%"XE$62F3\9GZ#WX4>_X^I-Q%J;P4R#_]Z/V8_]8K916]ZGN5"0"_O_0
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M!OB[N"J#0FE_;=E2E@D-'2WY+&+,K!Y4IA(6&DF:TF :XIDQCX#@6FMYJ;&
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ML7VT;?'V8C]^#MUGBZN7C VM7D0VJB:&YJA0="8R696CM3W7>0+ 1J2"1CP
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M^/O6XS@ ^"7/&<*!5)FVF3+@YGU/EB> LA&:\]DF#VN!/*3JU$W>O@&HV4X
M8*Z'?!<V9&N:3%"W&RFQ$Z?7!$6JM9Z!%ZJ>!(LS6&#"H,;HW;%6$@#XZR9E
ML71ZE_@BD@. ^W:L#N=!3?\1 "SC_>[-E[ASP5NCN(QO,@'0"1C2.,3.Q@1=
MZSJB3;4\! /UE;SQ%?Q(!Y^57)16;2 O)1$ +-^CJ3,X=.88%FY>@C!SQC*E
M<X&5L1D]BVQ@'9H#4==IW,0M2I1Q*/RS$12N5  1M($.)X6Y$6FA3?C/B,*
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M6C%_^VU7-&SX%>/#!"M 6=I  ../G3XK18=VJC,00Q51 ,I(,*: =@_#!\^
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M-\R?MU^/$ENW!*5SY8N03R7SL3%4S?@I\X P$!0OG@LCAC1%8QH.?*[ILP:
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M$?Q.2EP*:?H \.AXSS*QV)TV[7O<)?5?J5*E<//F+5H;66/6S!F,6:(1 A(
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MX\>TP)B1']=)\WWJ]SYY/V\ >!\!X#P.2F$W>MPTK-RTD[%XS13P*DH"0RH
M9&&1"2!7EDP$?Y>A2D4-6O^A'L"ZC2MQ-2]>OD8W_;NXY^I&S[<7!*!>,G#U
M*](M^7/W2&]D6EM+'60RBF2,S-JDH-ZS8RV%(GH/Z:0W?F_H =P1M]P?Q@/
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M0D0HJ0)IE"%+>N'<-FA>.1=:?)&'5+MT _T?I\]*+DJKMI*)3GG\BG0E*X<
MP!K&A< P.FWLVH =QWY')L8_C29 9.QG!C,O(V2/S8@ QORU*ID37A&O$$5:
M<B=K.V77&FM#@#>;&:),A&J9H0@L; BVLG3*- 9FC.7+6QI&\E9<@,3IPXCS
M>0Q!8,,8 A TO+5EO[?-9 LOWTB$D-E,^KG,!\(J%$TA2/)+Z#*)*6Y"L%CB
M^DKBK$WU(:/]<O[6 +U" 9T  LL:+GH%^:=B_W)-D7*%O4+ O3".A]"P$ +3
MW'_RMZ@(@L7T (X)CL7P7L/1O%8CI< V8E[M>%0W_N^/7@NDQUHD-]RQ(0X
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MJJ%&-:OB]^WKM%D^RF=: L!;MKN12L *%<IEP^K-=PGL94"SKYSH.94PH0H
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MO'#.C&K^C:4A09!_.+X=4 -]AM55<5*%/EH X&RY;;%Z>P]D2\$#6 ' 8PD
MNR0 P*I8_DG- UC[H.D- +?^I@(IH%/PW.-P20X OD, >/)0QO9]XD>#>3..
M+)EBY&]<BC]F>])01.*)MNA2 2,F->9XUP"2VJPR+MGH_P' "0WR3D=%2X\@
MQN*K!P2*!W"G3M4P?4I[Y8%Z]KQKO#>IO!\QQ)LWNS-I\1EC>_!Z6!(0UJ80
M[NDV;QY,2M\\^*+&)+5FZ(*![P\ OT,,X+=10*<3 "PQD9WR$  ^2@_@=Z"
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M@"4S]T,A@2^Q\_<C.'TE$&\":65+H<4V2Q8,']0>UA3&9L[?C(>/A0*Z%SV
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M)O-H$&K4G<:7IYF?50;^20" 6W ?:$H/U^78\,N9)#%Y0^A)/&!@ \:Y?3L
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M&<89JZ=8'FAL$NE#(Y8GO_#=R6!Z2]*\$I@6GP_##*62[$3^ X#?TGX?<%I
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M95A1\6B7Q5K%Z"U6T)ZR5@Y%A^WUX@U.7W)%2%B4\D*TL\U(ZN@2"FS3WD'
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MC7,T(0UT840^7D#)2-_X0KJA7'WT?##N/8Q SU89D+E %_@$6&/Q#S\2W U
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MM(G@;VS$*WJ9>-/+Q%_S:R+!6YLUR:=XYQ3H!Y-LLC]-FOX#@).V25K](I[
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M\U!SU7'-R?ED/C+F/$>]GBH4,)Q$XYC ;0' :EO6K=O>>1L[N5>JHCOH]H#
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MY*!@%0=;4ZL6B-?8.Z44'I9]NQWW_I(6P%1XN.<O%V+Z62ENL%LU.%"09UD
M9^W)QX6S)^+7]YZC"ILF9O_YY2]A^:)=F$(9XV/_N-(H6.S<FHU[;WT3&]=E
M8=9E8W#-S:>B=\)!3Q;>%8FR4K(0?9I/UGW+PC1M?9:Y29.WQ?Q-:]%=F3F.
M-$GLVPT]XIOOBW=):X;4F9;ZY9W[NQ\?[K6H-0#X[X_^Q "H]S_X%N;\Y<,F
M(*WWW<A*O'^_6,S[^&XD]>W1;@"X@N_RA"EW8S.!SL9*<=7T-I'(4!BW,7[O
MQ1=-,GWQ;G/[CFR\^/*7>/&5;R@#K[#&FE<&)[V8G'/6:,;:_57]V?^\L0BW
MTJ5U(?/[:VQZ)7F6F#1Q .ZZXSR<?.(PX^+9<UG6K@L7I^'A/W^ +[[:V*2O
M4A[2^_;.&[=CYFF65X 6 6#2:AB]HCSWU#4& -;X%S955EZ-]#T'L'C)5EK6
M+L?.772O307)QJF2-'OLD2MPR\_/;'RI_O?1 (#5[P\_7H5+KWS<K'T"<CVI
MBLJ>B?'1!("OQTE3DPW(Z[FF_=_\KU/QF[M>1UI:5H/W2M?T7.[[W44F;K.G
MS/'PW24!8"V$$J8+</$6+'H_D(X P,6T*K[W#W_&BW/?@)MM9_A$%^((LOQ@
MYC2<?NK)&)H\"-%TU2R-CN+B,BQ?N1;/O_)OK%R_@2YIK$&KR3J$QY^]^T],
M&#?*NSL-CK-S<G#&N5=BP^8M"(BDE95[L34:)KRWA%X],'7R>*0,'D0S]C#D
MYA5@1T8FUJ_9@&WI>VDA22LL7_IPY_PN,_PJ@CC#1Z;@T_?G(KY70Y!4#1]N
M +BPJ HC)KR-*DX.5_QD$/HEAC*^'S?4U#YY?UX&EJW.I9"H!K/.2L#)D^)H
M>7-0P"FMWPK^?O>##*Q++<"/+DG"J&%1U@9 !%3B?<F?_)8=)7CC@SV8-B46
MTR>S'@Y@+8:*SU+&^O?G5.#O?SJ1 _GH+'16YSKV>2P!X.K<I2A:]W<*A03H
MMISJ:-$;V'T$0>"?H#+U'O>^X>#$V6Q);L;\^UW/=S 7KJS_\J'08L&SX=#C
MX-_\Y65X]^MJ[,[B1H@:N ZZMXWN%HG33^J+B\X>@E "227%57CEOZE8O"H+
M!;2.]*?+3BFU1H0%8<+(7KABUC#$QH9B7Q;=EG^R!8O69!GW86H@,-"!_O&1
MN/:R$S%B"JU']GZ+TH(LRP7T\@S\B!;&EY^;C.7K]^%O_UI'UQL._/22%$R9
M.)AQ$Z?1TLG:A&_8L %///$4W77L-1:_<LU\^^V_X=B3!?!M!KQ]AD+)S^8U
MM0 6;:21^^RSS^&CCSZFB_(44\=;;[V-3S[Y%+-FG8MKKKFZ@06PK$)EE?O:
M:W,QFC$[;KSQ>KS#F'>+%BWF>T^W5*Q/FUW%#Y(;U=C8'A  _.*+= %]*EU
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M*FIVS^W8:\<US1'5!P%#7VSPRC?7R%$'@,T>F3+-1(8CZ74M[ZLI ^;=3QL
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M+1B-8!4-;17:IMS%.*&//X E&Y=23,$]);TOA7#.]'7YT)M?$/P)L-4:&4<
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M3_V1'F.V(H#N6H5%.3AG^Q(A]@\.140$PX^1S7%*.916M^*A0B/(0Q&D]2$
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MN*IF?HL^2E(LT7TKYO6PY'A<\:.IN/**D^GMMOTXS/:=V7Q>OS6*%5:MUJ<
M^,LNFX*_/SK[L + JGW-VMVX[\&W&#-Z,\,F, :W 'QSX\W=O6AI/;M XF0S
M3DW!@_=?BA2NX\=K.BX 8.M!K270FF\>@%YVQ0$=/7H,+3<\(%+''L'.'3L8
M!#K=JH]/G*\OQHP=2^V(CFD8I._-Q-:MV["/H' 1-V82>H1'A" A(9XOQE#T
M[M6S8QUK1^[M.W=C]ZY=C!.:@S*:7@51"S"F6P1C0M#]QN#^';9F*2@HP-*E
M2^D6E#%*9)7!S<*))YU$[8;8=DT";7596FL??+J++G6J,>OL?CR6U:[ \>Y&
M,Z2RTH6_/[,!(VG)>\;,1*,9OX 6P+MI 7PN+8"[T0*XG!O:5_Z5QG@G@?C1
M#P>9)K.RR_#E-WLQ9$"4L=Q:1TOCBV8-0,_8UMT*MM7?HWG]F + O%%7R2[&
M 7[ NN6V+'((&H7VOP#^D7T9F_!Q-X#;W$39B((L1R2%(.],6O&>1 !X%6IR
M/R>^FVMEY+SJU^LR8^5;D_\-Z[7 +5D$.\).H&5B&&KR5J"N/*.5R;E1FQK1
MO!^_7F>ANF CG'GK66];BQ&%R &A"$FB=9)O6WD;MV?_/A84Z&J"#DOSE:^Y
M]B&TR*VEP$!"75^^NUF9!_#*RV_CDX^_,>Z1?.DF.B#0LF@WH!891&W"I#FK
M?V(8&:3>/!8Q^E*>DE:K-FT"V+1A]&%LJU_]^FI<>=V%!'Y+B1W3';1/* JJ
MZO#8&__#O-7KI.!.+<I*](ABW.V^NS&N7Q7"65P;9458-9M ]TY0?&:G2M[3
MDS;(9@_'<:X-OINAUG$5!3QUO-%A?2['H#Z7\-[H9I,T$MA>1P!8EM%=65AR
MY 4=[7LK]NW;A[ESYV+5JE5\)F3<^ P4-^IP)!._AN]I-RKF*>;O.>><<SBJ
M-74XLYZ!BZ$1VKUAXGL8D#P'OA&C6^T#LZ%Z^^VHS=W ]:O5K-9%%A#8ZC]R
M+I40N[59H*:Z ,[U5UA@DO=8:;-DHPSJJ,IS_C%6\F8"XY@)BH1/: K!65JA
M1(QM-WE4NZH4 %S3;@!X* *2[N$^HG6/-ZK[2*2NMA;E4@DHXZ&G$%9< >?8
M%/2[[]8. <"BL01TZ?_[%.O_^A@5B"J-.VC/:\97Y9 !8%D!;WS^!>1_]!'V
M,_R$K&F5].7/^4*6P'&GG(*!%UV$\#Y]S#7OC^+TW=CQP8?(_?9;E'#.X>R/
M(+I6[G/Q)4B^]AI:5AW<_[4$ !L+X*<$ *MMO:W6_;KH3:IL_W[D< [+^/HK
M5)+7+"LKA],-5"NGG_I(0+<7YZ$QM]QBRGI_- L <ZWO-GDRAM]\"P'@UF-[
M>]=UO!UWEK7H>*.;W5^; AX*=+6UR'-?A^.[A@"PK *I!@LG-5;7;%V/.4\^
MA%+&S95E< "]'HD/<]4%$!R(HIR"<0Q#0Q!,1=PRQK4OIR(/)<7\\Z&@/- H
MU I\U5JG;V\+8 L$IM&*3Q ":DO(-)&?"XZ@MZ023!LU$+OW[,6671D8,R01
M)11 [\HNQ)@QH[ Q=8.)[1L4'(+U&S89KQ%^_O2,1B74Z@H*\QEJR55+U\_T
M2JCU1$8RDCW*Q7,Y^SAM[$GX^>R;&.>QA[%2KJ5RKC_7-S_R,0+/9*1B;<;T
MVUH[#P=MNUH=]EK4U9YH9[H?C5S; KBC3T1NES,9]UDQI37Y:<]?P9CMIY\V
M K^^[1RZ4+9"*DDD==U-SV'#QCT,G\:)W9UDE"89F0#=<\\>P_+6_">7SC?]
M['GC#MC(A_1XF,IIZ7G]-=,Q^ZI3FEC,6CFL3P'.;[^S#-\2H!6864R06<8<
MU;2(50L!@?07P;"$<K$^=' OG#YC)"X\?P*5C!HJG'K7V=KQ@F\WXYWWEF'=
MAKW(R,RG 8,3U6Q/1B2RK/>C-7D0@=R$>!HUC.R+6>>.Q?13AK=6)=:M3\?U
M/_V'Z6>K&7E1<IFPT$"$TZ*X1TP8A@V-Q_AQ S%V3'^SOK95OO'UO9EYN.*J
M)XR,LOX:"5?)9WOFS!-P.Y]M%.,6'XGTU3<;\=[[*[!R]4[D'"@AWE3%-57R
M5TM6*/?UP02W>_2(P,3Q W#^>1-H+)I\)+IR5.L\;@#@HTH5N[$C0H$//]N-
MO()*;-M1@G,(]$ZFZV=/*F$,WQ=>WHRA*3&,^YN(A4NSL#.]B!J, \TD_Z^Y
M:8CM$8R++N1OIDI:G#W^CU0\_LQ&) ^,Q-DS$W#5E4.YX6WH/MA3?V?]/M8
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M1D8B)24%%UQP 08.M/81':VOI?RU%=O@.O!.^]X1<:94,/*+_QE?Q;;67,X
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M:JB%JPT@]T_^?7_,'5L/U!Q80/!6C M/'Q)SPI*TPO"+/=5LXBKV?,+^M0=
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MSHPW45<I2^ .:IYRXW/( # W9-I(.<+ZP1$Y$JZB[;1FWN!^'&8GY#YNX8M
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M&>W'#)3-/2$ONI/N1 JQVB,V#R9Y<MK?;5/ 7HO:IE%]#B&>Y,F/!P#X \8
M=OC1D$1*ZAH\&C;UR?KA0SY+T/ (6O[^9M0H*FEHS)I;K,^Y/"<;3ZY;3R7X
M<HDQ::D?AGO'34"?R+:54#W@[;:T_?C9Y:_ 20!8@+0J,IX"ZEMAFV[:R@)X
MVODC\,='?\BK;+!QA[S*=)9#>RWJ+$_"[H=-@884L '@AO2P?]D4.*H4Z)0
M,"E0ZRQ%R<:_PEFXTP)M.T05;4S([(30JJCG-+J%'L_?U;0&7@Y7P6K451Y@
M Q6L44P*X2#F]4^Z@MZB>Z(F^VL# $N;3KL;'X+!CD"Z7@E)A&]87W)BU)(M
MV,QXOSMX3 #',#KUW _+M)$,H$PF+FXBW3\S1H>)4]Q&&?MRIZ6 O;D\&H^F
MU@@\+($"QR2;--KKQDJ7XY02%!^Z5=9PKJDK15E%)K(.+$!>V5)JQJ:SF*R'
M68CY*+L@@*4?3.:D^\N<<H]CG3<*'>Y\/&U^JHS[0%EJ69_)P?KTVU$;@.C0
MD8CK-A4]HDY :% O"FTH@%&C?KP'9F(/.&5(841EK/(^/*83-E6N%KZ7R19T
M?"\?NWW3AY$"]EIT&(EI5_6]I8"]%GUO'[U]XX>) O9:U HAY1V(_()$!V)A
M]&< 7A:11$(@L %<R/74DM]P,B,C UN,2G4-P5B&VJAA[%U:]OHQ[(VCCC()
M9PU*JRI14%Z*K)P<9.1F([^T& <*Z*FDL!!EQ;00=%:03Z(2/*L*"@U'6'@,
M(L(BR:]$T7(P K$QL>@=UP?A05$, Q)BXOJ2RS'YB3VC1N"OS!'IN:C:Y:3'
MED #!.M.'>P+[XI'^F,6\3DV &QH\5T^[+6H ]0S@ZJS <!KZ0(ZW1T#V&,!
MG&9B $>&!>-6QA6.#0F%T\@;&]TKAYH_!VL"/0I)H<)2/%4>7F#:0$6/1]>N
M0V%I$8*#0A@SG-X"JJK1([(;'I@\'CU9;^M)8]4''0. G02 1]H <.N$M:_:
M%+ IT X*V !P.XAD9[$I<*0HT%D!8-UO#>-Z%F^8@]JJ8NY3#D6;5!9_C+$9
M$(G [B>8^,!^H7W(TU309?-> L'[^;V?QGBE\.U^,F/Z,FY.T4;4,;:OCU\$
M@=\86@6'LPY:]U5FPU6XG6&%&6N4EL2RX/5LQ#KT;.ABR3\Z&8&QDPA,>;1S
M.U2#G;D34< 6=+3G85B,1GMR-I='@@6/6$'7!9O6TH6ZK((==?Z,>^-OW"_[
MN"U^)5%Q.DM0X=R#XHI-*"K;C-S"+2BCF_8:QKDR&*[ 6!Z(E3*_5;%IA.=X
MTK3H[K;YS6/QEP)Q35;SQ5A:OD&T\.V%F,AD1 0G(S*8+N@#>[,_&ML$GFO$
MN*D5UNB0^WB"O9S+6-((=4S;5 IQ&$424_7W\L,6='PO'[M]TX>1 O9:=!B)
M:5?UO:6 O19];Q^]?>.'B0+V6M0Q0EI<16.)@G76@+_NZ@PX3';"\"'\%B_D
M5D,U.9170)$\M=302K>:GLN<!&M=!(B-^R,+2J8XQ8]>6 ),[%Y_>E_QI;6A
M/+N(-VF0I =O^"&+_Y$NJY(!H\P/BS>S."GUU_M.W)E-"?OC4"A@KT4=H)IX
M<S+4]1; Y168-7C048\!K!&@-U^ [+V,T9NZ9R]2&';F#^,] / FO)>ZF4KB
MD7CTQ*F("I+'P=:31QXAF852>G$)_K9^'79FYQA%C.L8*B>[HA+O;4WC6'=A
M4&P<XPN/0??@UNJV>MH1 +B\HMH P']Z]&+V@N5-%9U[G-MKD7EE[ ^; IV.
M C8 W.D>B=VA[Q,%.C, K.?@*MZ.XM1'J;U*]Z^-F9-V/R@"P7+AS,V3;V D
M_"/ZF1B^CJ X@L.,:4,K7U_&X=7>JHY@<"WSZKNNBH!1&8%?Q?>MH<6PVC=]
M.,0-#\%HO_"^".AU(KU0A[6[]W;&SDN!SKFYU*Y<+HDM[MUBSD5#_N:K*_==
M$AH8T-&\SQZF7_GUYZW<8#$)*FVEQK\]YYM^RX690% Q+76U&CNJO<HP1XKC
M2[D$8\Y(4[R-Q":M.[) 6_/#Z,Q+P4.NG3FN:4#KPSA9:L_HT=,-L]% I[:Z
MLR8/955;4%RVD];!NWF<B?+R(E14E1$0KH*KSHK%:VGCJS=DM]0@DX-]=_ '
M12/4RO>G"[4@! 6$("0D$N'!O0G^]D=DV' $^?>'GT-C6K337,.^F3IDENS+
M/K+OOM+:5S_IRI9QM'3CAF=E"<T]W^=D"SJ^ST_?OO?#08'.N18=CCNSZ[ I
M</0H8*]%1X_6=DM=DP+V6G3LGJO 626+I>!G&[Q%??[O.Q-R[!Y9BRW;:U&+
MI&GQ0GIQ,7Z[> DJZ!;YO"&#<75*2H.\V67E>'C-6NS8EX490X?@AN1D!/L=
M#$GCR5S&L#//;-R(!=NW86!\'_R&UKJ]0H*PE*#K7U8L8QSM&MP^>1).BNOI
M*=+@NXYREKM7KJ8%< :2XQ/P@!L ?FGS)GRP*0W1D1%X:,KD=ECJ>JK5N/;!
M 0*]3Z:F8MW>=+J1]L/%PX;ALH&#C##AR?7K\?GV'4;F,BZI+WXY/ 5A 5)&
MM\IZ:K*^K7,= 8#_G[TS ="I^M_X,_O8EZP14K9(*5':E"A)>U(B"64G6_:=
MD*14HH4*15JU:%&AC62)+-F*[/LR^\S]/]_[SCN_F5)_FG?&NSSW]YMYWWOO
MN6?YG-&YYSSG^_W&Q\L"."M#G8F "/Q7 A* _RLY/2<"/B#@[P*P-3'EZ'H<
M6_,,W4*;RV436+)Q,/Z-6073;)"94(2A<F3N5?)5:4TQN"B2=WU-*SV^##*=
MY^#W_VKMFU%-OFA1#(N@I6!,J6MH65PHXXZ^!#8!OUKHR'C'-_&1[H"HL)K(
M&^'&CJ$E*BW9[4^9D6HI#B=1S+3%@5A.*=R+_&[_)DRT-8'2NW!@F=KA747(
M*,1S^1]^VQI$2DH2ZY' ,B.XJ8+QLVW[>OAA-Z\(,"8NA=NH*(_%[3]DDW[9
MRK1ZV<%_LZY%K>?,?E/J9MYVW^IO$SEK3^;Z\WE6R!/[*ID"^!'NCC^.N*2#
M.')\!^MYB,\<IQLF^XFC6$O+8NZ&CXCP"+[AR,^X6T5HV5L2>6-*(SJ\(+.+
MIA!<A.GLOQ]6)NN5Y; ZIQ^LBYVYOUV,7I;>!/K40H?^!D0@>P3\:BS*7E/T
MM B<,0(:B\X8>A4<) 0T%IVYCO0*NJ=; Z]UX>D^I_0Y1T!CT>FSW4$!N,]W
MWR$N/AZW5:( 3!$T\V$"\-B5*[')!. J52D 5_U' 7@*!>!O7 &X/ 7@FED%
M8%K:]KSB"EQ=ZN0"\)+=NS!MS:^N"_8+RYZ#875JNY;VL]9OQ%MK?D&>O'G0
MFN)TX_+E,U<OZW?/PD'&M:.,ZSWEUW7X?MOO[GK.#97/1YNJ59'7W0'/50S&
M I^X^A<L_^-W1#!&][7E*Z!#]0MHZ7^R=5-/YID%X$B+ 7R2PW5)S_4B5P"^
MXR*,>O(NIO)LE/?W_VYH+#I)A^J2"/@! 0G ?M )JD+H$@@$ =AZ)_78;SCZ
MZPLTQ#V8'A/85R(*7V+H+BE_Y9:, 5P<23N_HGZ4UX=_$/:215DJ7QE:_EXM
MRU\?DO6'K/SJY3)CLF Q;RWFK->UL%F@\L^:8K!Y&K9DJ6G<3&'2;[A9RJ;_
M6W(M:$U(C7;O\=>_'!F%_6.:-'.=;N4P:1CR> 3@B!.N&)N2$H.HR"C6TT3I
MOXJG?\W2ZF0_=EC:]$;8J8G*KM6O]]/$6/YD5,^[D2-=Y.9U-Z6)X>ZS=L&N
M>'Y,3+8ZF?%R.%V<A5$(9L4]C/B9EN)QZ6P<;<ZEPS<$M-#A&X[*)70)^-58
M%+K=H)8'. &-10'>@:K^&2>@L>C,=8$$X#/'WM<E:RPZ-:(IG,]_24O;3<>.
MX$A"$GZFC\]]:P  0 !)1$%4N&M>MRRV]05G%49L>!0:ERN',OGS8_>)$QCS
M\TILW;,3UU,@;D\1-F_DWR?SQRBFOK!F+99L_@WGT8*WS\474P#.BQ\88WO"
M3\N0G)2"RL6+H3Q=.:?0HY=G%<76%8!X6O^NW;N/&\R/TX-@(NZ]^"+<5[FR
MN^E^[?X#&$*!.B4E!04+Y$.5XL51,"K:LPSA78M);W8JUR8KYL^'V\XMC_C4
M-,S\[3=\M&$#-]2GH1;;TYGBMNOFV98OTI=Q]B<D8.SRY=BP<Q=B*3(W.?]\
MW$\+X2@W3G=&L@RPF];O1H<6TQD)+Y$>V4P MC61C-L97VP5Y$1",JZ[HR9&
MCO<(P)Z;Z05GI/2O+QJ+_*L_5!L1\!*0 .PEH4\1. ,$ D4 -C2IQ[?C^":^
MJ!S9S#,39DZ^6^VT,5+PR5?I 0K Q2@ ?TUEY]_B9IQ&[K3"#*.%8&2ABF[\
MX;#(V--X6$D#@8!?O5QF3 ),]&2$7+HHLOBS89S\@*Z270-<^V?SU[F.^[)/
MQ=.U &8"UXVQ7;3O=MAW$V#MW/NRGU$8K_W383M$4Y":XG$!'1%! 34LSBTG
MC%:UJ<F>,J.C_[]_%U:V5\BU.GCK877PULT^+8W]-\$LF/GA5M6NV?,F 'O:
MXSZ5+OJZ5LGN?5YE>HLK;.*Y1_)E>K.2MO+(,8T,G8R)'EU#LSWN;:;0D3T"
M6NC('C\]+0)^-1:I.T0@0 EH+ K0CE.U_8: QJ(SUQ42@,\<>U^7K+'HU(@>
M3(C'X!^6XH_]^_B S=DY/[=INWG?HK>_*%K#MJ$%;Y-S*V(O!>#ARY9CZXX_
M<-.%-=&.%K*Q)Q& S9IV\B]KL'C].IS+&+[]:]?&V?GR8<GNW9CP_?<4F&U=
MP<)2V;J"9\'!LY[ %0>N%9@70?-^5K-L.72M2:$V/=9O,G?CSZ55\;SUZY%L
ML;G=P]82,A8MTJ]9_5,99JH IC2HC^,I#@92.-Z]=P_./Z<<NM,E=86"!3+2
MVA?JX*X O?7H$8Q<N@Q[]NY'V=*E,;1N;=?5=.82[+\39KV[?LT.M+IU*I+C
MDA'%D%PNLRRY>DZXW,$06LEHTKP6QC[;/#U%YAQ/\I ?7-)8Y >=H"J(P$D(
M2  ^"11=$H'<(A!( K Q24LZ@KBM<Y"T;QFM\1A/U,0M]X4O&\1\+@#SI8@[
M ,.C\R.J2#5$%;N8E;.71!W!1L"O7BXSWL5-^#7K6Z-MKHS#\<OJ=9CQ\L>\
M%DFY<S^*%,V/.G7JX-IKZR%O?HL18Q,19N!0*+7YDWONM:1-OY=A66L96R+^
M6)EVN,]XOMI%TU=M$F23&K.D7;UB$UZ9/@,W-;X"-S2LSTE9#.='C 0<:QG\
M?QLY+,W_)DJ>4KP%>BM@GU8OF_5E4K@S7$-S8L-RTCCY,E?05B>+[VOQD"U>
MK]73S9$B.&O/7.R,D\?TGS36U2/^1O)9YL.B3-#V=_=''E;^_UL+'?[?1ZJA
M?Q/PJ['(OU&I=B+PCP0T%OTC&MT0@5,BH+'HE# ID0C\*P&-1?^*)^-F"B?D
M'](M\MI#!]UYO6FS$>'T@I9F,_E4%& <W-LJE$/Y@H5A NS'O_^.7PX>P.T5
M*^*"(D7=9S(R2_^2RHW@RVGM^\7V';B$EK[7T8US# 7=+4>.XLW-F[C.P#4'
MKB&X*Q#\GLH?6S6PE3X:'[MK ]6+%D9]6@\7C<GJ52V!X;F6[]N';QE/.)&6
MP+:.8-G9VDGF@_[(4+%@(3Q0J1*MC!TLI)7SSWSN%L;WO?"L8GS&(^)ZGW%7
M9BPC$W8/'L3[6W_')26*HV'9,JP;:^<N<GA3>S[_W+X?D\=]B83$9$1&>M8I
M/77)FL[JF$2KY]J7GX>6;>MEO>G'9QJ+_+AS5+60)B !.*2[7XT_TP0"30!V
M>3G)2-S]#>)W?$&W);OX4F.N;3.)/J<+E6\[/K, 3DMVZQ-A+I^+U63<WW-.
MMS9*'T $_.KETN8.[@N^30.\ JR)E,#"+Q>CW4-#4:3P62A>VL'.G=MI@9L7
M]:Z\"CU[M4'E:N<@B1. B' 3@RU>;H+K'CHMA6(GDK@SU$1=C[MHVY5J$JD=
MEC>E5/[B!(@3&7/G[!&?*;=RLN2Z46:BCSY8@O;M.Z-?_W9H_V@[/D/+>*9-
M95YIG+Q9S%UO;%][QA5A^9P)K:G<P6MYF<!K;IT\\7G#W>=2.9F+C+0XO.#D
M)-ZM<P1=2R?&6UT\XG-XA$VCK!Q.SHP/15ZW7JQ#FFL5;%.C"#</)O0<EB[C
ML.?3!6)79#:V-O'RQO_-2*@O_Y& %CK^(S@])@+I!/QJ+%*OB$" $M!8%* =
MIVK[#0&-17[3%:I( !/06'3JG9?&=3SO]/UD3]F&;^^TWILV\[63/>--9\]9
M6CNL#+M^*D?FY_Z:WFIK%KNG<D2DE^VMS_]7;\O36\]_JX.;CFVQ=157@4XO
MYQ_KQ+1A7$0QHX) .306!4I/J9ZA1D "<*CUN-KK5P0"4@!.)YAR= N%X*^0
MN)?6P$G'Z1&:N^S^BUMHOM1D6P"F2&4"57AL4405JH2(0I45[]>O_M)SIC+^
M]W)IK_WV8SM*^>K/K^:A:,GBG]"AW7#<V^Q.#!S>&JM7K</,US[!S-??QYWW
MU,?H)WHA?X$"V+WS('Y>_C-V[/X-!?,71ZV+ZN"\2N?@X.%=6+YL/4H4+X>+
M:YV'Q,0D+/UQ)0X=.H+++[\4)4L7Q>&#1_#%EPMQ69W+4*'".:Y ZPFA&XX%
M'R]#]V[]T*MO:SS0\E[JQ1'8O'DS5O_R"XX=/8'2I4O@DDMJH52I$CA\Y!A6
MK5R-?/GRX-CQ$]BR92N*<;=KO2LO1Y$BW,'+W;,'#QW"CW3YM(]Q=LK1'5(=
MNC@J5#@_W5X[6+WR5ZQ;MXWNE1)0I6HY7%'O$D1&F3!M5$P0MRF1'>[4*/V3
M'UYT=LN.S,G<"R:L9TYDDZ# F0BY3?#37UKH\-..4;4"AH#_C44!@TX5%8$,
M AJ+,E#HBPC\)P(:B_X3-CTD ED(:"S*@D,G(G#:!#06G38R/2 "N4)  G"N
M8%8A(G!R H$L +LM2DU TN&U%((7(^G +W!2$J@!TXKQ=(3@[ C 9O%+X3<L
MJ@"%W_,06? \BL E6+Y7/3HY=UT-#@+^]W+I%2@I>'H,@5T!>/$WR]&EPS"T
M:'4W>C_>TH6_X_?#>+!%7\0E[L7+T\=09"V#,2.F8OF*;W%6J53LW96(XD4J
M8]38;BA4-!J=.PY"@7RE\-(KH[%YTU;T?&P8UOZZ%B-'#$"KA^ZBF#R/UL2]
M,6?N&[CFFGH>*]EPNC=B3-X%'_^$[ET'X+'>K?!PN_NQ?.E&].G;CSM/XRGZ
MEL:.'3M1M^YEO-85\7%QKEA\Z/ AWBN%Q(0$K%WS&UH_U!K]^G7&+L;@>?+)
M25B[=BU*E2R%K=MVHE'#ANCS^*/XX;OEZ-UG!,J>71Z%B\2@4N5RZ-F[$V)C
M(RD.FU4PK9*S_.G9F?U;]?YDOFDLO8>7JYVG?W?_&Y,U-V]J?9X> 2UTG!XO
MI1:!OQ+PO['HKS74N0CX/P&-1?[?1ZJA?Q/06.3?_:/:!08!C46!T4^JI?\2
MT%CDOWVCFH4V 0G H=W_:OT9)A#P G Z/XL-G')L,Q+W?(?D@ZN1FGB,PA==
MUIIK:#.!_+?C= 5@4]8<L_BEB]GHPH@J?!XB\E= >$Q1&@1:3&(=H4+ _UXN
MO:(E+8"S", _HT/[ 6C9ZG;T'?  DI/2D! 7B<']7\*2[[_"Y.<',$[P'WAJ
MW.MHW^%.-+O_>FQ<OPN='AF!:QM4P\1G!F/2A%F8\^:G>'W6.&S<L!G3IKZ%
M/^E*^HHK+L'$22/Q2/MNM.K=A'GOO($2)<]BO%V*OQ$F ,=0 %Z.;ET&XO'^
M;=#\OKO0L_L8?/7-0KPX=2PJ5ZZ(N7,^QG///8_^ WKARBOKHG.GWMA_X"#&
MC!F"BN>61[NV_7#LV'&\]\&K6+Y\.08,&(&.'1[&'7<TQ=,37\;\^5_BS;F3
M,._M#_'DN&D8/W8,;KF]/F*BPU'DK'S\EYI,L3G5C=L;P=B]'L'7_DJ]\8?M
MFOUWPLLOL^!KZ;Q'YOOVK/=Y[WU]_A<"6NCX+]3TC C\CX#_C47_JYN^B4"@
M$-!8%"@]I7KZ*X'@&XM2Z$$HD2%K;(X0R>\6MH:N4-V-WC9WL'F ?:9PGL$-
MX;P7S@VB'J>T%CZ&(6O2P\<X:1&>YQ@V)XUYIG$M(3$Q!5%1^1#-\#7>PT+I
MI*8F<R^YY<<?AIRQV*8V3PGCFH:%M;$RPMUY"V<N=L^F)QG3&Y[P6=N@#H;T
M@1-#STO1;OU<;V5TXVKYI%FF?(:U043DWT-I)2<SY ]#]40PI(X;BL?)G,9;
MJ'&Q@GEXITAV:K?MR%B"2>6)W?!>\":P:Y[G4Y(MO Z_,Y]P8DWCUS26'TX&
MQMOJ&TX6MJ[C*<K:Z6',3(+JT%@45-VIQIP! L$W%IT!B"I2!'* @ 3@'("J
M+$7@5 D$BP#L;:^3<@*I"7M=$3AQWX](98S@-+J"=85@BL%A-J/(F'RDSU3^
M/P&8]QF)E!,23E8X$0GC1"TB3TF/M2\_PZ/R,\O,DR)O;?09[ 3\^>72L0 S
MG#S;9'K1U\OQ2+O>:-WF+O3M]R#_E"-Q]' 8NG4:C_4;5V'2Y"%X?]YB?/_=
M.CSW8F]<<.$Y8*AMW'E[3^S<NQ(+OIB-7U;N1J\>H]&E6PMLH]7MOGT'*+!&
MTCIW X8-'XB>/?O@HDLJX9EG1]L_$\[]*?Z&)W.RG@>??VHNH >@WX#VN/[Z
M^KCWGD=P0?5J>/&ED>Z?R*^_;,&#+7N@Z6W7X][FMZ!3A\&H<.XYF/3L$.3+
MGP>M6O1C^>OP]KM3\=572_#,,Y-QY547TVJY.+9N_9,NHS>PW&%<('$P9-!X
MY,]?!!=??#$:-VZ >E=79PSC)#<&<%A8%.OC66AP"\[TU3UWEQ32_[N0>27#
M7?AA"DOOO9WE6>]%3RZ>W]Y%CLS7O-\SI\^2D3<!/S.GL<O_E"[3(P'Z50L=
M =IQJK;?$/#GL<AO(*DB(O#_$-!8]/\ TFT1^'\(!-M89.*OXR3A>%PJHJ/S
M(R**:PE\'3_9K#\Q(0E1,=&<9_P/DE?FM"N99P6V,34Y)0XIJ>$4@/.XPN;V
M[?LH?(;CK(*%D:] !#T7)7#N8@(TURZX?A'!4%>1S,1F!YF*<,76^/@4UH^2
ML"4P]37,!%<^F\8-\6GY.1_+"VK*?)9K(GPX+"P&:0R;DY*6A-B\L6Z&\7&)
M.'3XH+O<4;QX*41RPVP*-\^&120B@B*LS><\)5L-,K7,%8:]-4J?NS ,D2V?
MN'OP73':ZL/#H=!M29B?9YICSWF>3:( ;-E:^""[E&H59?(T<HJT]E! CPR/
MY2T*P+SE6!Y\(#Q#A.=ID!P:BX*D(]6,,T8@V,:B,P92!8N CPE( /8Q4&4G
M J=#(-@$X(RVVX0IC3MVX_8@Y>@ZI!Q>@^1C?[J6P:#;67=&$LX=L3;+< 7@
M5G3=7 Q).[_FS(,3(5.P.'&R(RPB#\(B8RGZED!XWK*(S%O"=?GLNIEV9S9N
M,OT*00+^\W)ID^#T50'K!^Z(MAW='&#Y/1)+%OV,1Q_IBW;M'D"WQQYT>VK^
M>S_@L>Y#*?:6QY07Q^'9B6]BX1??8_*+_7!IG2I(30)NOK$=XI*WX(./7\>Q
M0^%XM-T@%&2L8%L]J']=;90K?PY&#7\.]:^Y$9]^^@'C"[?''7?>Y"XJ)'-A
M(3K6C;J++Q:L0->N?>CB^6$TN:41[KZK'<J7*X?79DYTZ[)JU2JTNG<4+8\;
MH%GSZ_'(0T^@^D7E,69<9^3+4Q2M'^R)M:NWT<IW"A8O^@'/3)Z$E@_>C/,J
MGL>JV![X?*A>O2K*GWLV-FW:0L%[&5U2?\S%BA@\^71/U+JT(A=2DGB>EVLH
MGH4&M^#,OVQ!PGNX23P+"VPL_WO Q1?O?;OG+F988CNQ&Y;6#O=!SU=;D+!;
M]N,^DWXY2WJ[;YM2,AT967@+_%L&F1*?Y*LW^4EN9=3E9/?.X#4M=)Q!^"HZ
M* CXSU@4%#C5B! EH+$H1#M>S?89@6 ;B](H@#IIM);ENL"B1;]BVJNS*=A2
M&$V.=U_MP].BN5S N0[G77W[M\=WWZW"_(\6(#8/Q5**N='1>5" \Z:X^'@D
MGCB!/-PXN^_ =EQ]S>7HWJ,C(J,C\,'[WV+6['G8\>=V+DFDHD3ADFC8\&K<
M=<^-#&=3 'GR1&/3YKT8R?F6P_E'4K*)TG&<^U @-H&6\X;FS>_!S;<T9'E1
M;AZ>>4HJ[U-H3HC!WCV'$!,;A:+%\[C>D,(0S;D:YXU\=MFR59@SYUULV+B6
MWI:.("HR!F>7/A>W-FW".=MUB,T7P3*/N9M^W<(R!%=3:KV'35YL F)K)S8?
M-8G<YC><'X79-0N9Q7/C9??M^-M\A[;2]!X5$1&)@X<.X?D77T94;#YT?/1A
MY+.EF12SAJ98SK4;Q^:YS-=FNQ&F$O\O,S?K0/^EL2C0>U#U/],$@FTL.M,\
M5;X(^(J !&!?D50^(O ?" 2M )R9A6O!RRD"A5\3A%.3]L(YL9."\!^T%CZ
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MZ/ 52>43J@0T%H5JSZO=OB2@L<B7-)57*!+06!2*O:XV^YJ QB)?$U5^H49
M8U&H];C:&R@$)  '2D^IGD%)0 )P4':K&I5+!/1RF4N@54Q0$]!"1U!WKQJ7
M"P0T%N4"9!41] 0T%@5]%ZN!.4Q 8U$. U;V(4% 8U%(=+,:F8,$-!;E(%QE
M+0+9(" !.!OP]*@(9)> !.#L$M3SH4Q +Y>AW/MJNZ\(:*'#5R253Z@2T%@4
MJCVO=ON2@,8B7])47J%(0&-1*/:ZVNQK AJ+?$U4^84: 8U%H=;C:F^@$)
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M0 1$P*\)2 #VZ^Y1Y41 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1
M!$1 !$1 !$3@U E( #YU5DHI B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@
M B(@ B(@ B(@ B(@ GY-0 *P7W>/*B<"(B "(B "(B "(B "(B "(B "(B "
M(B "(B "(B "(B "(B "(B "ITY  O"ILU)*$1 !$1 !$1 !$1 !$1 !$1 !
M$1 !$1 !$1 !$1 !$1 !$1 !$1 !$?!K A* _;I[5#D1$ $1$ $1$ $1$ $1
M$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1.'4"$H!/G952BH (B( (B( (
MB( (B( (B( (B( (B( (B( (B( (B( (B( (B( (B(!?$Y  [-?=H\J)@ B(
M@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(P*D3D !\ZJR4
M4@1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 3\FH $
M8+_N'E5.!$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1
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M([ME9\DL_:3!+74P_9UA" L+RW*[9_NG*&)_EN6:3D1 !$1 !$1 !$1 !$1
M!$1 !$1 !$1 !$1 !$1 !$1 !$1 !$1 !'*/0% (P,.?[H VG6X[96I)2<EH
M>\]P+/QX699GEFU[':7+%,]R[9].^G::A)E3/_FGVUFN-V_3"$^^^%B6:_]T
MLN6W'6A<IPM.'(_/2/+J.T/0L.D5&>?_]N61^T;BH[>79"3);MD9&:5_,<OC
M^=\]BP(%\_[U%@5H"<!_@Z(+(B "(B "(B "(B "(B "(B "(B "(B "(B "
M(B "(B "(B "(I"+! )> *YS=0V\L_#)OR$SM\U;?ON3;J!C<$[Y4G^[;]:V
M]6NT0]R)A(Q[?Q6 [5Z>O#%_LW2U!S:LW88&%S^:\>R_??FK")N:FHKDI!28
M9>_)CO;-1^#C>=^ZM\ZO6A9?K9[VMSIL7/<[BA0M\#>+YU4_;423*[IF9)N=
MLC,R2?]BHN_\[Y_!>97+_O66>RX!^*18=%$$1$ $1$ $1$ $1$ $1$ $1$ $
M1$ $1$ $1$ $1$ $1$ $1$ $<HU 0 O 4=&16/#3<XSY6SX+,(N)V^'^46[<
M7KMQX^U7X*EI/6$Q?C,?TR:]@V&]IF9<,@$X?X%\F/KTVY@SXPO\^<=>%"U6
M$.VZW8$NC]^7D<Z^F(A;N?#M2$Q(SG+]9"=>$?9'QOF=.'HFEGW[*Y+X7*VZ
M5?#<&X__3:!^9LPLC!O\FIN5N7YNV?Z6+-D^-_XMC.G_*NN:!Q]^-\F-=YPY
MP>W7]LB(Q9N=LC/G:>Z>7WUW"&YH<GGFRUF^2P#.@D,G(B "(B "(B "(B "
M(B "(B "(B "(B "(B "(B "(B "(B "(I#K! ): *Y=KQK>^V9B%FB)B<FX
MJNI#V+5C?Y;K)XN%>^30,50O<4]&.A-DMVS\$T<.'<^X9E]B8J.P=M\\Q,9&
M9[E>H^0].'SP6)9K)SLI4:H(2I0NBC4K-O_M=H]!]Z/GX%99KEN,X<'=7W"O
M??SCLZAY2:6,^Q:#V,KUUO'!CK=@U*3.&??MR[ ^+V+:Q'?=:]DI.W.F?8:W
M0M=^]V=<VO[[[K\)UQ* ,_#HBPB(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(
M@ B(@ B(@ B(@ B<$0(!+0![K5LSDWMCVD=XO..SF2^YW\/#P_'MQE?^)EI>
M7*8Y]N\]_+?TF2_DS1>+-7OG(CHZ*N/RYHT[<&WUMAGG__7+7X55RZ?C V/P
MP5O?N%G^O'TF2I0Z*R/[O[J>ON"BBOCLI^<S[MN7*4^]C9%]7\IR[60G_U_9
MWF=NONM*3'USD/<4VS;O1)<'Q^+#)9,RKMD7"<!9<.A$!$1 !$1 !$1 !$1
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MS#R3N2<[9T08IUO4'H#-JPX@9=I$- ";0J6;!$B !$B !$B !$B !$B !$B
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M+QRV#-2NYGWTZ@+$3QA;(]L9S\R):]"WXU1GDC(-"9  "9  "9  "9  "9
M"9  "9  "9  "9  "9  "9  "9  "9" C@1"M &X=)6\F+F\KP;'I0LW4#1+
M"PL#;8:L*;#UZ&2(%;#*);8TSIJ@%AX_?*8$R??Z+<MAX-@V%ML^KU^Q&QT:
MC<#;-^\UZ9WUQ$T0$[-6]D6V7.DTCSQ]\@+-:_Z" [^?U(0+S^[3,R!6VRJ7
M.(,W4]SJTAF\'^2@\M4+2(;JH!7!(G!XWSD8/WB)\HA\#T[>- !K$-)# B1
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M67C_[H,F3H^\-0*_>+@"V!H5AI$ "9  "9  "9  "9  "9  "9  "9  "9
M"9  "9  "9  "9" ;PD$E %802FV3?XF5UJLW3,&H4*%4H)QY=];J%.F)ZY?
MN8MHT;]"]!A19+>:( 0XQ#G"R5,G0*KT2?!*.N?WW-]7<?_N8Y^4/&*D")I\
MW[U]AP\?/FK"Z"$!$B !$B !$B !$B !$B !$B !$B !$B !$B !$B !$B !
M$B !$O >@8 T "OX?I?.!DZ3/JGB5>]/'CU'E&B1I2V@WR%;HMIX*1E2>9$
M"9  "9  "9  "9  "9  "9  "9  "9  "9  "9  "9  "9  "9! 2"<0T ;@
MVDU*8>2T3G;;*%/<ZGCZ^(7=-(PD 1(@ 1(@ 1(@ 1(@ 1(@ 1(@ 1(@ 1(@
M 1(@ 1(@ 1(@ 1(@ 1(@@9! (* -P*(!.O:IBS;=:EN<FZLT#@W "@G>28 $
M2( $2( $2( $2( $2( $2( $2( $2( $2( $2( $2( $2( $0CJ!9=N'(U_A
MK+I5(]0GZ0J.M .[3Z)&B6[!>=3A,_$3Q4+N@IF1*DTB1(T>!:]>OL:+YR_Q
M[X6;V+[^,,^M=4B0"4B !$B !$B !$B !$B !$B !$B !$B !$B !$B !$B
M!$B !$B !$("@4X_UT/G/C_H5E2_- #K5CL*(@$2( $2( $2( $2( $2( $2
M( $2( $2( $2( $2( $2( $2( $2( $_)N!7!N":'EH![,?\6302T(U QS[U
M5%EC!BQ4W720  DX1R"/M!U&WD)9Y,0']YS"(6EG"EXD0 *N$: N<HT74Y.
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M(<"/2[X*). ^ >HB]QE2@K$)4!<9N_U9>WT(4!?IPY%2C$N NLBX;<^:ZT>
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M "R,I)V:C<:;5V_1J$U%#!S;1E.&!=,WXN>.4_#VS7MTZ%T;7?LUTL2WJ#T
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MU1O%:_/NZ/NP2;M*^&5T:YO/FT=,'KD,@WO.,@^F7R) 701L_W/K@< X  !
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M31C$4F=((GW4QI+/NKM[^Y%L6+IU_;[-+6R=S<V3LITM0Z"F\]7'I2\'[L7
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M6;_AS%^73+.@VXR /^LB7^@$<814A9J%$$GZ-DJ3/BF^KU=<LPWTXX?/I#.
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M3 T3O_.R)Z[MM2VIU8P]Z#"B+G*$,TSXT @=/I2C9$[%?WS["1_>.F<H,S<
MV\M ; ]=*D<K7)=6N?#R+0%W=)%O2QZ4>]:&*9"[?=J@  >NP^//X^3<RPY2
M::/'S.Z,&O5+JH%+YVY!YV9C,'%!=WC" *QF9.(0$XBJ%^N*!_>>F(1JG:Y\
M'UHS3FFE!?E^[C09LR:L"PJ@2T/ GW61+W1"S\&-T:9K+0TCQ?/T\7,TJSD
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MV>+=U "<(V\&K-D]6O.;:OV*W9@Y<:V\XK%]CSK(9[+%LZAHX<Q-U<E2[AJ
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M#&!K,]V/'SXKG?GQ$>'#AT6V7.DT97KTX"F^35I7VF;C@R:<'N\24#JSMPS
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M8*PXT:45B@M4(Y@P].1)W1"W;S@W8.G*#[8?*OT/OV\^JJF?N_W G3ZH*4@
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M %XC&6QSYLUH_JA5OR,#\!C)>%Y#6CEM>AT_?!8U2G23MW@T#0_I;G_]N.3
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M=[!VR>]HU^/SUM#"F+IRX0[-&;E].T]!_U&MY.>5/_G3-\;5?V\K7IMW/0S
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M>ZL6[2R?7>>, ?CUJS<HF:,5+E^X94U4B _CQV6(;T)6P \(!+HN\@/$+$*
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MVK*LE[<(!((N\A8KYD,"M@A0%]DBPW 2<(X =9%SG)B*!!P14/21HW3.QM,
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MI[N]8K?3VBA<[!)9O6.J9,Z<.:TA:?;?<NTCLGG]KC3WQ\(.<E$LK")S"*>
MVUP4SFOEW A$J@"Y*%)7ANN*%@%R4;2L%-<9Z0(J'^FZ3@K NB2)@X!+ ?5A
MI@#L$H[A" 0$N+GDK8" =P%RD7=#(I@MX#871>HCH*U5O+96.?EDV<M!%S1^
M_4YI=&TW_S[KMVRMQT5GSYXMU=C$Q$2I'-=6?CM^RMZW+'ZBE"I=S&[OW7-
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M=V:M7T#E(UV1*0#KDB0. BX%U(>9 K!+.(8C$!#@YI*W @+>!<A%W@V)8+8
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MD AF"Y"+S%Y_9J]'@%RDQY$HY@J0B\Q=>V:N3X!<I,^22&8*D(O,7'=FK5]
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M N0B8Y>>B6L2(!=I@B2,\0+?;9NNU2#D O"N7;MDTJ1)6B^&8 @@@  """"
M  ((((   @@@@  """"   ((((   @@@@(!) O7KUQ?K?[K^* #KDB0. @@@
M@  """"   ((((   @@@@  """"   ((((   @@@X%(@H@K 6W_:YO+R&8X
M @@@@  """"   ((((   @@@@  """"   ((((   @@@H 2N+E-:2I8LJ9J>
M7T/^!K!UYE,G_O1\ 01   $$$$   0000  !!!!   $$$$   0000  !!!!
M  $$3!7(DS>GUJE3 -;*23 $$$   0000  !!!!   $$$$   0000  !!!!
M  $$$$ @_0(4@--OQ4@$$$   0000  !!!!   $$$$   0000  !!!!   $$
M$$ @H@4H $?T\G!Q"""   ((((   @@@@  """"   ((((   @@@@  """"
M0/H%* "GWXJ1"""   ((((   @@@@  """"   ((((   @@@@  """" 0$0+
M4 ".Z.7AXA!   $$$$   0000  !!!!   $$$$   0000  !!!!  ('T"U
M3K\5(Q%   $$$$   0000  !!!!   $$$$   0000  !!!!  (&(%J  '-'+
MP\4A@  """"   ((((   @@@@  """"   ((((   @@@@  "Z1>@ )Q^*T8B
M@  """"   ((((   @@@@  """"   ((((   @@@@  "$2U  3BBEX>+0P !
M!!!   $$$$   0000  !!!!   $$$$   0000  !!-(O0 $X_5:,1  !!!!
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MJY:MY?7_C9,\>?(X=NLXMR.@K_'''W_(S8T:^(K9/SIV+5JX1&K4J.GHHX$
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M=4[U^O++H^699P>JIN.5 K"#@P8""""   ((((   @@@@  """"   ((((
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M]L<J4:*$+%VRPO]X[0(%\U( /J\P.Q%   $$$$   0000  !!!!   $$$$
M 0000  !!!#(6(&H+@"_-/*_,F3H8(?8]JT[)2ZNL*-/-29/F22/=>^FFO[7
M;U9^*Y4J5G+TJ<:%+@!;W^QMVZZUO\BJSIFRP)OR&I[LTT\&#QJBAOM?TS/&
M<8"OD9YS6\>\\-\1\MSP8?[#<^7*)0OG+[)_-YD"L)^%_T,  0000  !!!!
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MO]70<>Y400,=%(#3DJ$? 0000  !!!!   $$$$   0000  !!!!   $$$$
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M@  """"   ((((   @@@@  """"   +G!(PH )^;+EL(((   @@@@  """"
M  ((((   @@@@  """"   ((((! [ I0 ([=M65F"""   ((((   @@@@  "
M"""   ((((   @@@@  """!@F  %8,,6G.DB@  """"   ((((   @@@@  "
M"""   ((((   @@@@$#L"E  CMVU968(((   @@@@  """"   ((((   @@@
M@  """"   (((&"8  5@PQ:<Z2*   ((((   @@@@  """"   ((((   @@@
M@  """" 0.P*4 ".W;5E9@@@@  """"   ((((   @@@@  """"   ((((
M @@@8)@ !6##%ISI(H   @@@@  """"   ((((   @@@@  """"   ((((!
M[ I0 ([=M65F"""   ((((   @@@@  """"   ((((   @@@@  """!@F  %
M8,,6G.DB@  """"   ((((   @@@@  """"   ((((   @@@@$#L"N3,G5VR
M9,FL;8*9SOK^0HF6F)@D?_[^=RB'<@P""""   ((((   @@@@  """"   ((
M((   @@@@  """" @$\@6_8LDCU'5FT6%("U41(( 0000  !!!!   $$$$
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M80@$!,A%O!40T"-  5B/(U$0"+L -Y=A7P(N(,H%N+F,\@7D\B-"@%P4$<O
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ML]<C0"[2XT@4<P7(1>:N/3/7)T NTF=))#,%R$5FKCNSUB]  5B_*1$1"(L
M-Y=A8>>D,23 S64,+293"9L N2AL])PX1@3(13&RD$PCK +DHK#R<_(8$" 7
MQ< B,H6P"Y"+PKX$7$"4"Y"+HGP!N?R($:  '#%+P84@X$V FTMO?AR- #>7
MO <0\"Y +O)N2 2S!<A%9J\_L]<C0"[2XT@4<P7(1>:N/3/7)T NTF=))#,%
MR$5FKCNSUB]  5B_*1$1"(L -Y=A8>>D,23 S64,+293"9L N2AL])PX1@3(
M13&RD$PCK +DHK#R<_(8$" 7Q< B,H6P"Y"+PKX$7$"4"Y"+HGP!N?R($:
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MVN@)YXVKR.A,-+)Q+PK@;/1#IFLQ3#&9)_8^7C.3L,""Q>#L]^80A!P2LH.
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M.DFJF&D$A!9ENGND<C6"@-"B&NDHJ69F$1!:E-FND8K5$ )"BVJHLZ2JF41
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MY)#2+<E".17<DA:F&C=N'&V[[;:%D?)+$! $! %!0! 0! 0!04 0$ 0$ 4%
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MHBEYU2L"0HOJM>>EW6DA(+0H+20EGWI&0&A1/?>^M#T-!(06I8&BY"$(I(^
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M7@@(+?*"2Q(+ D4(""TJ@D0B! %O!(06>4,F+P@"!0@(+2J 0WX( IE!0!3
MF>D*J4B](2#,9;WUN+0W;02$N4P;4<FO'A$06E2/O2YM3A,!H45IHBEYU2L"
M0HOJM>>EW6DA(+0H+20EGWI&0&A1/?>^M#T-!(06I8&BY"$(I(^ *(#3QU1R
M% 2<$!#FT@DF220(A"(@S&4H-/) $'!&0&B1,U224!"P(B"TR J+1 H"7@@(
M+?*"2Q(+ D4(""TJ@D0B! %O!(06>4,F+P@"!0@(+2J 0WX( IE!0!3 F>D*
MJ4B](2#,9;WUN+0W;02$N4P;4<FO'A$06E2/O2YM3A,!H45IHBEYU2L"0HOJ
MM>>EW6DA(+0H+20EGWI&0&A1/?>^M#T-!(06I8&BY"$(I(^ *(#3QU1R% 2<
M$!#FT@DF220(A"(@S&4H-/) $'!&0&B1,U224!"P(B"TR J+1 H"7@@(+?*"
M2Q(+ D4(""TJ@D0B! %O!(06>4,F+P@"!0@(+2J 0WX( IE!0!3 F>D*J4B]
M(2#,9;WUN+0W;02$N4P;4<FO'A$06E2/O2YM3A,!H45IHBEYU2L"0HOJM>>E
MW6DA(+0H+20EGWI&0&A1/?>^M#T-!(06I8&BY"$(I(^ *(#3QU1R% 2<$!#F
MT@DF220(A"(@S&4H-/) $'!&0&B1,U224!"P(B"TR J+1 H"7@@(+?*"2Q(+
M D4(""TJ@D0B! %O!(06>4,F+P@"!0@(+2J 0WX( IE!0!3 F>D*J4B](2#,
M9;WUN+0W;02$N4P;4<FO'A$06E2/O2YM3A,!H45IHBEYU2L"0HOJM>>EW6DA
M(+0H+20EGWI&0&A1/?>^M#T-!(06I8&BY"$(I(^ *(#3QU1R% 2<$!#FT@DF
M220(A"(@S&4H-/) $'!&0&B1,U224!"P(B"TR J+1 H"7@@(+?*"2Q(+ D4(
M""TJ@D0B! %O!(06>4,F+P@"!0@(+2J 0WX( IE!0!3 F>D*J4B](2#,9;WU
MN+0W;02$N4P;4<FO'A$06E2/O2YM3A,!H45IHBEYU2L"0HOJM>>EW6DA(+0H
M+20EGWI&0&A1/?>^M#T-!(06I8&BY"$(I(^ *(#3QU1R% 2<$!#FT@DF220(
MA"(@S&4H-/) $'!&0&B1,U224!"P(B"TR J+1 H"7@@(+?*"2Q(+ D4(""TJ
M@D0B! %O!(06>4,F+P@"!0@(+2J 0WX( IE!0!3 F>D*J4B](2#,9;WUN+0W
M;02$N4P;4<FO'A$06E2/O2YM3A,!H45IHBEYU2L"0HOJM>>EW6DA(+0H+20E
MGWI&0&A1/?>^M#T-!(06I8&BY"$(I(^ *( 5IG_^^2?]\Y__3!]=R9$^^>03
M&C%B!*VZZJJTSS[[Q"+R^>>?TT,//40KK[PR[;OOOK'I:SF!,)>UW'M2]RP@
M(,QE%GI!ZE#K" @MJO4>E/I7&P&A1=7N 2F_(2 @M*@A]**TH9H(""VJ)OI2
M=D-!0&A10^E):4>U$*@%6O2?__R'%EYXX6I!5!?E/O;88_311Q]1ERY=:/75
M5Z^+-F>]D76I /[YYY_IAAMNH/OOOY_FS)E#WWWW'2VWW'+4I$D36F>==6BO
MO?:BSIT[TS+++)/U_DN]?C_]]!--G#B1EEYZ:=IBBRU*SO_QQQ_7$[Y#APXT
M?OSXV/R>?OIIVGWWW779K[SR2FSZ6DX@S&4M]Y[4/0L(U )SF06<I Z"0!0"
M0HNBT)%G@D \ D*+XC&2%() ' )"B^(0DN>"0#0"0HNB\9&G@H + D*+7%"2
M-() . )9I$4??O@A77;9931]^G2:.7,F??OMMWK368L6+:AKUZ[4LV=/6G'%
M%<,;)4^\$=ADDTWHC3?>H.>>>XYVW'''V/?3UD7%%EB'">I. ?SO?_^;.G7J
M1!]__'&^NZ'L_.&''_*_<7/JJ:?J#T1!9!W\&#UZ-.VTTTZT\<8;T^3)DTMN
ML2B PR&L%^82AA9???45[;WWWK3::JN% R)/:AX!?$?Q/:U4R")S6:FVUW(Y
M#S[X('WQQ1?:V*IITZ:9:,HWWWQ#SSSS#+W__OOTCW_\@]9;;SU=/]?*_>]_
M_]/>1!9==%'75^C77W^EQ1=?W#E]N1+6"RURQ:^>/)&X8B+IHA&H)BWZ[W__
M2__W?_]'/(^C:]HPGXJ%>7G[M5+X\AC&.GWLV+'E;52-YEZIO@B#)XO\&^H*
MX_777W]=KS>77WYYVG___;7WL;!V1,7[>B^+RJO2SZI)BRK=5I?R:KDO7=J7
M)$VU,*E6N4DP$EJ4!+6&_\X??_RA=XR"YY80C4"6:%$NEZ/KKKN.^O7K1U P
M(BRVV&($F<WWWW^?;P@\PC[__//4L6/'?)S<E(: KP(X;5U4:;5OH&^K"5%7
M8=---\VIKLPU;]X\=\<==^3FS9NGVZ\45+D77WPQUZM7KYQR!9!3"N"ZPH4;
MJZPS-#Y* <Q1)5W50E7GIW8 .^7SU%-/Z?1J][%3^EI.A'&(/R7HJ%@S%.'+
M*<5&;LJ4*=8R+[_\\MR66VX9^W?%%5?DW__QQQ]SSS[[;$[MV,['F3?MVK73
M[7SAA1?,:+FO @+GG'..[MO33CO-6OKYYY\?V_?X3G)X[;77]#>S39LVN7_]
MZU^ZGW'%]T,I_G-**<9)RW(]]]QS=9F81TI86)8RPC+MW[]_ 59;;;553AG/
MY(X__OB<$D2%O=;@XC$&,/^__/++HK8]_/##FM8&O^=,AT>-&E7T3C4BE- P
MIXX=R(\EC"?4T27<=]]].JU2Y.;4@C#7JE4KS3_@NV@+2KF8.^200W)*\:W+
M4YY&<FJA4?'Q:]:MDK1("8 *Y@WHC;((S2G+V]R))YZ8&SER9$ZY9#*KE[\/
M&T_Y!"G=U!,?DA)D=9]-I6G1I$F3<NI8%?U]508KN4466237K%FS'.@0:).R
MMJZK/@'/@>\8UC 2TD>@4OA6DA;94%)NZO0:Z:BCCK(]]HJ+XHV\,@HDKE1?
MH%CP09"7@,_AD#7^#?4ZXH@C"O@WC"/0\:@0U3^^LHNH<BK]K-*T**I]@P8-
MTOS>)9=<8DUVS#''Z.=#A@RQ/C_II)/T<W4TF'YNXP'C9!"UW)=64%*(3(*)
M[5O@6Y4DY?J6D5;Z:M.BM-J1=CX77WQQT1HN2FZ(]5U6@RN]QYH4?/6&&VZH
M=01++KED;IMMMLG=>^^]66U:)NJ5)5IT^^VWYWD$C,D9,V;D90W0!8'':=FR
MI4X#.82$]!#PY5G3UD6EUY*&DQ,UG*;$MT3M[,E/_E=??37TA7???3>GK#^L
MSR'DAB+KSCOOU +;^?/G%Z53UO@YY58@=\\]]^2&#AVJ!3'*8J@H'>)0)[4;
M.?_L]]]_SRFWU#EEC9*/PXUR6ZT5;+?<<DMN^/#AN3???+/@N>N/3S_]5 OK
M\2'$!^ZMM][*OPHF&OF#Z6G;MJVN&^J'/U.XC[J]_/++N4<>>21WZZVWYNZ^
M^^X<\+0I>X+,'H2_CS[ZJ"X' BI@988XP6M:.)AE5NN^DLPE^@9*&K4[4_?O
M2R^]9&VV;1'-]32O$-1SB/M0BP*8D:KN]?KKK\]__Y2;=6MEU+G;^31F?YOW
MZDSO_+MJ5W<^/91?RRZ[;/XWWCG[[+/S:<MQ4TWFLGOW[@5M-3'"_7[[[5?T
M?2L'!M7.$PL_M-?&,-]XXXWZF3H#OJ":61,@,G.*;Q4$4;?==EONJJNN*JBS
M[<=AAQV6'P/*NT&N=>O66@D,/+"0""J!ITZ=FE/'3>AWH# &G54[5?)Y8(Y6
M(_#8K80Q$G@.+B_L"BS-[PQC$C:>^'E:US@^)*UR))^&@T E:1&$ZN;<45;L
M6@%LQN$^^/UI.&@7MX2_X:( +L8FC9A*X<MCN!*T*(B+\@*24[M&]=S:88<=
M@H^]?T?Q1MZ9&2]4JB]0Y$HKK:3Q@&R 0];X-_">&#<P/H5Q'>0NX.,@AXD*
M4?T3E%U$Y9.U9Y6D17%MO_+**W7?K+_^^D5)(>\"'XR^6WOMM8N>0SX$ TD\
M9P-S&P\8)X.HY;XL B6EB"28V+X%OM5)4JYO&6FEKR8M2JL-Y<CG\,,/UW.2
M\8F[8@YG,;C2>\CJ]]ACCWR;82R^U%)+Y7\K=\)9;%XFZI056O3UUU_G5EAA
M!=UG1QYYI%5? <"45[;<@ $#<D$9.70]T M!1@/Y '0IM@!%,G0FO_SR2P[C
M!H:Z-]UT4T[M:-5Z''X'M _/;K[YYAR,FFSY!?/"1@6D5YY5"W0RG">N/OH9
M,W_. QL48!01U,W,G3LWAV^W.CY5&]D"S["@7&IK?<,UUUR3@^'69Y]]IC<%
MX3OALCYSU46A?-=^":LKXJ$?@=X/&U+NNNLNK==ZXHDG<LI+H?4U$S<8AD"N
M!UT8# B 4ZV$NE( 0VG*A J6GSY!G1.<._300_/O<S[*54"N6[=N^:R4;_G<
MUEMO791.G2V<FS9M6CX=;C")D0]VQRI?]+GMMMLNIUP1Z#C38@KIE#_ZHCRQ
MVPP*59> CPV(-G8W<]WYBAU+J!MV!W)<\'KLL<?J8C[XX(.\@#N8!@Q\$%=F
M]M9==UU=?O"=W7;;+:?<QN:;$"5X30.'?$$9N&$LRBWHV';;;0N4#"@W2-P8
M#HRG6;-FA?ZU;]]>CY&^??OR*_J#CCPAE+ %40#;4*ELG#I;.X==0CSFXA3
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M5M!R6"AWZ]9-6U4><L@AVMTVC^6PQ8;9SK3ON5\K08M<%< X)X?KQ8(N&W\
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MX6DP@.&&=2/R05M= NJ/\U$P:8/GNKB\SVG2P('SJN:5/S3E9BX/.^PP;?0
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M?ZG/*D6+?.L)A0G/;WBC"P88/O":!NELLB<;;Q8G@TC2E\&ZV7YOM]UV^?:
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M%K&63!)\Z#WGCV/0((\Q92V0E<%M/>B>!#L"6:5%]MIF*]94 &>K9E*;AH#
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M2_L(O;_BBBOB&F0**W'=A$9ON^VV>CW6U80OP2R^8[F,&\HV*^L /=)8'JN
M'A]/DA;U*'[BGS!7[' <UVSZG[X#UXQ=QJ-I2<<R2_<P:46[[)'2].E]%]JJ
M]%W6%J4==DW7]Q+ZVI5^@.-T/]YE?SVLKLO\7/-WGK2(/;;%N0X6JRV88G@1
M.CEWP =@38?.<#:&7]"D*U_[VM?B?HGQ\=&/?C2>GXH*&I*8<<.9@W77/(?%
M_8\I&PVD[CLFH3_0%O8DM)&]BP#ZPWF0/0]G'6B9^I(TS?$]ZKS)-Z7GD=(Y
M"H[H)_95.CM2KJ#K/JUDWZF\IWF=!2U*<9W;[]+W7<_^H\ZU\"%R?976H61-
M9EQQ?N<\ M^/LQE[!\[BS7U,6S_UW8>,FJ-INW*XU5FBA*Z5C-&^>[<N-)E]
M/6<T]O!F0%)T3NTZ']OZK.2=UJ]YTJ*2^DXC+>MV%WY7U[&8CFWXA>/P\)IY
M07OA!\)+,T7?R%])<3)->L+8A_8Q7].S7EI^6E_-Z_3]*M[/@A:-@S=X79QG
M.$\R'N$IP-^!!\'Y!%D-^P/V-P*+01L>_O"'!WBL\/NTAS!7PC$?]C\ ]$&\
M)_@VD@,IG_1JQA9Q#Y*NCRE_5VE3F0K[+_,"&WG0\-7-8#&>RTP '/DDSW[V
MLX,9]@7S9A;,*EA9U%?);\1'ZE/?.K/,#?O!)SWI29%?F+ZFC<B_P$FIC*NK
M[(SRV(.>??;9P3Q719Z9ZD _F:5V_,F<;?)U><%^D+T!ZQ,\OR:?5GDM]=46
M1(<&!G #B&L^W!K+I[MU<C2S)VFI!; M#E$SA#R,2,32L)CE]_WO?_]&Z8,_
M%3_8F"Z#+\;\A44*Y=L&ISKZZ*.'YH8[;-(][&$/VY#&#I&U%0M:M$WH6D;S
M.[< ;F)D.K]M08M]:\2J0A.=L4!?ZP_WWJEO?&G H#5TV&&'U7$^E1YK4%M,
M!RJ+%;W>IU<[K$5-*<:00/7!PAC7F<1=0#.>[Q1D7=I1:)7A5C/-$]<;N %%
M Q67Z>D[M)J:,2)+ZJ8ZHMEOC/"!O"F'. >XVQ#0EE2[2W798X\]!K3-C9C'
MO'(:6K;AB._L0!JSQ>V$\LE=P3WUXUTN!G"7NI?B9)4L@(WI%W%'3,X4;+,7
MG^,R) 4[Q,?GQ&$G[A'0Q#]6BKF^XADQWX#2>=4L(V9B_S0W3# ;W0>FY3+?
ML-X=%TRH%;UCD/<[W_G..CM3VHGMQ$UT,R:I'7KB.^J0NMBM/\[<* :';1XS
M;_./H$$F9-J ;]:0IH5DE[E *5A9*@Q"BD\3AE1VV!RHB/"/AB-6S^DZ@4L9
MP(2!D9:F>7&/&V#6@B: 8]:N-#WC3;]9ZR8!RL\8'9/(KC@/W&6RSJD>7-$(
M16/4&!!U?JD;\C0M]&L4R%KVN<]][H:D<O?<U=J\R_@T 4)LSS#K+U7"#IHQ
MW3 +8&E00SN:P-[2& GQ^]3K0Y]OFGGK-[&+P/6P,"#RG&,*D/$3Z@0=2<>I
M^LH.K!OFC<KI>C4F8.V%0/GJBCML+(7F <(Y=3$EBGE486)ELI?8<\\]8[\+
MMUQEU6@,D[JLDCU,_9'==-TCI=^D]UUH*^F[KBUIWKE[K>\E]+6$?FC_6[*_
MSM5SV9]IO,V+%H$_60"; +@(G5@+X"Z0-KSC'>^H% <M1P,4,L,4FHK*&):8
MO94I3F^8LUAAF()X_5F?,8G;.[Q90)/5/UP?][C'Q3,BU_0Y]WOMM== S#N-
M[Z[G32I<>AXIG:/#SB\E^[22?6?="5.^F04M$JZ'[7>[]EV7<RWHRO65ZE"R
M)IL@.5HC-<<K_ .>I;2MK9OZ[$.ZSE&U:QANJ5<)7>LZ1L?=NW6AR6I;29^5
MS,>V/BM]IS$R3UI46N=)IN]Z3BX9B^I_UJAQ>7C*B[BL:5@<^@T+OV:8AJYK
MDG"H_+N,5?&)L/24-:?RX6H*3Q4\$.H&?W-=8!:T:!Q<:E\"#\84_0>RXC?]
M90+@@>>LDXJMRQQAKT<Z>$5-, %P?&=*X\U7V=\:<\,\))CP-.8';RSEC9#9
M_OOO']_) MB$K/%W;O])^IP%<&E]R:<-X/'C18=SXH$''EA;WM).H%3&U55V
M1M[0<OH%3X9-H+]YU^3CD0XY'>_X,\.@^*GXM,@G5@70L'08@0$"03,0&+S
M) 3 R@-BD0K9FE5A TC99N&Q@;'>3-OE-PN&7!5 C%(F?NY[""CELP"FPCK2
MFF9$?$<^"$,$I67H.UU= "Q,3/>J!8W^Y0]&+V.=@[N$P<."H),>(>L!!QP0
M8WV*,7C((8<,5)KO&>,P(&"\LY'B7NEQ_R!0?7@'TX(RN.*'ORD YAT" YX3
M!](T[F)Z"0@0^B! AB$BA@SU18 E**D;WVB#1]D0^N<___F56?#'V)$\HVV
M69C%NM .YAKQ&![[V,?6@AQ<80AXQ[>M(9M[  !  $E$050Y 3#,)+63],P_
M!!4B7+@1I0WZ8QW1NM(4 '>M>RE.<H=RM6T6UTEN+A&0@N\F@1<SD'?$_Q"P
MJ> 9+F4%3?R?=MII-;,!EZ_J*ZZL<X#&/7GQ-VI>-<M0V=HXD@=K\FZ[[189
M:#ID,2?,PDC)BZXP+JBG69[&.II&W !SC_5?RAH<Q%"@$N!:ASH-VX0JG:Y\
M2WKF/8>F+D"[M''%=37C N$A92*(,NW^.INN<X%-H(2X"*Y@;IB5: 4SE/IQ
MP$2X+1#^50_2,%=AFB( ABY*H0SWO&QD83 K/]*G0KR33SXYEL-SW/W@CA(F
MK#;M/%\% 3 *:+0%F@,]@2:P;NJPG KO&4LZ>+$&:S[EA.?J%UTEJ*0L\M&>
MA4,>^RN>F\:JD@^]=AV?T%'R;#(AFAF/$@!#8\B'^N= XPZ!LZ#/-_JV>47P
M2_D(5YL /96B$P=AX.E/?WI,#T,5>D5H$00$4LY0NF9>77^;M5 <*\P#]ALH
M:H(;E+"H)WL!*>1TS7,2Z5AS*)^_918 FZ50I?A(K%^<>U"*@KD@992425ZR
MAQ&>2_9(^J9Y[4);2]:69O[-WYIG]&\7^EI*/TKW <WZK<IOS:%Y,MVUYT.Q
M"'=[,.-P%==DN*4XI[]%R\WJ);YJ$P!S+J*MT'#R/^:88Z)+P=>__O4Q#EV:
M]ZA[ZJ4YR_Z#]9;]S[[[[AO'*GL08-PQR1K.>B %*.JO,Q=T#'J<*HZD2H?-
M\3WJO$E]R:_K^9'TI7,T=WXIV:>5[#NIWZQ@%K1(N!ZVW^W:=UW.M> MUU>J
M0]<UF= ?4FCC/,8^D[EJUEQ9VM;67Z7[D*YSE#+5KF&X+:%K)6-TW+U;%YJL
MMG7MLY+YV-9??=Y11_[F28OZU'L2WW0])Y>,1>J5]O^X/+PT+\[CX@=*& S=
M,R\$-3JZKDGZ(,U_U)X/H:#BE.?.HYQ3&$N$(EHGF 4M&@>?X@OLM]]^&[(9
M)@ F(490]"=AF5@?N,_)4^#%\@X\= &-N9P &!ZO>//FY65#=DT!,&=MRF9N
MH$23 N<\\]P9WZ=\I-+ZIGEVN3?O?+%,ZF4>W:)+:.Z[RKC$_QPE.Z,N\$#)
MF[6L"=JKLWXU07&)H;\"[5^;_&&]7\:K"X!_W6ML#-E@TO%-T.26<$L#,!6R
MM T." .#D#\.8  ,*N(,\PQ-8,H7H#UD+IDC<]A,T.L-*P<K:2,H+0QHA%PY
M#0>ET94)CU4G93)YS.V47@V]PN S-Z7QFS2.'9LR!&SDQ6%9T*<,?:NK"X"%
MB>E>-68Y"#472%EU(("5D$/I80(2&SL-A"XM'H2M*<!D9ZPT :8P8X<Q)%#^
M/$>H!A-5\\)<4\1D(HZ,8S39!1 2$48$HQS.!&C\RAK)W,/H<10 =*T;A!<E
M".J&57P*X %&QW$63YOY+8&S!'Q*BU6-ZB%KKS[,4VDUF5L+95U?<VM3U[J3
M24E_D3YW*.?YK(!-%7W"'^-E'."@0#X<2C3N6'_%X.(= D !"@T\0Q% D,,_
MFRO2(;#(@<9]UWF5*X-\-3<X!+')$D!K-"89;Z4 4T *&UQIM[FOW9 -EG<J
MA_8B,)+ &&&8N8C:\$WS 7,)X3+?P\#L"F*T(@1*E3SX'ER@"0F4S 480]0#
MBQ6^$T#/Q0#E0"D0_K'(A%9J?6(,4:?7OO:U,3\84.21@N+:2CF$/8"\&(#_
MIO*5-J_IQCW-K_2>=O(W:T8'8P+Z0]G-L:FXTJR9J>*%!*NYPU9;N^D#*2-0
M'O,<921S%Q;G>"I '99/U_$)S6&N(!QMCL=FWJ,$P%C64E_VA#G@0,)[! >"
M/M_HV^8U5>X0W5(:*0C2!NT'1">;_<G>$!J9.[@JORY7Y@[>,9J DHK*MC L
MS==3_SU)6C3URK84@#4'XXFQ:Z[_!E)*Z6D< 7#I'FF@ HT?;;2US]K2R'[@
MI];WKO2UE'Z4[@,&*K="/QA[_,V:%J4HE !8==&5]>7E+W_Y!GK,VH>PE73I
MGD#[DJ;R&^<9Y2DE,_WF"N,:#S%-NI_6,;V7D@[UXRR4 OM:>? :9TRRGJ?U
MD;4QBGJL&>D[ZDX[4@]G&M]=SYNTH?0\4CI'<^>7DGV:^G?4OC/MCUG<SX(6
M"=?#]KNE?==VK@5GN;Y2';JNR9S?&)?PWL374'_D:)O>Y:ZE^Y"N<Y2RU*X<
M;N$!ENR92\:H]D_C[-W::'+:MJY]5C(?<_TTSC.MR?.D1>/4O^^W7<_)??98
M&MN3X.$I+X1WZ9F LX 4HE#R$)2N2<J_ZUB%9\&8:?)Z./N(-]+EG*GZKL)U
M%K1H'#SAK8T^X[PC^0SYP4.FWWG'NM@$"^%1\YQ)@P!3?,,T;<I+1T$F!?9,
M)YQPPH !D,9<3@#,.)+'+WCH O:?\*#%JV3-!^!O2_$:GCH\%0LY%<_A%O8@
MMHVZIWRDTOJJ#LTK/#!SUUPKVNL]<B?*1+8 GZ14QM55=D9Y[,4IZ]%F)-8$
M^"6\0V$\Y9>R1H@'B<&%0/M7%P +(RMT)0@X@X$_)@P'0 XXFB18G4CXFF/
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M+1H7AUAEIPI^]!_\/NW?$!KF( W3U?26E*9GCY?R&LA??^R?4H4D\1G90^4
M5\[:*RD/]I&,1WG<>\M;WC+P*3&GV;LBR\(("<M69$8HOI-'TRM727T'"DI^
MX(4+/ISXA:HK/ 2$PZFB))^5RKBZR,Z@NRAGIG6 9X&5+P O P^\Z7OJB:"Z
MR:\8M7^-&2[9/Q< 9SJ,@QW:._SAMG46 ',=@L5$A$@- P0/3!28ZV@;M3'4
MA^71]SF3B;+9]%YQQ15]L_'O?HT!+8CSVER.6M#D!DV,Y[;TJ9*#!, LKK*@
M1S"$$!]WN1 GN?69I  832APFA, RY), N#2NA&'DKPAHFV@&#IL&""TP_YF
M:0'<M>ZE. $/N4-Y&WXF_6[2FTMIC,&PPY(=!IRT\W3881./<@[C@?Y-(2><
M'74@+IU7N3*H0]MA18(T-HGC E: M!UM.0$Q(GF6A@/0.^8<FR[>IS%N]5Y7
MN86'\8"PK12@U]H\4Y;^L/Y7N5WG BZD]/VP/8"T)\\___Q8U3;\8\VL_+#.
M'+8N\!SZ+^U)8A#F8%4$P!Q$P LN(W. NTW>X])8T$< S-HF+5^4.5)@OR<%
MH>9\3M-U'9\2EJ:QP=-\FO>C!,":;\RQ'&@LL'8)^GRC;X==8>;3%Q*NL@[R
MNSGG$92P+J,<PWO]\1OZF/,0,JS,W',$CCJP(6B')B-41"% >P#5,??]M)Y-
MFA9-JYYM^;+VJ+]PS]6$').\5 !<ND=JUB']W49;^ZPM:=[-^[;UO4E?^]"/
MTGT GGE8$YI_.>\<S;8L\F^-OWF=B]IPP_E;=%\*</(*@4<)]B[IGX07K'T\
M9WT""&E .UG'FHPPWLOS"VE2]W2\:P("'N&L[5P^Z3$)'X!R<P)@>4@I$0 W
MSYM]SB,E<Q0\-L\OI?LT\NBR[R3=+&$6M*@-UWWZ;M("X.::G-*VIOMG^B9'
MV]KZK&0?TG6.JKPVW/:A:UW'Z"3V;FTTF?:UM:W99WWFHW XB:O6U46D19-H
MW[ \NIZ3^XS%MO[7_KT+#X^ZM^7%.8_^@R[#N^ZS)K7EWQRKPJ5"%T'S40A#
MV8IZ\%N")Z5=A^LL:-$D\ C?&J$B7BJ;830FD;_RN.JJJZ+7*H2RR'WZ @)<
M#!Q8V]MD1L/RI[T(8QF;XMGGTHY;7Q0+D1LAT.;:-"YLEEDJX^HB.Z-]*%XQ
M%Z%Q30!_>!)#:,T^>5W !<#KTM/>SH7#P+PWEVT,)Y"%.S/J*,9R6_J< %AN
MP-# N^BBBP;PSV_RGI< N+1N6%=1WU&6Z'*7CHOV+B#F:=-"@&]'60#GXG[G
MA(-=ZUZ*$^K89*#P;)8PZ<TEEFST,X)?7*=P+U<E; KYC4 1;3[NFQJ=.?SK
M0(QK\QR4SJM<&>3;Y["2J\^H9Q+*I8P_N5[-N3<F/VGV(MC, 0<EN;$A!DE?
MX*#'P8\\L-Z6%2^X ;K.!=*V60NPH:3_^9,E4!O^R4\>-,X[[SQ^MH+BA>$J
M* <2^C&V)@%JRZP9';(&'*9I+BWK0PXYI&YF'P'P*:><$OL*EV8YD#43B@HY
MU^,EXU-> YI:N+ER>39* (Q[4/I'<1S3?!COTESFX"KH\XV^'7;5W$&+F')E
MY9R6FW[+0>J,,\ZH<$V-VRN-,=:[<4#A')[TI"=M"+.P__[[QW)< -P?PV(*
MP*!H0HY)7KJ'*=TC->N0_FZCK7W6EC3OYGW;^IYC!I;2C])]0+-^J_);Z\2L
M:5%7_&F]?L<[WA$_P7H$+Q*Y/XT!F-"\9Q\$<%Z24EPN]  *<,)#Z@DL?ISY
MIW*^\(4O9-[^YI'2Y:P0<WN:MC$Y:0%P\[S9YSQ2.D=SYY>2?9HP.VK?J72S
MND[Z7)2K=QNN^_2=!,"Y<RWEY_JJK0ZY-5E[I:;G.O+/T3:>#X/2?8CFWJ@Y
M2GEM[>I+UTK&Z#A[MS::/*IMN3[K,Q^']5GI<ZW!BTJ+2MO3-;WV^J/X77W&
M8MO8GJ0 6(+8V][VMK'9?=:DMKKFQJKP*WX(Y_BG/.4ID9;CL64=81:T:!WQ
MVK7-&"BP5TL5KQ%X8J'.^K9*+HV[XL3378L!%P#[2' ,S D#\]Y<MAWN<7^
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M+6S*#\T=;C#WV[$4YA!S:5$!4FNN:.-8H']-^6%1JUK7RQB4X=)++XUU-H%
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M8?"][WVOLM"'E;F9KBR429WLM--.B[1<5LB4W28 /N644V)9*.^;>_*8#WN
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MM]%<85>Y\X0IS5<F^*W3$8,7JVK6?'@I)@0?4D)5/?[QCX_?F6!Z:!I>C+(
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M&@6E=9N$ !BE(/@W\#BH)\)5\WY7?><[W]E07<Z74O1):07"]*]][6L;TO.
M/0/T ;?9HQ3G1PF _^,__F-#_Z2%HG1+&Q"Z"_I\HV\7\>H"X$7L%:_36F"
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M4P8E<UW?C'/5>CQ+6F2ND<([W_G.L,<>>\38.^"K+Q!CF1B6YO(NF'NG#=E
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MW[3F)IX@[U)AP3SG3(H;[J=)BYIEM?V6T)^] /NB%%!H>]C#'A8?#5L?Q?R
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M%KG#J+3(L![.,4UQ-4H^TF"2]3*"=Q'<@8JOV(]I;B[5?^L^CMOFXAU,2
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M]7A:2P'A.VD(%=8&\K:1YI?>IYZHE _\#_A1*4\?NH4U^#!EOC[?J+Q%NKH
M>)%ZP^NR5AC0PK1JFTOB]M(V8A^V :XQ2(>;P!P0XXGWN!,2M!W0B?]$^IP
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MQGFF-LR2%B%@5+G@B;4?AI[H!HR?)F#E2NQ;OGO_^]_??#WP^ZYWO6M,E\8
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MOK(AB]RXS3V;Q!JM^@T3 )>,SPT-:3PHX96P?P)/P\+3-+*N?[+?4G^U724
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M0@<$8_+%=7B<=AE#*ECLL&!60L'""XR35>NWYB8^&',[F")0V&&''6+_MWW
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M>,<[.GXUNV2K1(M< #R[<>,E#6+ :=$@/OR78Z 4 ZM$BTK;[ND= XN, 1<
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M>=8YF1O>^.R((XZH3.!1XPN<F4"X>O.;WURGU8TQM*L]]]QS("WI3>@:GYD
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MP&G1:O:KMVKY,8!ECH-CP#$P!PSXYG(.2/<B5PH#OKD<[,ZF((>W$M2PWB
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M]);,#P-.B^:'>R]Y-3#@M&@U^M%;L7H8< 'PZO6IMVA),.";RR7I**_FPF+
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M=7U.//'$])7?=\" ^F\2M*A#<9[$,;!R&'!:M')=Z@V: P:<%LT!Z5[D2F'
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M >#-'QL#OKD<&X5KD8&YZ@W_\B__$LSZ,QQ]]-%KT>:21CHM*L&6IW4,;,2
MTZ*-.)G%$PL3$"S6?+CE+6]9%X?"C[GX#N9./@IC[WWO>]?OIGESP047!'.-
M'LS=>%1P&*4$-<VZ+&O>3HN6M>>\WHN" :=%B](37H]EQH#3HF7N/:_[(F#
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MM,)/G1:M<.=ZTV:" :=%,T&S%[+B&'!:M.(=[,V;.@:<%DT=Q5Z 8Z 7!EP
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MA X"<F-_CO'OHH X!#-"1R!,L2AT<#$X-@2(1;%Q-0,M$ %B48' TBP$*DA
M5?!Y'H< !/(DP.0R3W \!H'_$6!RR:L @8H3(!;ESO#::Z\U0LUVVVWG7'31
M1<[]]]_O7'+))8Y> 6SR1<B1)$*K7EEI\O;>>V_GH8<><AY\\$%'K_XU><+^
MDT\^<0UXY957W'P1WVZ]]5;GTDLO=?0J2I-_QQUW.$.'#G6./OIH<Z]7;#K=
MNG5S_SS[[+.FK8<??MB4ZU4,SGGGG>?T[]_?N>RRRYQJU:J9_*NNNLKM4RZL
M@%6G3AU3+G:)0"V",0)P JJT-V&)1?(^ZA6\QL?B:WEGY1<"NG3I8MX-\;<D
MO6K6_24 ^84&$6WONNLN][VM4:.&HU>]NBST*G3WO9%W1Z\H-N_=::>=YE2N
M7-F4]>S9T]3/YOVU[<FS(DQ+F_)9LV9-QPK V;[C(OJ*^"MMR/<K.0T<.-"4
MM6_?WBW*]7M;WO<GVY\7;[_]MK'%*P#G:DNV?;F##="%^$C^(  'R"F8$BH"
M88E%H8**L;$C0"R*G<L9L,\$B$4^ Z4Y"/A$  '8)Y T X%<"3"YS)48]2&0
M2(#)92(/[B"0#P%B4>[4]#;*1JAX^NFG$Q[66[@Z0X8,<?2VT";?BDMZ"V='
M5N9YTY577FG:$#%7TJI5JQS;;J]>O;Q5G<V;-SN//_ZX:5L*WGWW7?.LK+A,
M3GI+7$>$8?%KLGT??/"!R9>5R_JL4?=1*V#I;7*=?OWZ.;+Z4])OO_WFZ*UW
MW7I<I"<0EECTP ,/&/_+>S9W[MR$P<R:-<NL5)=,O76;J:>W'3?OI:TH[[ (
ML/)NR2\>V&0%V]JU:SN//?:8>5]MV8 ! TQ]O:6QS<KX_DHEVY[T<_#!!YL=
M/NSJW=6K5SNYON-_^]O?C WVN^8:HB_L+V@\\\PS;G8NWUMYJ+SOC_U>)W\?
MDW]>I!. <[4EV[[<P0;H@E@4(&=@2B@)A"46A1(N1L>& +$H-JYFH 4B0"PJ
M$%B:A4 %"2  5Q @CT,@7P),+O,EQW,0^"\!)I>\"1"H. %B4>X,=]UU5R,H
MB5 K(DY9J6W;MJ;>DT\^F5)%5OX*^_KUZYLR*WKI<TK3;E7K;2"3 "PK+*5=
M6;DIPG%RL@*>K%JVR0I88@,I=P)AB476SX,&#<HX2+M*^+GGGDNI)RO"Y?V2
MU;@VV7=7MFQ.3OK<6E-?5A?;7R;(]/[*\[8]62F?[AW.]1V77W80FV5%_/??
M?^^:.&G2)),O*_G7KEWKYN?RO96'+->ROC_9_KQ()P#G:DNV?;F##="%^$C^
ML (X0$[!E% 1"$LL"A54C(T= 6)1[%S.@'TF0"SR&2C-0< G @C /H&D&0CD
M2H#)9:[$J ^!1 ),+A-Y< >!? @0BW*G=MUUUQFA0MCMLLLNYCQ@6?FX<.'"
MA,9D1:34V7[[[<WJ7EF=9__4JU?/;6/=NG7.???=9^YEV]SR4B8!S;9SUEEG
MI6WFYIMO-OW(]K\V60'K_???MUE\YD @#+%HRY8MCFS=+.^C]XSJY&%ZZWW[
M[;?)Q>:7$T1(E786+%A@RJU@FTX ENVDI:[\D6M)F=Y?*<_4GI3G\XZ+J"@V
M_/WO?Y<F3))MT25/5N-[4R[?6WFNO.]/MC\OT@G N=J2;5_>\0;EVKXG",!!
M\0AVA(U &&)1V)AB;_P($(OBYW-&["\!8I&_/&D- GX10 #VBR3M0"!' DPN
M<P1&=0@D$6!RF02$6PCD08!8E#LT$6SEY\_66V_MBEO"4>[E#$Y9Z2A;.ENV
M<I[O44<=5>8?67THY_)*?3GSM[R424"[YIIK3#N77WYYVF;NO?=>4]ZU:U>W
MO#P!RZW(15H"8? :0(H  $  241!5(A%LFVR?1\7+5J4=AR2N7+E2K?>DB5+
MTM:3K<*EK2^__-*49Q)L9=MHVZ]? G ^[_C++[]L[)"MJ&55L7R'[9G77W_]
MM3O.7+^W\F!YWY]L?EY(.\D"<#ZV9-N7]!>T9-\3!."@>09[PD(@#+$H+"RQ
M,[X$B$7Q]3TC]X< L<@?CK0" ;\)( #[393V() E 2:768*B&@3*(,#DL@PP
M9$,@!P+$HAQ@)545L6S,F#'.G7?>Z9XE*CSM5K!68)HR94K2DZFW#SWTD!&H
M3CGEE-3"I!PK ,L6N<FI?__^IIVR5A)??_WUIKQGSY[NH^4)6&Y%+M(2"$LL
MVG;;;8WO)T^>G'8<-M/62[=2V+NB=^G2I>:1? 7@=.^O-)BI/2G/YQT7(7JG
MG78RXW_GG7><YY]_WES++V<DIUR^M_)LMM^?\GY>) O TG:NML@SDLKKZ[^U
M@O4WL2A8_L":\!$(2RP*'UDLCA,!8E&<O,U8"T& 6%0(JK0)@8H30 "N.$-:
M@$!>!)A<YH6-AR#@$F!RZ:+@ @)Y$R 6Y8TNY<%NW;H94>F""RXP91TZ=##W
M\K.JO&3%']DN6E;^94ICQXXU[>ZYYYXIU88/'V[*=MYYY[1G"=LS10<,&. ^
MFZV Y3[ 10*!L,2B=NW:F7=#?F$A4Q)A5GXN//SPPRG51HX<:<I$F+0IDV";
M;@5PIO=7VLS4GI3G\X[+<S?<<(.Q_4]_^I,Y9U;&^,(++TA10LKE>RL/YOO]
M2?YY87\&2/\VY6J+?2[Y,[FOY/(@W!.+@N %; @S@;#$HC SQO;H$R 61=_'
MC+"P!(A%A>5+ZQ#(EP "<+[D> X"%23 Y+*" 'D\]@287,;^%0" #P2(1;E!
M7+]^O2-"F@AAR<F>,VI7UPX>/-@(3E6K5G6&#AV:4%W.6GWII9<<NU+WUU]_
M-><)BS_./__\!/%6MG7MV[>O\^"##YHVYLR98]JM5*F2(]?>)'5EFUMIYZ:;
M;O(6.4\]]93)KUFSIGM^JU3(5\!*:#S&-V&)10,'#C3^%_%V_/CQ"1Z;.'&B
MT[%C1Y,W:- @4Z]APX;.[-FSW7K+EBUS]M]_?U,FVS#;E$FP32< 9WI_I<U,
M[4EY/N^X/#=SYDS'GE\LWX\==]PQX7LF=23E\KV5^IF^/[G\O$@G .=B2RY]
MB=U!2\2BH'D$>\)&("RQ*&Q<L3=>!(A%\?(WH_6? +'(?Z:T" $_""  ^T&1
M-B"0!P$FEWE XQ$(> @PN?3 X!(">1(@%N4&3L[KM<Q:M&CAG'GFF4[W[MV=
M???=U^3+-K-V:UQI^8033G#KMVK5RI'5AT<<<82[M>M>>^WE&C!LV#!7H&K2
MI(DCVT&?>NJICMV2]XX[[C!U-VW:Y,CJ7[&C;MVZ3I<N78QX=_755YMR.>_4
M"EWMV[=W>O3H8<X?MG;WZ]?/[5,N,@E8"16Y24L@++%(WAMY'^0]J%*EBG/X
MX8>;][=UZ]8F3WZA0-+OO__N[+???B9/Q.)SSCG'_&G0H(')D]7E<J:P39D$
MVW0"<'GO;Z;V;)^YON/VN2.//-*,01A<=]UU-COE,Y?O;:;O3RX_+]()P&)8
MMK;DTE?*@ .087\^<09P )R!":$D$)98%$JX&!T; L2BV+B:@1:( +&H0&!I
M%@(5)(  7$& / Z!? DPN<R7',]!X+\$F%SR)D"@X@2(1;DQ%/%*A",1P2P[
M^RGBVKAQXQ(:E/JRHK)^_?HI]=NT:>,\_OCC"?4G3)C@R!:\5L"5MBM7KNR<
M=-))SN>??^[6G31IDK/;;KLEM&D%8*DT:M0H1U9P6MOD4\2\(4.&N&W8"[LM
M]$<??62S^,R!0)ABD:R>[=6KER.KP+WOAJP:[].GCSOJU:M7FY7H(@I[ZQUW
MW''.PH4+W7IRD4FP]0K (E#:E.G]S=2>?5X^<WG'[7.OOOJJ.YX9,V;8[)3/
M7+ZWF;X_N?R\L *P78EMC<K6EESZLFT'Z=.^9PC 0?(*MH2)0)AB49BX8FN\
M"!"+XN5O1NL_ 6*1_TQI$0)^$-A*&M%!C@0!"!29@/[/7=.C_H\.I<]#*W+O
M= >!\!.X_?;;E=X6U0Q$OD/R72)!  *Y$2 6Y<;+6UMOB:N^__Y[D]6T:5-5
MKUX];W'*]<\__ZSTEKJJ1HT:JEFS9JI6K5HI=6S&FC5KE-ZR5E6K5DTU;][<
M/&/+[*=,X7_\\4>U?/ERI05FU:A1(UOD?LZ;-T]IH4N)?2U;ME1:T'/+N/"'
M0!ACD;P[\^?/5XL6+5)ZM;G2JWN5_5G@I:(%8S5MVC2U<>-&I5>P*_U+!-[B
M"EUG\_YFTT&AW_%<OK>9[,WUYT6ZMK*UQ8^^TO5?R#S[_O'OHD)2INTH$PAC
M+(JR/QA;. D0B\+I-ZP.#@%B47!\@240\!)  /;2X!H"123 Y+*(L.DJD@28
M7$;2K0RJR 2(144&3G>1(T LBIQ+&5 )"!"+2@"=+B-%@%@4*7<RF!(1(!:5
M"#S=1H8 L2@RKF0@$2.  !PQAS*<\!!@<AD>7V%I, DPN0RF7[ J7 2(1>'R
M%]8&CP"Q*'@^P:+P$2 6A<]G6!PL L2B8/D#:\))@%@43K]A=7 ($(N"XPLL
M@8"7  *PEP;7$"@B 2:7181-5Y$DP.0RDFYE4$4F0"PJ,G"ZBQP!8E'D7,J
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M19F\AUVZ=%$=.W94X\>/+[C-Q**"(Z:#&!"P/[L[=^ZLQHX=&X,1,T0(^$N
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M1,*R5@TG//2_F\LNN\ST9\_YE>V(I1V[NM6>BRO;'$LZY9133+ELH^Q-V0K
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MVY2Y+DL ED)9[2VKE@</'NS(*F9A(.VDXYO2<!D9Q*(RP) -@1P(R/=0_B
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M5ZK6K5NKNG7K)@S$+WX)C0;DAE@4$$=@1J@)$(M"[3Z,#P !8E$ G( )H2=
M+ J]"QE B0D0BTKL +J'0!D$$(#+ $,V! I-@,EEH0G3?M0),+F,NH<97S$(
M$(NRH_SXXX^KRR^_7#5LV% M6+ @NX?2U(JR 'S((8>H"1,FJ!$C1JB33SXY
M8?1^\4MH-" WQ** . (S0DV 6!1J]V%\  @0BP+@!$P(/0%B4>A=R !*3(!8
M5&('T#T$RB"  %P&&+(A4&@"3"X+39CVHTZ R674/<SXBD& 6)0=91%]IT^?
MKJI7KZX./?30[!Y*4RNN K!?_-(@+7D6L:CD+L" "! @%D7 B0RAI 2(127%
M3^<1(4 LBH@C&4;)"!"+2H:>CB&0D0 "<$8\%$*@< 287!:.+2W'@P"3RWCX
MF5$6ED"I8]&B18O4M&G3U$\__:3JU:NG6K1HH?;::R]WT+___KN:/W^^VGKK
MK56C1HW4XL6+U6>??::6+EVJ#CSP0'7  0>HRI4KN_6]%^O6K5-3ITXU[=>L
M65/ML\\^:O_]]_=62;A>MFR9:XN<S]NJ52NUPPX[F#J;-FU2\^;-,P)PX\:-
MW><<QU&S9LU2WW__O;%IPX8-9IOH@PXZR(S'K?B_BUP%X!]__%%MW+C1K#RN
M4J6*^O+++]7DR9,-IXX=.ZH:-6J8EJ7.5U]]I:9,F:)VW'%')64-&C1([M[<
M9\,EF;NPD2V>Q1=[[+&'.NRPPY388].<.7/466>=96Q[\LDGU9%''FF+5-.F
M395P2L?/5OKEEU^,[3-FS##U91OI=/9[>52K5LWXZ_///U>U:M52'3IT,,_:
M-HOU22PJ%FGZB3*!4L>B*+-E;/$@0"R*AY\996$)$(L*RY?6HT^ 6!1]'S/"
MD!+0_R%#@@ $2D! _\APY$_GSIU+T#M=0B#\!&Z[[3;S'9+OT=BQ8\,_($8
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M+@(B$_<-&S:XW"HB .NS?TT[EU]^>5KV]]Y[KRG79T"[Y9D$8"L8(P"[N+B
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M ('"$B 6%98OK<># +$H'GYFE(4C0"PJ'%M:AD!%""  5X0>ST*@ @287%8
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M.%Z,'S]>'7KHH6JOO?92WW[[;58(+K[X8C5X\."$NF^__;8Z\<03$_*XR8X
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M'78P>4\__;1;3RX^^. #DR^KA;6([);9%<!Z^V>G7[]^CJQVEB3]RBK?Y!7
M6E!UM+!LVM*BMUGYZS:F+TXXX013]L(++WBSG4+8]L ##YB^]-;6CMX*.Z$_
M82DK?B5IP=O4VWWWW1WQFS=IT=J4'7WTT=[L0%T3BP+E#HP)*8$PQ**0HL7L
MF! @%L7$T0RSH 2(107%2^,Q($ LBH&3&6(H"<C* 1($(% " DPN2P"=+B-%
M@,EEI-S)8$I$( RQ*), +-LNRQB>>^ZY%(*R1;*4U:Q9TRVS K!>>>N(6)IK
MVG7774V;(KQ*LNU=<,$%)E^?/>PV>?CAAYL\$7<E#1TZU-R+D)VN;RM8WW__
M_6X;5@"6?M(EKP"LST%VMUL6\7?V[-DICY0E !?"-FO[H$&#4NSP9K1MV]9P
M>?+))[W9YEJO_#5E>N5P2EE0,HA%0?$$=H290!AB49CY8GOT"1"+HN]C1EAX
M L2BPC.FAV@3(!9%V[^,+KP$$(##ZSLL#SD!)I<A=R#FEYP D\N2NP #(D @
M#+&H+ %8!$^]Q;,1"/7VQRG>D%6Z>BLW4[Y@P0)3;@5;.0,XGZ2W2C;MW7//
M/>9Q*_Q^\\TWCA4R9\Z<:<[R%=N\JX7ON^\^\ZR<)9PNV17#EUQRB5ML1=3W
MWW_?S?->6 %XSSWW="Z]]%+3OHB_<^;,\59SK\L2@/VVS>N;Y'.876/^=Z&W
M]C9V;[_]]HZL%O;^J5>OGBF3]W3=NG7)CP;BGE@4"#=@1,@)A"$6A1PQYD><
M +$HX@YF>$4A0"PJ"F8ZB3 !8E&$G<O00DT  3C4[L/X,!-@<AEF[V%[$ @P
MN0R"%[ A[ 3"$(O*$H!7KESIBH-+EBQ)ZPK9.EG&J,_1->45%8!??/%%T]Y)
M)YUDMF#>;KOM''W^KFG;BJBR5?/GGW]NZAUUU%&N7?I\79-W^>67NWG>BWOO
MO=>4ZW..W>QL!6#K1_ELT:*%4Q:/L@1@OVV3+:6M38L6+7+'DWPAVW;;>OJ,
M7T=XE?5G[=JUR8\'XIY8% @W8$3("=B? QR-$W)'8G[)"!"+2H:>CB-$@%@4
M(6<RE)(0(!:5!#N=0J!< @C Y2*B @0*0X#)96&XTFI\"#"YC(^O&6GA"(0A
M%I4E  N5;;?=U@B(Z5:9KEFSQA47ERY=:B!65 !>O'BQ:5.$WW?>><=<]^G3
MQ[0MY]P*S]:M6SNR[;%<BQAL4__^_4W>::>=9K,2/J^__GI3WK-G3S<_%P%8
MMI 6\5?ZE>=$($].90G A;#-^F;RY,G)9B3<UZE3Q]@\9<J4A/RPW!"+PN(I
M[ PR@3#$HB#SPS8($(MX!R!0<0+$HHHSI(5X$R 6Q=O_C#ZX!!" @^L;+(LX
M 2:7$7<PPRLX 2:7!4=,!S$@$(98E$D EK-\90P//_QPBK=&CAQIRD1@M*FB
M K"TL^^^^YIV.W3H8#ZG39MFFW>W@3[HH(-,F=ANT_#APTW>SCOO[,CVU,G)
M;B$]8,  MRA; ;A)DR9F1;)L_2Q;* L3V>8Z>=ODL@3@0MC6KET[8\>==][I
MCB?=A>4H/]/#F(A%8?0:-@>-0!AB4="880\$O 2(15X:7$,@/P+$HORX\10$
M+ %BD27!)P2"10 !.%C^P)H8$6!R&2-G,]2"$&!R61"L-!HS F&(19D$8+O2
MMF'#AL[LV;-=[RU;MLS9?__]C0 IVQO;Y(< ?/755YMVA9V<O>M-=AMH*1/A
M>=.F36ZQB+%R/J^4W73336Z^7#SUU%,FOV;-FHX]KUCRLQ6 [3;4\HRLAI85
MRM*/;%7]^^^_2[9)90G A;!MX,"!Q@;A,'[\>&N"^9PX<:+3L6-'<SUX\&!3
MKVK5JL[0H4,3ZLE9PB^]]))3UJKIA,HENB%J]<(;  !  $E$0506E0@\W4:*
M@/R\DC]L 1TIMS*8(A(@%A41-EU%E@"Q*+*N96!%(D L*A)HNH% C@00@',$
M1G4(^$6 R:5?)&DGK@287,;5\XS;3P)AB$69!& 1-_?;;S]7:#SGG',<^6-7
MP<IJ6SF/UB8_!. 1(T:8_H1=[]Z];=/FTVX#+66GG')*0IG<O/SRR\Y66VUE
MGF_?OKW3HT</<^:M]8-WRVBIGX\ +,]]_/''CCW_^+SSSG-$2)54E@ L97[;
M)N*WC%'&5J5*%>?PPP]WSCSS3+-%MN15JE1)NC7)VB7YK5JU<O[TIS\Y1QQQ
MA!'1)<\K<-MG@O))+ J*)[ CS 3D>RY_$(##[$5L+R4!8E$IZ=-W5 @0BZ+B
M2<91*@+$HE*1IU\(9":  )R9#Z40*!@!)I<%0TO#,2' Y#(FCF:8!240AEB4
M20 6.*M7KW;./_]\(RC:\<CG<<<=YRQ<N#"!GQ\"L/0G@J;TD>[L8;N5LZR
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MR\B*1X!85#S6]!1- L2B:/J5486?  )P^'W("$)*@,EE2!V'V8$AP.0R,*[
MD! 3(!:%V'F8'@@"Q*) N $C0DZ 6!1R!V)^R0D0BTKN @R(  %B402<R!!*
M2H!85%+\= Z!,@D@ )>)A@((%)8 D\O"\J7UZ!-@<AE]'S/"PA,@%A6>,3U$
MFP"Q*-K^973%(4 L*@YG>HDN 6)1='W+R(I'@%A4/-;T%$T"Q*)H^I51A9\
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M.0/VF0"QR&>@-!=+ L2B6+J=0?M(@%CD(TR:BBT!8E%L7<_ ?2) +/()),U
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M.PCD0X!8E \UGH' 'P2(17^PX H"02*  !PD;V!+K @PN8R5NQEL 0@PN2P
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M(  !"$   A H$@$$X"*!IAL(0  "$(  !"   0A   (0@  $(  !"$   A"
M  0@  $(0  "A2:  %QHPK0/ 0A   (0@  $(  !"$   A"   0@  $(0  "
M$(  !"   0A H$@$BBH S_UUOAE6\]I-BC0\NH$ !"   0A   (0@  $(  !
M"$   A"   0@  $(0  "$(  !" 0'P)%%8"?GOVR(7MQRW/B0YB10@ "$(
M!"   0A   (0@  $(  !"$   A"   0@  $(0  "$"@2@:()P--7S5:OSAMA
MAO7G7;NH/>NT+-(0Z08"$(  !"   0A   (0@  $(  !"$   A"   0@  $(
M0  "$(! / @410#>XCCJB9G/JZ4;?C94ZU7?45VZ>S=5::NMXD&944(  A"
M  0@  $(0  "$(  !"   0A   (0@  $(  !"$   A H H&B",!35TQ7__IQ
M5,)P3MOE!-5J^ST3\KB!  0@  $(0  "$(  !"   0A   (0@  $(  !"$
M A"   0@ ('\"11< -[L;%:/3O^G6O'[J@0KMZ]:1_UUSPM5Y:TJ)^1S P$(
M0  "$(  !"   0A   (0@  $(  !"$   A"   0@  $(0  "^1$HN #\^<]3
MU=L+WD]KW4F-CE)M=VR5MHQ,"$   A"   0@  $(0  "$(  !"   0A   (0
M@  $(  !"$   A#(C4!!!>!-6S:I1Z8_HW[=M#:M5;6KU%17[=E#5:E4)6TY
MF1"   0@  $(0  "$(  !"   0A   (0@  $(  !"$   A"   0@D#V!@@K
M$Y9]KMY;]$E&:XYIT$EUK-LV8QT*(0 !"$   A"   0@  $(0  "$(  !"
M 0A   (0@  $(  !"$"@? (%$X W;-Z@!DX?K'[3GYG2-I6KJZOWO$A5UY\D
M"$   A"   0@  $(0  "$(  !"   0A   (0@  $(  !"$   A#(GT#!!. /
M%T]0'RW]+"O+#J]WD.J\<\>LZE() A"   0@  $(0  "$(  !"   0A   (0
M@  $(  !"$   A"   32$RB( +QNTV]Z]>\S:N.6C>E[3<JM5JF:7@7<0]6H
MLDU2";<0@  $(  !"$   A"   0@  $(0  "$(  !"   0A   (0@  $() M
M@8((P.\N_%A]NOR+;&TP]0[>J8TZMN%A.3U#90A   (0@  $(  !"$   A"
M  0@  $(0  "$(  !"   0A   (0^(. [P+PZM_7J$?TZM_-SN8_>LGBJO)6
ME=55>A7PME5K95&;*A"   0@  $(0  "$(  !"   0A   (0@  $(  !"$
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M9CZ?Y]K?/URPE;Z\=/=NJO[6._V1R14$(  !"$   A"   0@  $(0  "$(
M!"   0A   (0@  $(  !")1+P#<!^)4?AJL9J^>4VV$V%?;8MH4ZN^DIV52E
M#@0@  $(0  "$(  !"   0A   (0@  $(  !"$   A"   0@  $(_(^ +P+P
M3VL7J<%S7O$5ZD4MSE:-:S;PM4T:@P $(  !"$   A"   0@  $(0  "$(
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M@M_=FC5KU/GGGZ\V;]ZL!@T:I)HV;9I@- P3<' # 0A   (0@  $(  !"$
M A"   0@  $(0  "$(  !"!00 ((P 6$&X6F/_[X8R4K?R6]_?;;",!IG+IX
M\6+5H$$#4S)UZE2UWW[[)=2"80(.;B   0A   (0@  $(  !"$   A"   0@
M  $(0  "$(  ! I(  &X@'!I.AX$RA. XT&!44(  A"   0@  $(0  "$(
M!"   0A   (0@  $(  !" 2!0"0$X(D3)ZJU:]>J77?=535OWCPMUP4+%JB9
M,V>JJE6KJD,//=2M(^*=K-"</7NVVK!A@VK2I(G:>^^]58<.'=166VWEULOW
M8LN6+>J33SY1\GGPP0>K]>O7FWNQN4J5*JI]^_;JZ*./-G9Y^_CNN^^4V+;S
MSCNKO?;:RQ3]\LLOZMMOOU5;;[VU:MVZM:I<N;+)__WWW]7X\>.5K#Z=.W>N
MV8*X5:M6ZL@CCW2;7+ITJ?KFFV_,F X__/ RQS9NW#@E[>V^^^ZJ4:-&RG$<
M8Z]L;WS000>I&C5JN&W*Q:I5JTSY5U]]9:YE]:N,LV7+E@GUY&;CQHUJPH0)
MILW##CO,M=]6M..0/CMUZF3XV#+)$]MD#//GSU<[[;23\;>T4[=N75LMXV>R
M+X2CY G3%2M6J!8M6I@SCA<M6J2^^.(+TX]P$Y_MN...:O_]]S>^JE2IDMO/
MLF7+U/OOOZ_..><<D_?TTT\GO(/[[+./L4_>@62&R?9(N;R+\FY(G\+R]--/
M5]6K5W?[\U[(.__!!Q^8^G+.L+S[4G_APH7F^R!]UZM7S_L(UQ"   0@  $(
M0  "$(  !"   0A   (0@  $(  !"$   A$GX*L /.?7>>K'=8M\0;9+C0:J
M1>U=LVKKD$,.,<*B?(I(F"Z=>>:9ZHTWWE#MVK4S@IG4N>VVV]3]]]]OQ+;D
M9W;991<C[.VVVV[)13G=B[!LV[CEEEO4XX\_KD3(]28Y8_?--]]4VV^_O9O=
MK5LW]<(++RCY_.M?_VK^3)X\V8BG4DD$[88-&RH1BN7\62E+3L<<<XP:,F2(
M$7+?>^\]=>RQQYHJ<BVB<W+Z^NNOW>V+9;OG$T\\T8B@(JQ+DK[VW'-/][$/
M/_S0]"VV>),(TWWZ]%&WWGIK@L@KXJ_X2-*OO_ZJ:M6JY7W,^$5$9DDBR&ZW
MW7;F6OH]]]QSU9=??FGNO7^)B'[UU5>K!Q]\T)N=]MKK"Q&2GW_^>?7HHX\:
M6^2!2RZY1#WYY)-JVVVW=?.2&Q)A^_777U<'''" *9+WYZ:;;DJNYMZ__/++
MJF/'CD:LEDPO0Z\]_?OW5P,&#% __?23^ZQ<[+OOOFKTZ-'&A]X"82GOA@C^
MWB0\1$@6P?REEUYRA6EO':XA  $(0  "$(  !"   0A   (0@  $(  !"$
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M8YO$C[+MLVS-C0!LJ? ) 0A   (0@  $(  !"$   A"   0@  $(0  "$(
M!.)#(!("L+CKFFNN40,'#C3BEPBX<M:O37*6JFQO+(+NH$&#3+;-Z]*EBQH^
M?+BMZONG5^23Z^0SBN6,6=EN6H0[L?^JJZXR-E@!6+9,EBV D[=+_O[[[]VV
M9'6L%8[M #9MVF3.#_[YYY_5O??>:[8IEKY$0):S=A]^^&&S=;*M+ZN/15 6
M;B)8RMG#DM*)E[+"6%8Q2Q)VPM";1)"7%:ER/JYL WW777>9XGP$X*%#AYK5
MQ=* ;',M0FF^R>N+?_WK7ZIKUZY9-25BK/QR@6S=+0*MB.2//?:8NNRRR\SS
M?@C Z=Z-,6/&F-7-TLF2)4O,N^WUAVP1?MYYYZ6,081]L56VGQ81F00!"$
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MB4O%;!%FAB+@C<^XG3QY<EB]>G6XZ**+0A&J=FG8A@T;PG>^\YUPQ157Q.<
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M 7#9<XK+##EPJ_:4!<!YO_,<Z%UVV66C-AH ;T3B!PHHH( ""BB@@ (***"
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MMVI/60#,CHP]QB/+_/GS8R4X7C???',@1$\+_9E^7) ^\Z\""BB@@ (***"
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MXG.0VQD ,TY///'$>AB=MVOWW7>/TWD3D%]RR24Q(,[7^UH!!1100 $%%%!
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M0 $%%%!  0444$ !!110H-,$#( [K<=LKP(***"  @HHH( ""BB@@ (***"
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M8"!77?ZM\-QMU_?*=-M#YX:)IYS1JWW=20$%%%!  0444$ !!1100 $%%%!
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M9VZ^*CQU]?]6MF#\B>\*V\TYJ7(;5RJ@@ (***"  @HHH( ""BB@@ (***"
M @HHH( ""BB@@ (*M!;HTP!XPTOKPB/_=598O_KITI8,&S,N[/3O7PU#AX\H
M7>^'"BB@@ (***"  @HHH( ""BB@@ (***"  @HHH( ""BB@@ +=%^C3 )AF
M/'O;]>&)R[]5VJ()IYP11A\ZMW2='RJ@@ (***"  @HHH( ""BB@@ (***"
M @HHH( ""BB@@ (*]$R@SP/@VOKU8<6Y'PXO/?E8EY8-WWY2F/+1_PY#A@WK
M\KEO%%!  0444$ !!1100 $%%%!  0444$ !!1100 $%%%!  05Z)]#G 3#-
M>O8WOPQ/_-__=&GAA+?_2QC]ZM=U^<PW"BB@@ (***"  @HHH( ""BB@@ (*
M**"  @HHH( ""BB@@ *]%^B7 +BV84-8\>5SPDN//1);.GS23F'*1[X8A@P=
MVON6NZ<""BB@@ (***"  @HHH( ""BB@@ (***"  @HHH( ""BB@0!>!?@F
M.>.:I7>$QR_\4CSY*]_S;V&;6:_ITA#?**"  @HHH( ""BB@@ (***"  @HH
MH( ""BB@@ (***"  @ILFD"_!< T<\57/AY;.^5?/[=IK79O!1100 $%%%!
M 0444$ !!1100 $%%%!  0444$ !!1100(&-!/HU %Y[_SVQ 2-WG[U10_Q
M 0444$ !!1100 $%%%!  0444$ !!1100 $%%%!  0444&#3!/HU -ZTIKJW
M @HHH( ""BB@@ (***"  @HHH( ""BB@@ (***"  @HHH$"5@ %PE8[K%%!
M 0444$ !!1100 $%%%!  0444$ !!1100 $%%%! @0X2, #NH,ZRJ0HHH( "
M"BB@@ (***"  @HHH( ""BB@@ (***"  @HHH$"5@ %PE8[K%%!  0444$ !
M!1100 $%%%!  0444$ !!1100 $%%%! @0X2, #NH,ZRJ0HHH( ""BB@@ (*
M**"  @HHH( ""BB@@ (***"  @HHH$"5@ %PE8[K%%!  0444$ !!1100 $%
M%%!  0444$ !!1100 $%%%! @0X2, #NH,ZRJ0HHH( ""BB@@ (***"  @HH
MH( ""BB@@ (***"  @HHH$"5@ %PE8[K%%!  0444$ !!1100 $%%%!  044
M4$ !!1100 $%%%! @0X2, #NH,ZRJ0HHH( ""BB@@ (***"  @HHH( ""BB@
M@ (***"  @HHH$"5@ %PE8[K%%!  0444$ !!1100 $%%%!  0444$ !!110
M0 $%%%! @0X2, #NH,ZRJ0HHH( ""BB@@ (***"  @HHH( ""BB@@ (***"
M @HHH$"5@ %PE8[K%%!  0444$ !!1100 $%%%!  0444$ !!1100 $%%%!
M@0X2, #NH,ZRJ0HHH( ""BB@@ (***"  @HHH( ""BB@@ (***"  @HHH$"5
M@ %PE8[K%%!  0444$ !!1100 $%%%!  0444$ !!1100 $%%%! @0X2, #N
MH,ZRJ0HHH( ""BB@@ (***"  @HHH( ""BB@@ (***"  @HHH$"5@ %PE8[K
M%%!  0444$ !!1100 $%%%!  0444$ !!1100 $%%%! @0X2, #NH,ZRJ0HH
MH( ""BB@@ (***"  @HHH( ""BB@@ (***"  @HHH$"5@ %PE8[K%%!  044
M4$ !!1100 $%%%!  0444$ !!1100 $%%%! @0X2, #NH,ZRJ0HHH( ""BB@
M@ (***"  @HHH( ""BB@@ (***"  @HHH$"5@ %PE8[K%%!  0444$ !!110
M0 $%%%!  0444$ !!1100 $%%%! @0X2, #NH,ZRJ0HHH( ""BB@@ (***"
M @HHH( ""BB@@ (***"  @HHH$"5@ %PE8[K%%!  0444$ !!1100 $%%%!
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M9=.*IFE3J6">/7MV;#_[,+5I"H )XYCNE1"88](.MG_C&]\83U]UOCP\[&T
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M+X$<TSL3<++0)J8C)3A+P23');2EVIBP-G]V9]SI[_^D<)+C$;@0_- 6VDD
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MN?I9H"P [N<F>#H%%%!  0444$ !!1100 $%%%!  0444$ !!138P@0,@+>
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MP .D([T,!1100 $%%%!  0444$ !!1100 $%%%!  0444$ !!110P #8,:"
M @HHH( ""BB@@ (***"  @HHH( ""BB@@ (***"  @H,$('_!PJO0Z-PV+6+
,     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
